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UNIVERSITY OF SOUTHAMPTON 
ABSTRACT 
FACULTY OF MEDICINE, HEALTH AND LIFE SCIENCES 
SCHOOL OF MEDICINE 
Doctor of Philosophy 
THE ROLE OF GENETIC FACTORS IN BREAST CANCER AETIOLOGY 
By Victoria Naomi Hammond 
Breast cancer is the most common cancer in women and is also the leading cause of cancer 
mortality in women.  There are several known risk factors for breast cancer including genetic 
factors which account for at least 25% of the incidence of breast cancer, although only a small 
proportion of this is a result of mutations in known high penetrance susceptibility genes.  The 
majority of genetic risk is now thought to be due to common genetic variants, for example single 
nucleotide polymorphisms (SNPs).  We investigated whether SNPs in candidate genes, with a 
biological reason for being of interest to study in relation to breast cancer, were correlated with 
the development of tumours with a certain phenotype, such as grade, lymph node involvement, 
oestrogen receptor status and the presence of distant metastases.   
  We genotyped 206 SNPs across 30 candidate genes in 1001 patients.  Association was performed 
using Cochran-Armitage trend test and 2-by-3 tables of disease by genotype.   
  We replicated observations from previous studies such as the association of SNPs in FGFR2, 
TNRC9 and ATM with oestrogen receptor status and identified novel associations of SNPs in the 
oestrogen receptor gene and matrix metalloproteinase-9 gene (MMP-9) with grade and presence 
of distant metastasis respectively.     
  The function of two promoter SNPs in MMP-9 were further investigated using luciferase reporter 
gene assays.  The C allele of rs3918242 had a 1.5 fold increase in MMP-9 expression in MDA-MB-
231 cells and the A allele of rs3918241 showed a slight increase in MMP-9 expression in MCF-7 
and NIH-3T3 cell lines although not significant.   
  The novel results identified need to be replicated for validation but this study provides evidence 
that common genetic variants play a role in predisposing to certain tumour types.  i 
 
List of Contents  
 
CHAPTER 1  INTRODUCTION.....................................................................................................................1 
1.1  RESEARCH FRAMEWORK.....................................................................................................................1 
1.2  BACKGROUND.....................................................................................................................................3 
1.2.1  INTRODUCTION TO CANCER.....................................................................................................................3 
1.2.2  INTRODUCTION TO GENETICS...................................................................................................................7 
1.2.2.1 DNA................................................................................................................................................7 
1.2.2.2 Genes.............................................................................................................................................8 
1.2.2.3 Chromosomes..............................................................................................................................10 
1.2.2.4 Genotypes and Phenotypes .........................................................................................................11 
1.2.2.5 Alleles...........................................................................................................................................11 
1.2.2.6 Penetrance...................................................................................................................................11 
1.2.2.7 SNPs.............................................................................................................................................12 
1.2.2.8 Linkage Disequilibrium.................................................................................................................13 
1.2.3  GENETIC ASSOCIATION STUDIES.............................................................................................................14 
1.2.3.1 Family-based Association Studies – Linkage Studies ...................................................................14 
1.2.3.2 Population-based Association Studies - GWAS and CGAS ...........................................................15 
1.2.4  BREAST CANCER GENETICS....................................................................................................................17 
1.2.5  BREAST CANCER BIOLOGY.....................................................................................................................24 
1.2.5.1 Biology.........................................................................................................................................24 
1.2.5.2 Tumour and Stroma.....................................................................................................................29 
1.2.5.3 Fibroblasts ...................................................................................................................................32 
1.2.5.4 Macrophages...............................................................................................................................34 
1.2.5.5 Role of the Microenvironment.....................................................................................................38 
1.3  HYPOTHESIS DEVELOPMENT.............................................................................................................41 
CHAPTER 2  METHODS FOR ASSOCIATION STUDIES................................................................................42 
2.1  OVERVIEW........................................................................................................................................42 
2.2  RESOURCES.......................................................................................................................................44 
2.2.1  UCSC...............................................................................................................................................44 
2.2.2  HAPMAP...........................................................................................................................................45 
2.2.3  PLINK................................................................................................................................................46 
2.3  GENE SELECTION...............................................................................................................................47 
2.3.1  TRANSCRIPTION FACTORS.....................................................................................................................47 
2.3.1.1 Androgen Receptor (AR) ..............................................................................................................47 
2.3.1.2 Progesterone Receptor (PGR) ......................................................................................................48 
2.3.1.3 Oestrogen  Receptor Alpha (ESR1)...............................................................................................49 
2.3.1.4 GATA Binding Protein 3 (GATA3).................................................................................................50 
2.3.1.5 TOX3 ............................................................................................................................................50 
2.3.1.6 TWIST1.........................................................................................................................................51 
2.3.2  GROWTH FACTORS..............................................................................................................................51 
2.3.2.1 Mitogen Activated Protein Kinase Kinase Kinase 1/MEK kinase 1 (MAP3K1)..............................52 
2.3.2.2 Fibroblast Growth Factor Receptor 2 (FGFR2).............................................................................52 
2.3.2.3 ERBB2...........................................................................................................................................53 
2.3.2.4 Vascular Endothelial Growth Factor (VEGF)................................................................................53 ii 
 
2.3.2.5 Insulin-Like Growth Factor 1 (IGF-1)............................................................................................54 
2.3.3  CYTOKINES.........................................................................................................................................54 
2.3.3.1 Interleukin-6 (IL-6) .......................................................................................................................55 
2.3.3.2 Transforming Growth Factor Beta (TGFB)...................................................................................56 
2.3.3.3 Tumour Necrosis Factor Alpha (TNFA).........................................................................................57 
2.3.4  TUMOUR SUPPRESSORS........................................................................................................................57 
2.3.4.1 Tumour Suppressor Protein p53 (TP53).......................................................................................58 
2.3.4.2 Mouse Double Minute-2 (MDM2)................................................................................................58 
2.3.5  DNA REPLICATION AND REPAIR.............................................................................................................59 
2.3.5.1 Ataxia Telangiectasia Mutated Gene (ATM) ...............................................................................60 
2.3.5.2 BRCA1 ..........................................................................................................................................61 
2.3.6  METABOLISING GENES.........................................................................................................................61 
2.3.6.1 Cytochrome P450 1B1 (CYP1B1)..................................................................................................62 
2.3.6.2 Alcohol Dehydrogenase-1B (ADH1B)...........................................................................................63 
2.3.7  APOPTOSIS RELATED GENES..................................................................................................................63 
2.3.7.1 Death Associated Protein Kinase 1 (DAPK1)................................................................................63 
2.3.7.2 Caspase 8 (CASP8) .......................................................................................................................64 
2.3.8  INVASION AND METASTASIS ASSOCIATED GENES.......................................................................................64 
2.3.8.1 Fibronectin 1 (FN1) ......................................................................................................................65 
2.3.8.2 Integrin Binding Protein 4 (ITGB4)...............................................................................................65 
2.3.8.3 LSP1..............................................................................................................................................66 
2.3.8.4 Matrix Metalloproteinases (MMPs).............................................................................................66 
2.3.8.5 RHOC............................................................................................................................................68 
2.3.9  GENE DESERT.....................................................................................................................................68 
2.4  SNP SELECTION .................................................................................................................................69 
2.5  PATIENT SELECTION..........................................................................................................................78 
2.5.1  POSH STUDY (PROSPECTIVE OUTCOMES IN SPORADIC VERSUS HEREDITARY BREAST CANCER (POSH) STUDY)
396:.78 
2.6  DNA EXTRACTION .............................................................................................................................80 
2.7  GENOTYPING ....................................................................................................................................80 
2.8  QUALITY CONTROL............................................................................................................................80 
2.8.1  POPULATION STRATIFICATION................................................................................................................81 
2.8.2  ASSOCIATIONS....................................................................................................................................83 
2.8.2.1 Association with Survival.............................................................................................................83 
2.8.2.2 Association with Breast Cancer Phenotypes................................................................................83 
2.8.2.3 Significance..................................................................................................................................84 
CHAPTER 3  METHODS FOR FUNCTIONAL STUDIES.................................................................................85 
3.1  OVERVIEW........................................................................................................................................85 
3.2  GENERAL MATERIALS........................................................................................................................87 
3.2.1  CELL LINES.........................................................................................................................................87 
3.3  GENERAL METHODS..........................................................................................................................88 
3.3.1  PREPARATION OF NUCLEIC ACIDS...........................................................................................................88 
3.3.1.1 DNA Extraction from Whole Blood ..............................................................................................88 
3.3.1.2 Total RNA Extraction from Cell Culture Preparations; RNeasy® Mini Kit Spin Method (Quiagen)
.................................................................................................................................................................89 
3.3.1.3 Measurement of Nucleic Acid Concentrations.............................................................................90 
3.3.2  CDNA SYNTHESIS; FIRST-STRAND CDNA SYNTHESIS BY SUPER SCRIPT II REVERSE TRANSCRIPTASE..................91 iii 
 
3.3.3  POLYMERASE CHAIN REACTION (RT-PCR)...............................................................................................91 
3.3.4  ANALYSIS OF NUCLEIC ACIDS BY AGAROSE GEL ELECTROPHORESIS................................................................92 
3.3.5  CLONING PROCEDURES.........................................................................................................................92 
3.3.5.1 Preparation of LB Broth...............................................................................................................94 
3.3.5.2 Preparation of Selective Agar Plates............................................................................................94 
3.3.5.3 Transformations ..........................................................................................................................94 
3.3.5.4 Selection and Culture of Colonies.................................................................................................94 
3.3.5.5 DNA Extraction from Transformed Bacterial Cultures; QIAprep Spin Miniprep Kit (Qiagen).......95 
3.3.5.6 DNA Extraction from Transformed Bacterial Cultures;  QIAfilter Plasmid Maxi Kit (QIAgen)......95 
3.3.5.7 Sequencing of Plasmid DNA.........................................................................................................96 
3.3.6  TRANSFECTION PROCEDURES.................................................................................................................96 
3.3.6.1 Preparation of Cells......................................................................................................................97 
3.3.6.2 Transfection with Plasmid DNA ...................................................................................................98 
3.3.7  REPORTER GENE ASSAY........................................................................................................................99 
3.3.7.1 Luciferase Reporter Assay; Dual-Glo
™ Luciferase Assay System (Promega) ................................99 
CHAPTER 4  RESULTS ............................................................................................................................100 
4.1  ANALYSIS RESULTS..........................................................................................................................100 
4.1.1  OVERVIEW.......................................................................................................................................100 
4.1.2  ANALYSIS QC RESULTS .......................................................................................................................100 
4.1.3  PATIENT COHORT..............................................................................................................................100 
4.1.4  ASSOCIATION WITH PHENOTYPE...........................................................................................................101 
4.1.4.1 Association with Grade..............................................................................................................101 
4.1.4.2 Association with Lymph Node Involvement...............................................................................102 
4.1.4.3 Association with Oestrogen Receptor Status.............................................................................102 
4.1.4.4 Association with Distant Metastasis..........................................................................................102 
4.1.4.5 Association with Lymphovascular Invasion ...............................................................................104 
4.1.5  ASSOCIATION WITH SURVIVAL..............................................................................................................104 
4.2  FUNCTIONAL STUDY RESULTS.........................................................................................................106 
4.2.1  OVERVIEW.......................................................................................................................................106 
4.2.2  CELL LINE RT-PCR............................................................................................................................106 
4.2.3  LUCIFERASE REPORTER ASSAYS............................................................................................................107 
4.2.3.1 H1299 Transfections..................................................................................................................108 
4.2.3.2 MCF-7 Transfections..................................................................................................................108 
4.2.3.3 MDA-MB-231s Transfections.....................................................................................................108 
4.2.3.4 NIH-3T3 Transfections ...............................................................................................................108 
4.2.3.5 MRC-5 Transfections..................................................................................................................109 
CHAPTER 5  DISCUSSION.......................................................................................................................110 
5.1  DISCUSSION....................................................................................................................................110 
5.1.1  IDENTIFYING COMMON GENETIC VARIANTS............................................................................................110 
5.1.2  FUNCTIONAL SIGNIFICANCE OF COMMON GENETIC VARIANTS....................................................................112 
5.1.2.1 The Matrix Metalloproteinases .................................................................................................113 
5.1.2.2 The Role of MMP-9 in Breast Cancer.........................................................................................115 
5.1.2.3 The Potential Use of MMP-9 as a Target for Therapy ...............................................................122 
CHAPTER 6  CONCLUSIONS...................................................................................................................127 
CHAPTER 7  FUTURE WORK ..................................................................................................................130 
CHAPTER 8  PAPERS AND ABSTRACTS...................................................................................................135 
8.1  PAPERS ...........................................................................................................................................135 iv 
 
8.2  ABSTRACTS AND POSTERS ..............................................................................................................135 
CHAPTER 9  APPENDICES......................................................................................................................136 
9.1  APPENDIX 1 - SEQUENOM...............................................................................................................136 
9.2  APPENDIX 2 - SEQUENOM TIER DESCRIPTIONS ...............................................................................138 
9.3  APPENDIX 3 - SEQUENOM CLUSTER PLOTS .....................................................................................140 
9.4  APPENDIX 4 - DNA EXTRACTION REAGENTS....................................................................................142 v 
 
List of Tables 
 
Table 1- Familial breast cancer genes identified to date..................................................... 22 
Table 2: 206 Selected SNPs.................................................................................................. 70 
Table 3: Summary statistics - phenotypic characteristics..................................................101 
Table 4- Association with grade.........................................................................................101 
Table 5-Association with lymph node involvement...........................................................102 
Table 6-Association with oestrogen receptor status.........................................................102 
Table 7-Association with distant metastasis......................................................................103 
Table 8– Association with distant metastasis in ER-negative patients..............................103 
Table 9- Association with distant metastasis in ER-positive patients................................103 
Table 10-Association with lymphovascular invasion.........................................................104 vi 
 
List of Figures 
Figure 1: The 20 most commonly diagnosed cancers............................................................ 1 
Figure 2: Familial and sporadic cancers................................................................................. 5 
Figure 3: The most common cancers diagnosed in women in the UK in 2001.................... 17 
Figure 4: Age standardised incidence and mortality rates for breast cancer...................... 18 
Figure 5: The genetics of breast cancer............................................................................... 20 
Figure 6: The main steps in the formation of a metastasis................................................. 26 
Figure 7: Diagram of the tumour stroma............................................................................. 29 
Figure 8: Multi-dimensional scaling analysis ....................................................................... 82 
Figure 9: Diagram of pGL3-MMP-9 promoter construct ..................................................... 99 
Figure 10: SNPs affecting prognosis (p<0.05) identified by Kaplan-Meier analysis. .........105 
Figure 11: MMP-9 expression-primer set 1.......................................................................106 
Figure 12: MMP-9 expression-primer set 2.......................................................................107 
Figure 13: B-actin PCR........................................................................................................107 
Figure 14: Effects of MMP-9 promoter polymorphisms on MMP-9 expression...............109 
Figure 15: Schematic representation of the tumour microenvironment and cellular 
localisation of MMP-9............................................................................................................ 1 
Figure 16: Network diagram of factors affecting MMP-9 expression ................................... 1 vii 
 
Author’s Declaration 
I, the undersigned, Victoria Naomi Hammond, declare that the thesis entitled ‘The Role of 
Genetic Factors in Breast Cancer Aetiology’ and the work presented herein is entirely my 
own and reference to or quotation from the work of any other person has been correctly 
acknowledged within the work.   
Part of this work is published as: 
William Tapper, Victoria Hammond, Sue Gerty, Sarah Ennis, Peter Simmonds, Andrew 
Collins, the Prospective study of Outcomes in Sporadic versus Hereditary breast cancer 
(POSH) Steering Group and Diana Eccles.  The influence of genetic variation in 30 selected 
genes on the clinical characteristics of early onset breast cancer.   Breast Cancer Research 
2008, 10:R108 
 
 
 
Signed……………………………………………………………… 
Dated…................................................................viii 
 
Acknowledgements 
I would like to thank my principal supervisor Professor Diana Eccles for her continued 
support and guidance throughout my research.   
Thanks should also be attributed to Professor Andy Collins, my second supervisor, and Dr 
Will Tapper from the Department of Human Genetics, University of Southampton, for 
their assistance with bioinformatics.   
I would also like to thank Dr Jeremy Blaydes from the Cancer Sciences Division, University 
of Southampton, for his guidance with the functional studies.   
Finally, thank you to Dr Jon Strefford for his continued support and enthusiasm and help 
with proof reading my thesis.   
This work was funded by Breast Cancer Research Trust.  ix 
 
Definitions  
Aetiology  The cause of a disease 
Allele  An allele is an alternative form of a gene (one member of a pair) 
that is located at a specific position on a specific chromosome 
Autosomal  Pertaining to a chromosome that is not a sex chromosome 
Autosomal dominant  Autosomal dominant is one of several ways that a trait or 
disorder can be passed down through families.  If a disease is 
autosomal dominant, it means you only need to get the 
abnormal gene from one parent in order for you to inherit the 
disease.  
Basement membrane  Membrane separating the organ parenchyma from the 
underlying stroma 
Carcinogenesis  The process by which normal cells are transformed into cancer 
cells 
Endothelial cells  Cells that form the inner lining of a blood vessel 
Enzyme  large protein molecules capable of affecting the speed of a 
reaction without being altered thenselves 
Genetic marker  A gene or DNA sequence with a known location on a 
chromosome 
Genome  The entirety of an organism's hereditary information 
Genotype  The genetic constitution of a cell, an organism, or an individual 
(the specific allele makeup of the individual) 
Haplotype  Combination of alleles at multiple loci that are transmitted 
together on the same chromosome 
Heterogeneity  In genetics, heterogeneity refers to multiple origins causing the 
same disorder in different individuals 
Heterozygous  Having two different alleles for a single trait 
Homozygous  Having identical alleles for a single trait 
In silico  An expression used to mean "performed on computer or via 
computer simulation" 
Incidence  The number of new cases occurring, expressed as an absolute 
number of cases per year or as a rate per 100,000 persons per 
year x 
 
Linkage  The tendency of certain loci or alleles to be inherited together 
Metastasis  Spread of a disease from one organ or part to another non-
adjacent organ or part 
Oncogene   A gene that, when mutated or expressed at high levels, helps 
turn a normal cell into a tumour cell 
Penetrance  The proportion of individuals carrying a particular variation of a 
gene (allele or genotype) that also express an associated trait 
(phenotype) 
Phenotype  Any observable characteristic or trait of an organism: such as its 
morphology, development, biochemical or physiological 
properties, or behavior 
Polymorphism  Multiple alleles of a gene within a population, usually 
expressing different phenotypes 
Prevalence  The number of persons alive at a particular point in time with 
the disease of interest 
Proliferation  An increase in the number of cells as a result of cell growth and 
cell division. 
Proto-oncogene  A normal gene that can become an oncogene due to mutations 
or increased expression 
Single nucleotide 
polymorphism 
 DNA sequence variation occurring when a single nucleotide — 
A, T, C, or G — in the genome (or other shared sequence) 
differs between members of a species 
Somatic  Refers to cells of the body, rather than gametes 
Sporadic  When a genetic disease occurs without any family history or 
genetic defects in the parents, the disease is called a sporadic 
genetic disease 
Stroma   Structural tissue of organs, namely the connective tissues.  In 
cancer, stroma refers to surrounding connective tissue and 
associated cells that supports it - connective, functionally 
supportive framework of a biological cell, tissue or organ.   
Transfection  The process of deliberately introducing nucleic acids into cells xi 
 
Transformation  The genetic alteration of a cell resulting from the uptake, 
genomic incorporation, and expression of environmental 
genetic material (DNA), occurring ansformation occurring most 
commonly in bacteria 
Wild type  The phenotype of the typical form of a species as it occurs in 
nature 
 xii 
 
Abbreviations 
ADH1B1  Alcohol dehydrogenase 1B (class 1, beta polypeptide) 
AR  Androgen receptor 
ATM  Ataxia telangiectasia mutated gene 
BRCA1/2  Breast cancer susceptibility gene 1/2 
CASP8  Caspase 8 
CGAS  Candidate gene association study 
CYP1B1  Cytochrome P450, subfamily 1, polypeptide 1 
DAPK1  Death associated protein kinase 
DDFS  Distant disease-free survival 
dH2O  Distilled water 
ddH2O  Double distilled water 
ER  Oestrogen receptor 
ERBB2  (Her-2/neu) Epidermal growth factor receptor B2 
ESR1  Oestrogen receptor 1 (encoding oestrogen receptor α) 
FGFR2  Fibroblast growth factor receptor 2 
FN1  Fibronectin 1 
GATA3  GATA binding protein 3 
GWAS  Genome wide association study 
IGF-1  Insulin-like growth factor 1 
IL-6  Interleukin-6 
ITGB4  Integrin beta 4 subunit  
LB broth  Luria-Bertani broth 
LN  Lymph node 
LSP1  Lymphocyte specific protein 
Maf  Minor allele frequency xiii 
 
MAP3K1  Mitogen-activated protein kinase kinase kinase 1 
MDM2  Mouse double minute 2 homolog 
MMP  Matrix metalloproteinase 
NMSC  Non-melanoma skin cancer 
PGR  Progesterone receptor 
POSH 
Prospective study of Outcomes in Sporadic versus 
Hereditary breast cancer 
RHOC  Ras homolog gene family, member C 
SDS  Sodium dodecyl sulfate 
SNP  Single nucleotide polymorphism 
TGF-β  Transforming growth factor β 
TNF-α  Tumour necrosis factor α 
TOX3  TOX high mobility group box family member 3 
TP53  Tumour protein 53 (p53) gene 
TWIST1  Twist transcription factor 
VEGF  Vascular endothelial growth factor 
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Chapter 1  Introduction 
1.1  Research Framework 
This study investigates whether genetic variations in certain genes are associated with tumours 
with a specific phenotype (grade and oestrogen receptor status) or propensity to metastasise 
(lymphovascular invasion, presence of lymph node involvement and distant metastasis). 
Introduction:  Breast cancer is the most common cancer in women.  There are many risk factors 
for breast cancer, including genetic factors which account for 25-30% of the incidence.  Only 15-
30% of the heritable component of breast cancer is due to known highly penetrant genes such as 
BRCA1 and BRCA2.  A significant proportion of genetic factors remain undetermined.  Recent 
Genome Wide Association Studies (GWAS) have confirmed the existence of several common 
genetic variants affecting breast cancer risk.  It has also been shown that some low penetrance 
variants may increase the risk of a specific tumour phenotype.  Genetic variants may have an 
impact on breast cancer prognosis, currently routinely predicted on the basis of tumour 
characteristics and stage, either by influencing the development of specific breast cancer subtype 
or by influencing the host tumour defence mechanisms.  We investigated whether there was 
evidence that single nucleotide polymorphisms (SNPs), the most common type of genetic variant, 
in candidate genes might influence breast cancer phenotype and prognosis.   
Method:  We genotyped blood DNA from 1001 young onset symptomatic breast cancer cases from 
the POSH study.  206 tagging SNPs were typed reporting on 30 candidate genes.  We used 
Cochrane Armitage Trend test to compare phenotypic extremes (for example ER+ve vs ER–ve and 
Grade 1 vs Grade 3) and Kaplan Meier survival analysis to compare relapse free survival according 
to genotypic subgroups. The functional consequences of the potentially disease influencing SNPs 
located in the promoter regions of the MMP-9 gene were further investigated using Luciferase 
reporter assays.   
Results:  Replicating observations from recently published studies, SNPs in FGFR2 (p=0.000003) 
and TOX3 (p=0.0014) were associated with ER+ve breast cancer, whereas ATM SNPs were 
associated with ER–ve disease (p= 0.0000985).  SNPs associated with known prognostic tumour 
features included two adjacent SNPs in the oestrogen receptor alpha gene (tumour grade, 
p=0.0026 and p=0.0040) and three SNPs in the MMP-9 gene (distant metastasis, p= 0.00092, 2 
 
p=0.0034, p=0.0037 (p=0.000066, p=0.0.00044, p=0.00038 in ER+ patients)).  The wild type (C) 
allele of rs3918242 was found to have a 1.5 fold increase in MMP-9 expression over the minor 
allele in highly metastatic MDA-MB-231 cells, and the minor allele (A) of rs3918241 showed a 
slight increase in MMP-9 expression in oestrogen receptor positive MCF-7 cells and NIH-3T3 
fibroblasts. 
Conclusion:  These novel findings will need to be replicated in further studies but suggest inherited 
genetic variants may be either modulating the host response to malignant cell growth or 
predisposing to certain types of somatic mutation that drive malignant cell proliferation.  3 
 
1.2  Background 
1.2.1  Introduction to Cancer 
Cancer is a term that refers to a collection of diseases that have the common feature of 
uncontrolled cell growth and invasion.  Cancer is one of the leading health problems 
worldwide
1, in the year 2000 there were an estimated 22 million people living with cancer 
and 10 million new cases were diagnosed in that year
2.  In the UK, one in three people will 
develop cancer during their lives and one in four people will die from some form of 
cancer
3.  It is predominantly a disease of older people with approximately 25% of cases 
occurring in people over 60 years of age
4.   
 
 
In western countries, breast and prostate cancers are the most common, whereas cancers 
of the stomach and cervix are far more prevalent in developing countries.  Lung cancers 
are also more common in the Western countries
2.  In the UK four types of cancer; breast, 
lung, colorectal and prostate, account for over half of all cancer cases.  All cancer excludes 
Figure 1: The 20 most commonly diagnosed cancers (excluding non-melanoma skin 
cancers, NMSC) UK, 2006.  Data from CRUK
1 4 
 
non-melanoma skin cancers because of the difficulties of measurement and consequent 
lack of data (Figure 1). 
There are many possible causes of cancer, for example exposure to carcinogens, either in 
the external environment or through lifestyle choices such as smoking, is a major 
influence.  The impact of lifestyle and environmental factors are shown by the prevalence 
of certain cancers in different countries and the results of migration studies showing that 
breast
 cancer rates change when women move to a new country, providing
 evidence for 
the importance of lifestyle and environment in
 breast cancer risk. 
2;5;6.   
It was first suggested in 1914 by the German scientist Theodor Boveri, prompted by 
previous observations of aberrant mitoses by David von Hansemann
3, that there is a 
genetic component to cancer in his work entitled ‘Zur Frage der Entstehung Maligner 
Tumoren’ (The origin of malignant tumours) which was recently translated and 
republished 
7.   Boveri noted that there were chromosomal abnormalities in cancer cells 
and he proposed that the chromosomes are carriers of genetic information and that 
predisposition to cancer was inherited by inheriting a copy of a chromosome unable to 
sufficiently suppress tumour growth.    
More recent studies have confirmed Boveri’s predictions.  In 1971 Knudson performed 
statistical analysis on cases of retinoblastoma, a tumour of the retina, and he noted that 
sporadic cases affected older patients and were invariably unifocal, whereas the inherited 
form of the disease affected patients at younger ages than average and in the majority of 
cases they develop more than one tumour.  Based on these observations Knudson 
proposed a 2-step model of cancer
8.  He assumed that most cancers arose from a single 
cell and at least two mutational events are required for carcinogenesis (affecting both 
copies of a gene) and suggested that cancers could be classified into two categories, 
sporadic and inherited.  In sporadic cases two somatic mutations, occurring by chance, 
were required, however in inherited cases, one germline copy of a damaged gene is 
inherited so only one somatic mutation was required to the good copy of the gene which 5 
 
would rapidly lead to cancer explaining the younger age of onset in patients with the 
inherited form of the disease.     
 
Figure 2: Cancers are classified as familial or sporadic.  Sporadic cancers are characterised by a lack of 
family history and arise from somatic mutations occurring after birth, whereas inherited germline 
mutations contribute to familial cancer.  Adapted from Slijepcevic 2007
9.   
It is now accepted that the process of carcinogenesis is a multi-step process resulting from 
the accumulation of errors in regulatory pathways in the cell affecting proliferation, 
survival, apoptosis and cell motility.  It is thought that at least three to six mutations in key 
genes are needed for a cell to overcome all the normal cellular restraints and become 
cancerous
10.  However, in reality, most adult cancers are very complex and will also 
contain many acquired, but not critical, mutations; these are sometimes referred to as 
driver (critical) and passenger (background mutation ‘noise’) mutations.  Inherited 
mutations may be a single mutation in a high penetrance gene or multiple mutations in 
low penetrance genes (Section   1.2.2.6).  Somatic mutations that occur may, for example, 
enable the invasion of neighbouring tissue, evasion of immune system detection, 6 
 
recruitment of a new blood supply, dissemination and targeting of new sites, and the 
penetration and reinvasion through new blood and tissue layers.  Over time successful 
metastasis occurs.   7 
 
1.2.2  Introduction to Genetics 
 
The process of tumourigenesis is multifaceted and the role of genetics in the process is 
complex.  This section explains the basic terminology that is of relevance in this study.   
1.2.2.1 DNA 
The biological information an organism needs to reproduce itself is contained in its DNA.    
DNA is a polymer containing chains of nucleotide monomers.  Each nucleotide contains a 
sugar,2’-deoxyribose, one to three phosphate groups and a base.  There are four types of 
base, the purines adenine (A) and guanine (G) and the pyrimidines thymine (T) and 
cytosine (C).  Nucleotides occur as individual molecules or polymerised as nucleic acids 
DNA or RNA.  The sequence of bases encodes the genetic information.   
Two polynucleotide strands wrap around each other forming a DNA molecule known as a 
double helix, with the sugar phosphate part of the molecule forming a backbone and the 
bases facing inwards.  Hydrogen bonds form between the bases on the two strands, 
stabilising the double helix.  Due to the space that is available between the two strands in 
the helix, the pairing of bases is restricted such that purines always interact with 
pyrimidines, therefore A pairs only with T and G only with C, so that both strands of the 
helix are related to each other with one sequence determining and predicting the 
sequence of the other.  This is known as complementary base pairing and ensures the 
genetic information is preserved during replication.  The two polynucleotide strands run in 
opposite directions.  The double helix is right-handed, with a turn every 10 bases.  The 
major groove of the helix interacts with proteins.   
The human genome (the total human DNA sequence) contains over 3 billion DNA base 
pairs.  8 
 
1.2.2.2 Genes 
The DNA in an organism is organised into a large number of genes.  Genes are discrete 
segments of DNA and each gene codes for the amino acid sequence of a polypeptide.  
Genes can vary in size from less than 100 base pairs up to several million base pairs.   
Genes are very dispersed, being separated by non-coding DNA sequences which can be 
very long so that the coding gene sequences account for a very small percentage of the 
genome.  The human genome contains an estimated 20,000–30,000 protein-coding genes 
which account for only 1.5% of the genome.   
Only one of the two strands of DNA carries biological information.  This strand is called the 
template strand (also known as the antisense or non-coding strand) and is used to direct 
synthesis of a complementary RNA molecule (pre-mRNA) in a process known as 
transcription.  The other strand is known as the non-template strand (sense/coding).  Both 
strands can act as the template strand and individual genes may be encoded on different 
strands.   
Genes are composed of both coding (exons) and non coding (introns) regions of DNA.  The 
number of introns in a gene can vary greatly, from 0 to 50 or more.  The length of both the 
introns and exons vary greatly, but the introns are usually far longer, accounting for the 
majority of the gene sequence.  For the biological information contained in a gene to be 
used to synthesise a protein, the introns must be removed from the pre-mRNA molecules 
synthesised from the template strand of DNA.  This process is known as splicing and 
results in the formation of a mature mRNA molecule which is then exported from the 
nucleus to cytoplasmic organelles known as ribosomes where it acts as a template for 
protein synthesis (translation).  The amino acid (building blocks of protein) sequence of 
the protein determines its three-dimensional structure which in turn dictates its function.  
Expression of the biological information contained in the genes is highly regulated and the 
human genome has many different regulatory sequences which are crucial to controlling 
gene expression. Not all of the genes that are present in a cell are active and different 9 
 
genes are expressed in different cell types.  This differential expression determines the 
characteristics of a cell and the role it plays within an organism.  A segment of DNA 
upstream of the coding region of the gene, known as the promoter, regulates synthesis of 
mRNA from the gene and therefore expression of the gene.  The promoter region may 
extend up to about 1kbp (1000 base pairs) upstream of the gene.  Conserved regions in 
the promoter are recognised and bound to by transcription factors and RNA polymerase 
which initiate the synthesis of a gene.   
There are also other regulatory sequences that influence the transcription of a gene and 
may occur at sites much further away than the promoter, for example enhancers, which 
turn on and speed up the process of transcription, silencers, which slow or stop 
transcription and insulators, which protect genes from the effects of silencers and 
enhancers.   
The majority of the genome is made up of extragenic DNA sequences, this is all of the DNA 
sequence apart from the genes and gene-related sequences (introns, exons, pseudogenes 
and gene fragments).  Extragenic DNA sequences can be unique or exist only as a small 
number of copies which are known as interspersed genome-wide repeats, for example 
short interspersed nuclear elements (SINEs) and long interspersed nuclear elements, 
(LINEs), but some may contain long stretches of repeat elements known as tandemly 
repeating DNA and includes satellite DNA, minisatellites (variable number tandem 
repeats) and microsatellites (simple tandem repeats).  Some of these sequences are 
involved in the regulation of gene expression, some act as spacers and other regions have 
functions as yet undiscovered.   10 
 
1.2.2.3 Chromosomes 
The human genome is located in the nucleus of every cell in the body (except for red 
blood cells).  It is packaged into organized thread-like structures called chromosomes.  
Each of the chromosomes consists of DNA that is tightly coiled around proteins, known as 
histones, that maintain the structure.  The DNA and histones are then wound round and 
round itself in supercoils and this dense DNA is known as chromatin.  Each chromosome 
has a constriction point called the centromere which separates it into two arms; the 
shorter arm, above the centromere, is the p arm and the longer arm, below the 
centromere, is the q arm.    The location of the centromere on each chromosome gives the 
chromosome its characteristic shape and can be used to describe the location of specific 
genes.   11 
 
1.2.2.4  Genotypes and Phenotypes  
A genotype is the genetic makeup of a person, whereas phenotype refers to the physical 
manifestation of an inherited trait or disease.  In cancer, both genotype and phenotype 
keep changing over time, contributing to the heterogeneity of the disease.   
1.2.2.5 Alleles 
The human genome is stored on 23 chromosomes, 22 autosomal chromosomes and one 
that is sex-determining.  Each individual has two copies of each chromosome (46 
chromosomes in total, 23 chromosomal pairs), one is maternally inherited and one 
paternally inherited, giving each individual two copies of each gene.  There can be more 
than one form of a gene (allele) at a given locus and in humans two alleles for each gene 
will be inherited, one from each parent.  Paired alleles (one on each of two paired 
chromosomes) that are the same are called homozygous and those that are different are 
called heterozygous. Complex traits such as height and longevity are usually caused by the 
interactions of numerous pairs of alleles, while simple traits such as eye colour may be 
caused by just one pair.    
1.2.2.6 Penetrance 
Penetrance is a measure of the probability of a gene or genetic trait (phenotype) being 
expressed.  It is based on the proportion of individuals with a mutation causing a 
particular disorder who exhibit clinical symptoms of that disorder.   
A condition is said to have complete penetrance if clinical symptoms are present in all the 
population who have the disease causing mutations (usually inherited in an autosomal 
dominant fashion).   
A condition is said to have reduced penetrance, or incomplete penetrance, if the clinical 
symptoms are not always present in all the population who have the disease causing 
mutations.   12 
 
Reduced penetrance is common in many familial cancers such as hereditary nonpolyposis 
colorectal cancer (HNPCC) and breast cancer.  HNPCC results from germline mutations in 
mismatch repair genes, however 20% of the carriers of these mutations will not develop 
the disease
11.  Mutations in the high penetrance breast cancer susceptibility genes BRCA1 
and BRCA2 confer a lifetime risk of approximately 80% of developing breast cancer
12;13, 
which is five to ten times the risk in the control female population
14.  It is not possible to 
predict which people with the mutations will get the disease or when it may develop.  
Reduced penetrance is likely to result from a combination of genetic, environmental and 
lifestyle factors, many of which are still unknown.   
Penetrance is an age related trait, as traits not normally expressed at birth occur with an 
increased frequency as a carrier ages, for example mutations in mismatch repair genes 
associated with hereditary nonpolyposis colorectal cancer are incompletely penetrant and 
therefore not all people carrying these mutations will develop the disease, however the 
risk of disease increases with age
15. 
Penetrance can be affected by carcinogens, hormones, mutations in DNA damage 
response genes and modifier genes, which may affect the expression of some alleles that 
may increase or decrease penetrance of a germline mutation, such as an altered 
susceptibility allele. 
1.2.2.7 SNPs 
The DNA sequence in each individual is 99.9% the same.  The remaining 0.01% of the 
human DNA sequence differs between individuals.  The greatest type of genetic variation 
is a single nucleotide polymorphism (SNP, pronounced ‘snip’).  SNPs are certain sites 
within a human genome at which some individuals will have one nucleotide present while 
other individuals will have a different one.  These single base substitutions occur, on 
average, once in every 1200 bases.  SNPs are point mutations that become established in 
a population over time.  In order to be called a SNP, the single base substitution must be 
present in over 1% of a large population.  It is estimated that there are at least 10 million 13 
 
common SNPs in the human genome.  Each base is known as an allele and collections of 
alleles make up a persons genotype.  
SNPs can be used as markers to help locate genes in DNA sequences.  For example, if a 
large group of patients affected with a disease, such as breast cancer, is compared with 
the same number of healthy individuals and if a SNP is identified where one particular 
allele dominates in the disease group at that specific locus then that allele at that location 
is associated with the disease.  This association does not necessarily imply causation as 
large regions of genetic information are inherited together in sections known as haplotype 
blocks.  This means that all individuals with the same SNP at a particular locus will also 
have identical variants at all the other SNPs in the same haplotype block.  Therefore, when 
trying to identify genes involved with a certain disease, only one SNP, a tagging SNP, 
needs to be used in each haplotype block.  It is estimated that 300,000 to 600,000 tagging 
SNPs will contain most of the information on genetic variation in the human genome.  
Information from the Human Genome Project
16 can be used to identify the location of the 
SNP in the genome, which may be within or near to a specific gene.   
1.2.2.8 Linkage Disequilibrium 
In population genetics linkage equilibrium occurs where the genotype present at one 
locus is independent of the genotype at a second locus.  If, however, two alleles are not 
independent of one another and occur more or less frequently in a population than would 
be expected from a random formation of haplotypes from alleles based on their 
frequencies they are said to be in linkage disequilibrium.  Non-random associations 
between polymorphisms at different loci are measured by the degree of linkage 
disequilibrium (LD), that is, the degree of deviation from the expectation of non-
association along a genome. 
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1.2.3  Genetic Association Studies 
Researchers have spent decades trying to identify genes involved in breast cancer using 
different types of association studies.  The first breast cancer susceptibility gene BRCA1 
was mapped and cloned in the early 90s in a family-based linkage study and several 
further high penetrance susceptibility genes have since been identified in this way.  In the 
past few years, several new loci associated with various degrees of breast cancer risk have 
been identified using candidate gene association studies (CGAS) and genome wide 
association studies (GWAS).  
Genetic association studies look at a group of people with a particular disease (cases) and 
a group without the disease (controls) to see if a certain genotype (single-locus alleles or 
multilocus haplotype) is more frequent in the cases than the controls.  If the allele plays a 
causative role in the disease or is correlated with a causal allele it will have a higher 
frequency in the case population than the control population.   
Genetic association studies may take one of two approaches, either family-based or 
population based.   
1.2.3.1 Family-based Association Studies – Linkage Studies 
Linkage is the tendancy for genes and other genetic markers to be inherited together due 
to their proximity on the same chromosome and the genetic markers can be be of use in 
studying diseases running in families.  Identifying genetic markers that run in a family, in 
the same way as the disease, can locate an area of the genome in which the causative 
gene is assumed to be.  It can be difficult to genotype several generations of a family, so a 
common approach is to genotype affected siblings.   
Linkage studies identify large chromosomal regions (millions of base pairs long) and so the 
resolution is low and there could be many genes in the area that need to be tested.  The 
strongest linkage signals come from recessive and highly penetrant and therefore 
generally rare diseases.    15 
 
The high penetrance breast cancer susceptibility genes BRCA1
17;18 and BRCA2
19 were 
identified using family-based linkage studies.   
1.2.3.2 Population-based Association Studies - GWAS and CGAS 
The classical linkage studies identify high penetrance gene mutations linked to disease in 
affected families, however, mutations in low penetrance genes cannot be identified in this 
way as linkage studies lack power to detect the alleles responsible for low to moderate 
risk of developing breast cancer.   
These alleles are now being detected by population based gene association studies.  These 
studies use thousands of known SNPs present in the human genome, originally focusing 
on SNPs in candidate genes.  The disadvantage of such candidate gene association studies 
(CGAS) is the need to guess the gene in advance and type the causative SNP (or a tightly 
linked SNP in strong linkage disequilibrium), however these studies can be used to look for 
association of alleles with a disease in nominated candidate genes from linkage studies.  
This has a higher resolution than linkage studies.   
As it becomes increasingly more evident that many diseases result from polygenic effects 
of multiple low penetrance susceptibility alleles, there is a need for larger and larger 
association studies in order to have sufficient power to detect these loci.  Many 
technological advances such as large scale genomic projects including the sequencing of 
the human genome (The Human Genome Project
16) and the HapMap project
20 as well as 
new genotyping technology has allowed association to move from candidate gene studies 
to unbiased whole genome searches (Genome Wide Association Studies, GWAS) 
identifying moderate risk alleles without prior knowledge of position or function
21 making 
linkage scans unnecessary.   
CGAS and GWAS clearly have the power to identify common variants that are associated 
with low susceptibility loci for a disease although those susceptibility genes conferring 
very low risks may still be missed
22.  Also, a great degree of caution is needed to interpret 
the results of such studies correctly, considering factors such as sample size, genotyping 16 
 
quality controls and successful replication of results
23.  Case control studies are always 
subject to problems such as confounding due to population stratification which is not an 
issue in family based studies.   
The lack of success so far with association studies may be due to small sample sizes not 
having sufficient power to detect associations, or it may be that the studies have not 
looked at the right markers and there are important genes that are yet to be examined
22.   
The low penetrance susceptibility alleles are common in the general population and each 
confer only a very small overall risk (generally 1.3 fold or less
24) precluding the use of 
individual susceptibility alleles in genetic counselling
14.  However, the combined 
effects
 may be sufficiently large to be useful for risk prediction,
 as well as targeted 
screening and prevention, particularly as more
 loci are identified.
24   
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1.2.4  Breast Cancer Genetics 
Breast cancer is the most common cancer in the UK even though it is very rare in men 
(Figure 3).  In 2006, 45,822 people in the UK were diagnosed with breast cancer, 314 of 
which were men.  Breast cancer rates are increasing and it has become one of the biggest 
causes of death from cancer in women.  In 2007, 12,082 women died from breast cancer.  
It has been calculated that there is a lifetime risk of one in nine for women in the UK 
developing breast cancer 
1.  
 
Figure 3: The most common cancers diagnosed in women in the UK in 2001 out of a total of 136,153 cases, 
excluding NMSC.  Adapted from ABPI
25 
Breast cancer is the most common cancer in women worldwide with approximately one 
million new cases in the world each year
2;5, accounting for 22% of all cancers
6.  The rates 
of breast cancer vary in different countries, being less common among women in 
developing countries, with low incidence rates in most African and Asian populations.  
More than half of the breast cancer cases are in industrialised countries with the highest 18 
 
incidence rates occurring in Europe, North America, Australia and New Zealand
2;5(Figure 
4).   
 
Figure 4: Age standardised incidence and mortality rates for breast cancer.  Data shown per 100,000
5 
There is a striking variation in the risk of different cancers by geographic area.  The high 
incidence of breast cancer in developed countries may be largely due to the screening 
programs that can detect early invasive cancers that may otherwise have been diagnosed 
later if at all.  However some of this variation may be explained by exposure to risk factors 
that may be related to lifestyle, such as smoking, or environmental risk factors, such as 
exposure to radiation.  This is also demonstrated by migration studies with the risk for 
women who migrate from low to high risk countries typically increasing, for example; 
Japanese migrants to the USA experience rapidly increasing breast cancer rates,
26;27  
Italian and Polish women had a
 higher risk of breast cancer after they migrated to 
Australia,
 where incidence rates are higher, and breast cancer
 incidence in Polish
 migrant 
communities in America tripled within one generation,
 reaching the high rates of U.S.-
born women
6.  Many factors have been associated with these changes in breast cancer 19 
 
risk including having fewer children later in life, dietary changes, increasing rates of 
obesity and exposures to carcinogenic agents resulting from adoption of a Westernised 
lifestyle
6.   
It is thought that breast cancer is caused by an interaction between genes, the 
environment and a person’s lifestyle but very little is known about the exact causes of 
breast cancer.  Several risk factors have been identified including age, reproductive 
history, personal or family history of breast cancer, diet, lifestyle, exercise, exposure to 
ionising radiation, mammographic density and height.
28  
Most breast cancers are sporadic (approximately 65-75%)
29.  These cancers affect mainly 
older people and they are characterized by a lack of family history (no two first degree 
relatives in a family are affected).  A family history can increase a woman’s chance of 
being affected by breast cancer by two to three fold
14.  Inherited cancers affect younger 
patients and the bilateral form of the disease (affecting both breasts) is more common 
than in sporadic cancers
9.   
A Scandinavian register study has shown that daughters who get breast cancer if their 
mothers had breast cancer and died have a worse prognosis compared with those whose 
mother had breast cancer and survived
30 providing evidence that breast cancer prognosis 
is inherited.    
Many years of intensive studying have focussed on understanding susceptibility to breast 
cancer.  In the 1990s the high penetrance breast cancer susceptibility genes BRCA1
17;18 
and BRCA2
19 were identified using family-based linkage studies.  These genes are critical 
for genome integrity having an important role in DNA double strand break repair by 
homologous recombination
31;32.  Mutations in the BRCA genes account for approximately 
30-40% of all hereditary breast cancers
33 (Figure 5) and this accounts for only 2-3% of all 
breast cancers 
12;22.  Women with an inactivating mutation in one of these genes have a 
risk of approximately 60%-88% to develop breast cancer
12;13, which is five to ten times 
that of the control female population
14.   20 
 
The genetics of breast cancer BRCA1 and BRCA2 mutations occur in 
approximately 20% of families with evidence of inherited susceptibility to breast cancer.  
All other breast cancer cases are presumed to be due to an undefined number of additional 
susceptibility genes with various degrees of penetrance and exposure to hormonal and 
environmental factors. 
Sporadic
67%
BRCA1
20%
BRCA2
20%
CHEK2
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TP53
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Unknown
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33%
 
Figure 5: The genetics of breast cancer, adapted from
12;29.  Approximately one third of all breast cancer 
cases are familial, of these, over half of the cases result from as yet unknown genetic causes.   
Further genetic linkage studies were instrumental in identifying additional breast cancer 
susceptibility genes with high (TP53) and intermediate penetrance (PTEN, CHEK2, ATM, 
RAD50, BRIP1, PALB2 and NSB1) for inherited breast cancer
34.  However, despite intense 
efforts, linkage studies have failed to identify additional breast cancer susceptibility genes 
for familial breast cancer and it is likely there will be no other single gene responsible for a 
large proportion of the familial aggregation not arising due to mutations in BRCA1 and 
BRCA2
35;36 as the searches that mapped these genes would have had sufficient power to 
map a third gene, had it been responsible for a significant proportion of the remaining 
families
22.  Mutations in the known high and intermediate penetrance genes account for 
around 50% of the familial breast cancer cases
23 and so it is assumed the remainder of the 
genetic risk results from mutations in low penetrance susceptibility genes.  Linkage studies 
lack the power to detect low risk alleles so the search for further susceptibility genes has 
moved from the classical linkage studies to population-based genetic association studies 
made possible by completion of the ‘HapMap’
20, the Human Genome Project
16 and 21 
 
significant advances in techniques such as DNA sequencing and SNP screening 
technologies.   
The earlier population-based studies focused on the candidate gene approach looking for 
associations of SNPs in a limited number of genes with breast cancer, however this 
approach has not been very successful, yielding mixed results
23.  Large candidate gene 
association studies have been carried out by SEARCH and BCAC (Breast Cancer Association 
Consortium).  The study by SEARCH reported that common variants in the BRCA1, BRCA2, 
ATM, CHEK2 and TP53 genes are not likely to increase risk of breast cancer
37 and BCAC 
reported that common coding variants in caspase 8 and TGFβ1 were associated with a 
significant risk of invasive breast cancer
38.   Many studies however, including an earlier 
study by BCAC identifying an association of SNPs in caspase 8, IGFBP3, PGR, SOD2 and 
TGFβ1 with breast cancer, have only reached borderline statistical significance
39.   
More recently several genome-wide association studies have been conducted utilising 
unbiased scans of the genome to identify SNPs that may be associated with breast cancer 
risk and, over a decade since the discovery of the high penetrance BRCA genes, several 
low penetrance variants associated with breast cancer have been published.
21;40;41  
A recent genome wide association study by a large research consortium lead by a 
Cambridge group identified five new loci showing significant association with breast 
cancer, four of which contain plausible causative genes
21 (FGFR2, TOX3, MAP3K1, LSP1 
and 8q) and SNPs in FGFR2
40 and TOX3
41 have both been associated with oestrogen 
receptor positive breast cancer in independent GWASs.   
The new low penetrance susceptibility genes identified probably explain less than 5% of 
the excess familial risk of breast cancer
14 and so many more susceptibility factors are 
expected to be identified each conferring only a small increase in breast cancer 
(approximately 1.2-1.5 fold increase
23).  The low predicitive value and high frequency of 
the variants in the population precludes the use of these individual risk factors in genetic 
counselling.   22 
 
Table 1- Familial breast cancer genes identified to date
21;34 
Gene  Penetrance  Function  Reference 
ATM  Intermediate  DNA damage response  Walsh et al 2007 
BRCA1  High  DNA damage response  Walsh et al 2007 
BRCA2  High  DNA damage response  Walsh et al 2007 
BRIP1  Intermediate  DNA damage response  Walsh et al 2007 
CHEK2  Intermediate  DNA damage response  Walsh et al 2007 
FGFR2  Low  Tumour Suppressor  Easton et al 2007 
Gene Desert  Low  Unknown  Easton et al 2007 
LSP1  Low  Invasion/metastasis  Easton et al 2007 
MAP3K1  Low  Cell death (apoptosis)  Easton et al 2007 
NBS1  Intermediate  DNA damage response  Walsh et al 2007 
P53  High  Tumour suppressor  Walsh et al 2007 
PALB2  Intermediate  DNA damage response  Walsh et al 2007 
PTEN  Low  Tumour suppressor  Walsh et al 2007 
RAD50  Low  DNA damage response  Walsh et al 2007 
TOX3  Low  Transcription factor  Easton et al 2007 
A study was conducted to analyze the occurrence of breast cancer in relatives of affected 
individuals to find a genetic model that may account for the familial aggregation not due 
to mutations in the BRCA genes.  The study found that the model that best fit the data 
was, indeed, the polygenic model, with the susceptibility to breast cancer being conferred 
by a large number of alleles.  The risk that is associated with any one allele is small but the 
effects are multiplicative so a woman with several susceptibility alleles will be at high 
risk
35.  Breast tumours are very heterogeneous which suggests that they arise from 
multiple genetic events
42 likely to be caused by low penetrance genes, the number and 
identity of these genes is unknown 
12;35;36;42.   23 
 
Mechanisms by which the SNPs at these certain loci cause the susceptibility are still 
unknown
43, but some SNPs have been shown to affect the intrinsic properties and 
function of the proteins to a variable degree
44-49.   
The polygenic models suggest that multiple commonly occurring low to modestly 
penetrant SNPs of cancer related genes might have a greater effect on a disease when 
considered in combination and it has been found that the risk of breast cancer is 
approximately six times as great among women carrying 14 risk alleles as among those 
carrying no risk alleles at these loci
50, however this model does not specifically consider 
their possible interactions
35;51.   
Recently, attempts have been made to identify breast cancer risk that is conferred by SNP-
SNP interactions
44.  The strategy developed has the potential to identify complex 
biological links among breast cancer genes and processes.  The genetic effect of 
combinations of functionally relevant SNPs may additively or synergistically contribute to 
increased breast cancer risk
52.   
Many studies have also identified associations of mutations with certain breast cancer 
phenotypes.  There is evidence that mutations in the BRCA genes can cause tumours with 
a specific molecular phenotype and these phenotypes are accompanied by specific genetic 
profiles.
53  Mutations in TP53 are associated with a complex phenotype of different 
tumours called Li-Fraumeni syndrome
54.  Nordgard et al
43 investigated the expression 
levels of previously identified susceptibility genes (FGFR2, TOX3, LSP1 and MAP3K1)
21 in 
tumours and found that they are highly significantly differentially expressed between the 
five established breast cancer subtypes, suggesting expression of these genes in the 
tumour influence breast cancer subtype.  Therefore stratification of patients on the basis 
of their molecular subtypes may give much more power to classic case control studies and 
genes of no or borderline significance may become identifiable and possibly even appear 
to be high-penetrance genes for certain subtypes.   
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1.2.5  Breast Cancer Biology 
Breast cancer comprises a heterogeneous group of tumours with variable prognosis and 
aggressiveness, which is related to the capacity of malignant cells to invade neighbouring 
tissues and to metastasize to distant sites
55;56. 
1.2.5.1 Biology 
The breasts are made up of fat, connective tissue and glandular tissue.  Each breast is 
divided into sections called lobes.  There are 15-20 lobes in each breast.  The lobes contain 
several smaller lobules, which contains groups of tiny milk-producing glands.  The lobules 
end in milk-producing bulbs called terminal ductal lobular units.  Milk flows from the 
lobules, through thin tubes called ducts, to the nipple.  The spaces between the lobules 
and the ducts are filled with fat.   
Structure of the breast  Lymph vessels and lymph nodes 
   
Breasts also contain lymph vessels.  The lymph vessels carry lymph, a clear fluid that 
travels through the arteries and circulates through tissues to cleanse them.  The lymph 
vessels lead to lymph nodes, small, pea-sized organs that can be found in the axilla 
(underarm), near the collarbone and near the breastbone as well as many other sites in 
the body.  Lymph nodes are barriers to the spread of infection, acting as filters along the 
lymphatic system to trap or remove foreign particles such as bacteria, viruses, cancer cells 
and other unwanted substances to make sure that they are removed from the body.   25 
 
Breast tumours are derived from epithelial cells that line the terminal duct lobular unit of 
the breast.   
The most important factor determining the prognosis of a breast cancer is whether it is 
non-invasive (in situ) or invasive (infiltrating).  
Non-invasive cancers confine themselves to the ducts (ductal carcinoma in situ, DCIS) or 
lobules (lobular carinoma in situ, LCIS) and have not spread to the surrounding tissues in 
the breast or other parts of the body. They can, however, develop into or increase your 
risk of developing a more serious, invasive cancer
57. 
If cancer cells disseminate outside the basement membrane of the milk duct or milk-
making glands in the lobules and grows into surrounding adjacent normal tissue the 
cancer is known as invasive. Invasive cancers can spread to other parts of the body and 
form metastases (secondary tumours) at distant sites including regional lymph nodes or 
visceral organs such as the lungs, liver, brain, and bone (Figure 6).  When the lymph nodes 
are involved in the cancer, they are known as lymph node positive.  When lymph nodes 
are free of cancer, they are known as lymph node negative.  In most cases, the more 
extensive the lymph node involvement, the more aggressive the cancer will be.  The route 
of spread of cancer may include blood stream (hematogenous), lymphatic vessels 
(lymphovascular invasion) or third space extension (i.e. ascitic fluid dissemination as seen 
in ovarian cancer). 
58  The bone, bone marrow
59 and brain
60 are the most common sites of 
metastasis in breast cancer.  Despite significant improvements in diagnostic and 
therapeutic modalities for the treatment of cancer, metastasis remains the overwhelming 
cause of death for cancer patients, responsible for 90% of all cancer deaths
58;61 . 26 
 
 
Figure 6: The main steps in the formation of a metastasis. a | Cellular transformation and tumour 
growth. Growth of neoplastic cells must be progressive, with nutrients for the expanding tumour mass 
initially supplied by simple diffusion. b | Extensive vascularization must occur if a tumour mass is to 
exceed 1–2 mm in diameter. The synthesis and secretion of angiogenic factors establish a capillary 
network from the surrounding host tissue. c | Local invasion of the host stroma by some tumour cells occurs 
by several parallel mechanisms. Thin-walled venules, such as lymphatic channels, offer very little resistance 
to penetration by tumour cells and provide the most common route for tumour-cell entry into the 
circulation. d | Detachment and embolization of single tumour cells or aggregates occurs next, most 
circulating tumour cells being rapidly destroyed. After the tumour cells have survived the circulation, they 
become trapped in the capillary beds of distant organs by adhering either to capillary endothelial cells or to 
subendothelial basement membrane that might be exposed. e | Extravasation occurs next — probably by 
mechanisms similar to those that operate during invasion. f | Proliferation within the organ parenchyma 
completes the metastatic process. To continue growing, the micrometastasis must develop a vascular 
network and evade destruction by host defences. The cells can then invade blood vessels, enter the 
circulation and produce additional metastases.
62  
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The size of a tumour, whether the lymph nodes are involved and whether or not the 
cancer has spread to other parts of the body are assessed to give an indication of the 
tumour stage (tumour node metastasis, TNM staging).  The appearance of the cancer cells 
under the microscope is also assessed to give an indication of the grade of the cancer and 
indicates how quicly the cancer may develop.  There are three grades, grade 1 being low 
grade, grade 2 moderate or intermediate and grade 3 high grade.  The appearance of the 
cells are scored (1-3) on the frequency of mitosis (rate of cell division), tubule formation 
(percentage of the cancer composed of tubular structures) and nuclear pleomorphism 
(change in cell size and uniformity) and these three scores added together to allow 
classification of the grade.  A score of 3-5 indicates grade 1, 6-7 grade 2 and 8-9 grade 3.  
This is known as the Bloom and Richardson grade, after the originators of the scoring 
system.   
As well as the above clinical features oestrogen receptor status is also used as a prognostic 
marker in breast cancer.  The absence of oestrogen receptors in breast tumours is 
associated with an early recurrence independent of other known prognostic factors, such 
as axillary lymph node status and tumour size
63, and breast cancer patients with tumours 
that are ER-positive and/or PR-positive have lower risks of mortality after their diagnosis 
compared to women with ER-negative and/or PR-negative disease.
64 
Breast tumours are diverse in their history and treatment response.  A number of 
microarray studies have shown that the majority of human breast tumours can be 
classified into clinically relevant subtypes based on differences in their gene expression 
patterns.
65-69  Gene expression profiling allows stratification of breast tumours into these 
groups through the use of expression levels of thousands of genes rather than looking at 
one single prognostic factor.  The ability to stratify breast tumours into different 
subgroups illustrates how the phenotypic diversity of breast tumours is accompanied by 
an underlying diversity in gene expression patterns.
66-68;70-74   28 
 
There are four main subtypes that have been consistently identified:   
1.  Basal like subtype 
2.  ERBB2+ subtype (HER-2 over-expressing) 
3.  Luminal/ER+ subtype (may be divided into 2 or 3 subclasses with distinct 
expression profiles and clinical outcomes 
66) 
4.  Normal breast-like subtype 
These groups have different clinical outcomes, the basal subgroup having the worst 
prognosis, HER-2 over-expressing having a poor prognosis, luminal B an intermediate 
prognosis and the normal breast-like and luminal A subgroups having a good prognosis.  
The basal and HER-2 over-expressing groups are ER-negative, whereas the Luminal 
subgroup is ER-positive reflecting the significant role of ER status in prognosis.   
Currently tumour grade, stage and hormone receptor status are assessed to predict 
disease-free and overall survival and determine a patients treatment.  Recent work has 
demonstrated that gene expression profiles may also be used in prognostication.  A ‘poor 
prognosis’ profile has been developed that is indicative of a short time before developing 
metastases in lymph node negative patients.
68  Being able to identify the type of tumour a 
person is likely to develop may help select those patients that may benefit from adjuvant 
therapy and advise patients on prophylactic treatment.   29 
 
1.2.5.2 Tumour and Stroma 
The stroma (connective, functionally supportive framework) surrounding a tumour 
consists of many cell types and differs depending on the origin of the tumour.  Recent 
studies have shown that the cells in the stroma influence the process of tumourigenesis to 
varying degrees depending on the type of tumour (Section   1.2.5.5).
75   
As well as the neoplastic cells, the cellular microenvironment of a malignant tumour also 
contains a variety of non-neoplastic cellular elements such as adipocytes, fibroblasts, 
nerve cells, vascular cells (for example, lymph-endothelial, vascular-endothelial cells and 
pericytes) and large numbers of leukocytes involved in inflammation and immunity (for 
example lymphocytes (T-cells (helper, suppressor and cytotoxic), B cells, natural killer (NK) 
cells), dendritic cells, granulocytes, monocytes, and macrophages) surrounded by an 
extracellular matrix (Figure 7).
75-83  These non-neoplastic cellular elements, along with 
diffusible growth factors and cytokines, chemokines and other secreted molecules, make 
up the tumour stroma.  
58;84 
 
Figure 7: Diagram of the tumour stroma from Liotta and Kohn, 2001
77.  The tumour stroma is composed of 
many non-neoplasic cellular elements including immune cells and fibroblasts that may contribute to the 
metastastic potential of a tumour.   30 
 
The presence of immune cells in human tumours was first described
 in 1863 by Rudolf 
Virchow, who observed the presence of immune cells in neoplastic tissues and 
hypothesized that cancer originates at sites of previous chronic inflammation.  Over the 
past decade our understanding of the inflammatory microenvironment of malignant 
tissues has supported Virchow’s hypothesis and it is now recognized that cancers 
frequently arise in areas of chronic inflammation for example; colon carcinoma, which is 
associated with inflammatory bowel disease, stomach cancer following Helicobacter 
pylori infection and hepatocellular carcinomas after hepatitis C infection
85.   
Tumour stroma formation and wound healing have been shown to share many important 
properties
86 and tumours have been described as wounds that do not heal as wound 
healing is usually self limiting, but tumour cells and/or tumour associated leukocytes and 
platelets secrete several factors such as inflammatory cytokines, growth factors and 
chemokines that lead to a persistent immune response, for example by stimulating 
proliferation of epithelia and generating reactive oxygen species that can cause DNA 
damage
87 which may directly contribute to malignant progression
81 as well as influencing 
cancer initiation
84.      
As well as tumour-associated inflammatory cells arising from chronic inflammation, the 
malignant tumour cells can recruit vasculature and stroma through the production and 
secretion of stimulatory growth factors and cytokines
77;88 and the ‘activated’ stroma of the 
tumour microenvironment, consisting of several components including growth factors, 
other secreted molecules, fibroblasts and immune cells,  highly influences the behavior of 
tumour cells
77 critical to the overall survival of the cancer and, in many cases, is thought to 
enhance the tumour’s malignant capabilities.
89;90  An activated ‘metastatic tumour stroma’ 
is sufficient to convert non-metastatic cells to metastatic.
58 
It has been reported that inflammatory cells can account for as much as 50% of the total 
tumour mass
91 and up to 80% of the total cell mass in breast carcinoma.
83;92  31 
 
The metastatic potential of the tumour stroma is in part determined by macrophage and 
fibroblast secretion of matrix metalloproteinases, which initiate a cascade of events that 
contribute to activation of the stroma and chemokines (chemotactic proteins) and their 
associated receptors, which direct and modulate the cellular component of the 
stroma
58;93, therefore fibroblasts and macrophages play a significant role in breast cancer 
progression.   32 
 
1.2.5.3 Fibroblasts 
It has been demonstrated that several types of malignant cells, including breast and colon, 
actively recruit fibroblasts into tumours and, in fact, fibroblasts often represent the 
majority of the stromal cells within various types of human carcinomas, such as invasive 
breast cancer.
94  Recent studies have revealed that fibroblasts have a more profound 
influence on the development and progression of carcinomas than was previously 
appreciated,
84 however the specific contributions of these cells to tumour growth are 
poorly understood.
95 
It was initially believed that fibroblasts assumed a fairly passive role in breast cancer, 
responding to signals released from tumour cells, but recent evidence shows fibroblasts to 
play a far more active role in tumourigenesis
84 and are associated with cancer cells at all 
stages of cancer progression, being responsible for the synthesis, deposition and 
remodelling of much of the ECM in the tumour stroma, increasing the extent of 
extracellular matrix degradation (a prerequisite for invasion) and are a source of growth 
factors that influence the growth of carcinoma cells. 
84;96;97  It has long been known that 
these factors can be secreted by neoplastic cells, however it has become clear only in 
recent years that a major fraction is also produced by stromal fibroblasts.  The fibroblasts 
found in the tumour stroma are termed carcinoma-associated fibroblasts (CAFs) and have 
a different phenotype to normal fibroblasts.  There is substantial evidence that stromal 
fibroblasts from breast cancer are phenotypically distinct from those found in normal 
breast
98;99, with fibroblasts extracted from a number of invasive human breast carcinomas 
being more competent at promoting the growth of mammary carcinomas cells and 
tumour angiogenesis than comparable cells derived from outside of these tumour 
masses.
95   
Whereas normal fibroblasts at different anatomical sites have been shown to exhibit a 
considerable phenotypic and functional diversity
97, fibroblastic cells of the tumour stroma 
are less well characterized.
99   33 
 
Experiments have also shown orthotopic fibroblasts conferred morphogenic and 
mitogenic induction of breast cancer cells, while ectopic fibroblasts did not always affect 
the growth of breast cancer cells.
100  This has been supported by more recent work, with 
co-inoculation of breast cancer cells and breast fibroblasts having increased 
tumourigenicity and tumour size compared with inoculation of breast cancer cells 
alone
101.  The potent influence of organ-specific fibroblasts on epithelial morphogenesis 
and tumourigenesis may arise from the release of one or more soluble factors from 
orthotopic fibroblasts that exert more stimulatory activity upon cancer cells than factors 
from ectopic fibroblasts, playing a significant role in cell-cell regulation of cancer 
progression.    
The interaction of fibroblasts and tumour cells may also be crucial in promoting the 
tumourigenic process, for example the interaction of lung cancer cells and stroma 
fibroblasts promotes the expression of the angiogenic factor IL-8 both in cancer cells and 
in the stroma fibroblasts.
102    34 
 
1.2.5.4 Macrophages 
Macrophages are released from the bone marrow as immature monocytes which circulate 
in the blood stream before migrating into tissues where they undergo differentiation into 
resident macrophages.   The phenotype of these fully differentiated, resident 
macrophages can vary markedly within tissues, from that of microglial cells in the brain, 
Kupffer cells in the liver and Langerhans cells in the skin.
92;103  
Despite these organ specific differences, resident macrophages share a multitude of 
common functions.  They are vital for host defence, playing a fundamental role in immune 
and inflammatory responses, guarding against microbial infections and helping to repair 
sites of injury, as well as regulating normal cell turnover and tissue remodelling.
103;104   
Macrophages are pivotal members of the inflammatory infiltrate in the tumour stroma 
and represent a significant component of the leukocytic infiltrate closely associated with 
tumour cells seen in most, if not all, malignant tumours
79;81;83;104-107 including breast 
cancers.
92;108-110  It has been reported that macrophages can comprise 50% of the total 
mass of a tumour
108 and in invasive breast carcinomas, the neoplastic cell population is 
often outnumbered by stromal cells such as macrophages, which can constitute a large 
portion (up to 80%)
92 of the cell mass.
75;111  These macrophages are known as tumour-
associated macrophages (TAMs).    
There is still some controversy over whether the TAMs are derived from peripheral blood
 
monocytes recruited into the tumour from the local circulation,
 rather than resident 
macrophages present in the healthy tissue
 before tumour development.
79;112 Most TAMs 
are derived from peripheral blood monocytes recruited into the tumour mass from the 
circulation throughout the life span of the tumour
113, recruited by tumour derived 
chemokines (chemotactic cytokines) such as monocyte chemotactic protein-1 (MCP-1), 
colony stimulating factor-1 (CSF-1) and vascular endothelial growth factor (VEGF), 
81;83;103;105 however there is some evidence of local proliferation of macrophages.
92;114   35 
 
It was historically believed that macrophages found in tumours were part of an intrinsic 
defense mechanism, mounting an effective host anti-tumour response by producing anti-
tumour cytokines, stimulating the anti-tumour activity of T cells and destroying tumour 
cells
115;116  but it now appears that most components of the immune system are endowed 
with potential dual functions and macrophages are actually more likely to be recruited by 
the tumour cells to promote tumour phenotypes, such as angiogenesis, growth and 
invasion.
81;83;87;111;117-119 
TAMs exhibit a distinct phenotype which differs from that seen in macrophages in non-
malignant tissues.  This may be a consequence of their migration into tumour sites which 
exposes them to different microenvironmental signals that may regulate their localization 
and function
83 and  ‘‘educate’’ them to perform functions required by tumour cells in 
those areas.
103 
 The phenotype of TAMs has been described as relatively immature.  TAMs show a greatly 
reduced capacity to lyse tumour cells, present tumour-associated antigens to T cells and 
express immunostimulatory cytokines that stimulate the proliferation and antitumour 
functions of T cells and natural killer (NK) cells in vitro than macrophages derived from 
healthy or inflamed tissues.  This may be due in part to their exposure to tumour-derived 
molecules such as IL-4, IL-10 which may induce TAMs to develop into polarized type II 
(alternatively activated) or M2 macrophages, associated with poor antigen-presenting 
capability and production of factors that suppress T-cell proliferation and activity, and are 
generally better adapted to scavenging debris, promoting angiogenesis and repairing and 
remodelling wounded/damaged tissues than the classically activated type I or M1 
macrophages that are efficient immune effectors.
103;112  
Upon activation by tumour cells, TAMs release a wide array of growth factors, proteolytic 
enzymes (predominantly matrix metalloproteinases
58;111;120;121) and cytokines that modify 
the extracellular matrix (ECM) and play an important role in angiogenesis and 
vascularisation allowing proliferation, survival, cell invasion into surrounding normal 
tissues and metastasis to local and distant sites.
75;79;81;83;103-105;111;119;122-125 Therefore it is 36 
 
no surprise that the majority of studies published have identified a strong correlation 
between extensive TAM infiltration and a poor prognosis in a various forms of 
cancer
58;75;92;104;126;126;127 including carcinomas of the breast
105;109;128;129, ovaries, cervix and 
bladder, however there is conflicting evidence for their role in prostate, lung and brain 
tumours
92 inferring a clear role for macrophages in driving tumour progression.  In some 
cancers TAM numbers have been shown to be an independent prognostic factor.
92;103 
In breast cancer a high level of TAM infiltration has been associated with increased 
angiogenesis and increased involvement of local lymph nodes 
103;105;127;130, relapse free 
and overall survival
105;109, high tumour grade, large tumour size and tumour necrosis
131, 
high tumour grade and poor prognosis
109, promoting the progression of preinvasive 
mammary tumours to malignant lesions and increasing formation of lung metastases
110 
and also with a poor prognosis in invasive ductal tumours
129.  
Several of the actions of TAMs (promotion of angiogenesis, induction of tumour growth 
and enhancement of tumour cell migration and invasion) all contribute to the invasiveness 
and matrix-degrading activity of cancer cells
104 and this is by far the most common 
phenotype associated with TAM infiltration with many studies identifying a correlation 
between a high number of macrophages and the metastatic potential of a 
tumour.
83;105;110;132  TAMs seem to play roles in both the release of metastatic cells from 
the primary tumour as well as the establishment of secondary tumours at distant sites
103.   
Studies have shown that the increase in metastastatic potential resulting from high 
numbers of TAMs is MMP dependent with tumour-macrophage interactions inducing 
macrophages to release MMPs, supporting tumour cell invasion and leading to an 
increased invasive capacity of the tumour cell.
79  Expression of a panel of MMPs, MMP-7, -
9, -11, -13, -14, and their inhibitors, the tissue inhibitors of matrix metalloproteinase 
(TIMPs), TIMP-1 and -2, have been shown to characterise a phenotype of infiltrating 
macrophages associated with a poorer prognosis in breast cancer
91. In particular, MMP-9 
production by TAMs has been implicated with an increased malignant potential of 37 
 
tumours in several studies
81;104, for example promoting formation of lung
133;134, ovarian
135 
and brain metastases
60.
58 
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1.2.5.5 Role of the Microenvironment 
In the past decades the major focus of cancer research has been the transformed tumour 
cell itself
136;137, while the role of the cellular microenvironment in tumourigenesis has not 
been widely explored, however it is now beginning to be appreciated that interactions 
between the tumour and the host environment contribute to a state of malignancy. 
138 
The English surgeon Stephen Paget (1855–1926) is credited with being the first to suggest 
the key role played by the microenvironment in formation of metastasis proposing the 
‘seed and soil’ theory (1889), the concept of which has been supported and confirmed by 
numerous publications
61;139;140.   
Paget analysed autopsy records of 735 women with breast cancer and identified a non-
random pattern of metastasis to visceral organs and bones, suggesting that the process 
was not due to chance but rather that certain tumour cells had a specific affinity for the 
environment of certain organs.  Paget therefore proposed that the process of metastasis 
did not occur by chance, but rather that certain tumour cells with the ability to 
metastasise (the ‘seed’) had a special affinity for the growth-enhancing environment 
present within specific organs (the ‘soil’).  Paget concluded that the sites where 
metastases occur are defined not only by the tumour cell but also the microenvironment 
of the secondary metastatic site with metastases developing only when the seed and soil 
were compatible, that is, where the microenvironment of the tumour provided a ‘fertile 
soil’ for cells enabled with the ability to grow under the specific conditions provided by 
the soil, suggesting that the site of metastasis depended on the affinity of the tumour for 
the microenvironment.
141  
Stephen Paget’s theory fits with the current knowledge of tumourigenesis and the process 
of metastasis.  Tumours are biologically heterogeneous and contain subpopulations of 
cells with different angiogenic, invasive and metastatic properties.  Cells possessing the 
metastatic phenotype may represent a very small fraction of cells within a heterogeneous 
primary tumour.
139  The outcome of metastasis is dependent on multiple interactions of 39 
 
metastatic cells with homeostatic mechanisms and the cell’s ability to resist stresses that 
would otherwise impede metastasis. 
58;142   
Tumour cells leave the primary tumour through regulated lysis of surrounding stroma, 
pass through the tumour basement membrane and then through or between endothelial 
cells (invasion) in order to enter the circulation. While in the circulation, the tumour cells 
must resist the process of anoikis (programmed cell death associated with loss of cellular 
contact), evade immune recognition and cope with the sheer physical stress of the 
circulatory system.  Ultimately the metastasizing cells arrest in a distant capillary bed and 
extravasate (leave the circulation) into the organ parenchyma.
142  At the distant site the 
cell must survive the stresses of a new and likely hostile microenvironment, proliferate, 
induce angiogenesis and/or co-opt existing blood vessels and then successfully grow into a 
metastatic lesion.  
58;143  
Survival of metastatic cells at the secondary site, where the new microenvironment (the 
“soil”) encountered by the metastatic cell is considered to be foreign or inhospitable, may 
be a consequence of intrinsic features of the metastatic cell such as the ability to 
effectively engage in a molecular cross-talk with its surroundings, modulating the 
environment of the secondary site.  Aberrant expression of proteins by the tumour cell is 
thought to provide enhanced proliferative and survival capabilities
144-148 in the tumour 
cell’s new microenvironment,
58 for example, integrins, key mediators of cell–cell 
interactions, often have deregulated expression in tumour cells and may play a crucial role 
in this process
149;150.   
Successful metastatic cells that arrive at a secondary site in the body interact with cells in 
the microenvironment to modulate the secondary site, producing an environment that is 
conducive to survival of the metastatic cell.  Recent evidence has suggested that 
development of such an environment may happen even before the arrival of metastatic 
cells themselves via priming by bone marrow derived cells
58;151 or may even be related to 
the patient’s germline genetics and therefore precede primary tumour formation.
152  This 40 
 
links back to Paget’s hypothesis, suggesting that specific genetic determinants of the host 
(i.e. soil) contribute to the success of the metastatic process (i.e. seed).   
In summary, the work by several groups suggests that the risk for metastatic progression 
is in part defined by the genetics of the patient, genetic changes that develop early in the 
process of tumour development and the subsequent emergence of cells within the 
tumour that possess the cellular tools needed for metastasis.
58 
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1.3  Hypothesis Development 
This study is designed to investigate whether common genetic variants may have a 
functional significance in a large group of breast cancer affected women, i.e. 
predetermine breast cancer phenotype and/or prognosis, as well as statistical significance, 
i.e. determining risk.  This will help to understand susceptibility in young onset breast 
cancer cases and identify better ways to pick out high risk gene carriers.   
Identifying genetic variants that predict the type of breast cancer a woman may develop 
will be of significant benefit in advising risk management and directing adjuvant therapies, 
for example if a patient at risk of breast cancer was likely to get a particularly aggressive 
form of the disease, they may wish to have prophylactic treatment, such as mastectomy, 
whereas if they were likely to develop a less aggressive, oestrogen receptor positive 
cancer with low metastatic potential the patient may decide to have no prophylactic 
treatment and, if the cancer occurs, treat with Tamoxifen.  It will also be of use in 
determining who will respond to certain therapies and who will not.   
Several lines of evidence including the ethnic differences in tumour types,
153;154 specific 
subtypes of cancer seen with germline BRCA1 mutations
53 and the low penetrance 
variants like FGFR2
43, and the Scandinavian register study showing a worse prognosis for 
daughters who get breast cancer if their mothers had breast cancer and died compared 
with those whose mother had breast cancer and survived
30 suggest it is likely that genetic 
polymorphisms play a role in determining some of the biological features of the tumour, 
including invasiveness, metastatic potential and prognosis, as well as dictating the 
environment in which the tumour is growing which will also affect its growth and 
invasiveness.  Therefore this study was set up to investigate the association of common 
genetic variants in a range of candidate genes with the following prognostic phenotypes; 
grade, ER status, LN involvement, lymphovascular invasion and distant metastasis. 
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Chapter 2  Methods for Association Studies 
2.1  Overview 
To identify SNPs that might be associated with particular disease phenotypes, 30 
candidate genes were selected that had a biological reason for being of interest to study 
in relation to breast cancer.  After the 30 genes had been selected 260 SNPs were 
identified in these genes, some were previously reported, others were identified from 
genome databases or selected purely for their location within the gene to ensure 
coverage of the whole gene.  206 of these SNPs were genotyped successfully in our cohort 
of 1001 patients selected from the POSH study.  Patients were selected who had no 
significant family history of breast or ovarian cancer and where plenty of DNA was 
available.   
DNA for genotyping was extracted from whole blood samples and the DNA genotyped by 
Sequenom (San Diego, CA, USA) using the iPLEX service based on mass spectrometry.   
The genotype data was subjected to a screening procedure to remove poor quality data 
from the analysis and just over one third of all SNPs and 58 individuals were removed.  To 
avoid confounding due to population stratification, multidimensional scaling analysis was 
was carried out on the data to ensure only Caucasians were included in the final analysis.  
A further 44 samples, 35 African and 9 Asian, were excluded to leave only individuals of 
western European ancestry.    
The cases were then stratified into subgroups based on ER status (positive and negative), 
LN involvement (positive and negative), lymphovascular invasion (present or absent), 
distant metastasis (present and absent) and grade (grade one and grade three).  Grade is a 
subjective classification, and some grade 2 tumours might have a gene expression 
signature that is similar to tumours of grade 1 or 3
155 and a systematic expert review may 
lead some grade 2 cases to be reclassified into either grade 1 or grade 3 whereas grade 3 
and grade 1 are less often likely to move to grade 2 so, for clarity, we compared only the 
phenotypic extremes of grade 1 and grade 3 in this study.   43 
 
Associations of the SNPs passing QC with disease phenotypes were tested using the 
Cochran-Armitage trend test and 2-by-3 tables of disease by genotype using Plink
156, a 
whole genome analysis toolset.    
Associations of SNPs with prognosis were also investigated.  The mean follow up time for 
the patients in our study who passed quality control was 2.4 years so we used distant 
disease free survival times (taken as the time between initial diagnosis and the first distant 
metastasis) as a substitute for overall survival since the majority of patients developing 
distant metastases will ultimately die from the disease
157.   44 
 
2.2  Resources 
To perform the association studies, we used data from two openly available resources on 
the internet. 
2.2.1  UCSC 
The University of California Santa Cruz Genome Browser Database (UCSC)
158-160 is 
developed and maintained by the Genome Bioinformatics Group within the Center for 
Biomolecular Science and Engineering at the University of California Santa Cruz.  It is a 
genome browser website containing the reference sequences for a large collection of 
genomes.  The UCSC genome browser integrates the work of many scientists worldwide, 
including data from the MWG (Mammalian Gene Collection), RefSeq and Ensembl, in an 
interactive, graphical display that presents both experimentally validated and computer-
predicted genes as well as evidence to help scientists recognize key features of genes and 
predict their function. As of September 2009, genomic sequence and a basic set of 
annotation ‘tracks’ (known genes, predicted genes, ESTs, mRNAs, CpG islands, assembly 
gaps and coverage, chromosomal bands, mouse homologies) were provided for 47 
organisms.   
The UCSC site also provides links to many off-site repositories such as PubMed, GenBank, 
Entrez and OMIM.   
The Genome Browser, other tools, downloadable data files and links to documentation 
and other information can be found at http://genome.ucsc.edu/. 
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2.2.2  HapMap 
The International HapMap project
20;161-163 is a large collaboration among scientists and 
funding agencies from Japan, the United Kingdom, Canada, China, Nigeria, and the United 
States.  It began in 2002 to identify and catalogue common genetic variants occurring in 
humans.  
It gives information about these variations, including their location in the genome and 
distribution among populations from different countries.  
The Information collected by the HapMap project can be used by researchers to identify 
links between genes and common diseases as well as individual responses to medications 
and environmental factors. 
Data from four different populations with different ancestry are being collected: 
•  Yoruba in Imbadan, Nigeria (YRI) – African 
•  Japanese in Tokyo, Japan (JPT) - Asian 
•  Han Chinese in Beijing, China (CHB) – Asian 
•  Utah residents with ancestry from northern and western Europe (data provided by 
the Centre d'Etude du Polymorphisme Humain (CEPH)) (CEU) – Caucasian  
The DNA samples for the HapMap have come from 270 people, 30 sets of samples (two 
parents and an adult child, each set called a trio) from the Yoruba people of Ibadan, 30 
trios from U.S. residents with northern and western European ancestry, 45 unrelated 
individuals from Tokyo, Japan, and 45 unrelated individuals from Beijing, China.   46 
 
2.2.3  Plink 
The statistical analysis was carried out using the analysis software PLINK
156.   PLINK is a 
free, open-source, whole genome association analysis toolset developed by Shaun Purcell 
at the Center for Human Genetic Research (CHGR), Massachusetts General Hospital 
(MGH) and the Broad Institute of Harvard & MIT, with the support of others.  It is 
designed to perform a range of basic, large-scale analyses in a computationally efficient 
manner. The focus of PLINK is purely on analysis of genotype/phenotype data.  The 
statistical analysis was performed using SPSS version 17.   47 
 
2.3  Gene Selection 
Many genes have been implicated as potential candidates for breast cancer susceptibility.  
We selected 30 genes that were either potential candidate genes or contained SNPs that 
had previously been reported to have an association with breast cancer susceptibility.  
One SNP selected was a previously reported SNP found in a gene desert
21.   
These 30 genes can be broadly divided into different categories based on their function, 
however some may fall into more than one category, for example BRCA1 is involved in 
DNA replication and repair but, due to its impact on the cell cycle, is also known as a 
tumour suppressor.   
The following section details the categories of genes we selected and evidence implicating 
the particular genes in breast cancer.   
2.3.1  Transcription Factors 
Transcription factors are proteins that bind to specific DNA sequences and regulate the 
transcription of DNA to mRNA.  They act by increasing (activators) or decreasing 
(repressors) the binding of RNA Polymerase to specific genes.  Transcription factors can 
act by themselves or as part of a complex with other proteins.   
Genes encoding three members of the nuclear receptor superfamily, the androgen 
receptor, progesterone receptor and oestrogen receptor alpha were all chosen along with 
three additional transcription factor-encoding genes GATA3, TOX3 and TWIST.   
2.3.1.1 Androgen Receptor (AR) 
The androgen receptor, alternatively known as the dihydrotestosterone receptor, is a 
steroid hormone receptor.  It is activated by the binding of the androgenic hormones 
testosterone or dihydrotestosterone.  It is a member of the nuclear receptor superfamily 
and functions as a ligand activated transcription factor regulating gene expression.   48 
 
Nantermet et al
164 found that AR modulates the expression of genes involved in 
proliferation and differentiation, repressing expression of several key cell cycle inhibitors 
while modulating members of the Wnt and Notch signalling pathways, multiple growth 
factors, peptide hormone signalling systems and genes involved in MAP kinase and 
calcium signalling.  
There is evidence that androgens directly stimulate growth of human breast cancer cell 
lines
165.  ARs are expressed in approximately 70%-90% of invasive breast cancers, 
comparable with or higher than the frequency for ER (70%-80%) or PGR (50%-70%)
166-168.  
ARs are the sex hormone receptors found most frequently in both primary and secondary 
breast cancer and in metastatic tissues are present with twice the frequency of PGR, with 
one in four of these tumours expressing only AR
169.  There is evidence indicating steroids 
can upregulate MMPs, contributing to invasiveness of the tumour via degradation of the 
basement membrane and extracellular matrix
170.  A few studies have investigated the 
effect of AR expression on breast cancer prognosis but most studies have found no 
significant associations
166;171;172, however a specific value of AR expression has been 
shown to be a prognostic indicator in breast cancer although the functional role of AR in 
these neoplasms is still unclear.
173   
Many polymorphisms have been identified in the AR in prostate cancer
174 but have not 
been extensively investigated in relation to breast cancer, however long repeat lengths of 
the CAG repeat length polymorphism in exon 1 of the AR gene have been associated with 
a decreased ability to activate androgen responsive genes and a decreased age at 
diagnosis in BRCA1 mutation carriers, suggesting pathways involving androgen signalling 
may affect the risk of BRCA1-associated breast cancer.
175   
2.3.1.2 Progesterone Receptor (PGR) 
The progesterone receptor is a member of the steroid receptor superfamily and exists as 
two functionally distinct isoforms, PRA and PRB.  Hopp et al
176 indicated that PRA rich 
breast tumours have a heightened aggressiveness.  Leygue et al
177 identified several 49 
 
variants in the PGR in breast cancer, mainly exon deletions but the significance of these 
variants is unknown.  Yeates et al
178 identified a truncated PGR protein, found in breast 
cancers, that is ligand binding and seems to be derived from PRA.  De Vivo et al
179 
identified variants in the PR gene that may predispose to endometrial cancer.  One 
promoter region polymorphism, +331G>A, created a unique transcription start site, 
increasing transcription of the PGR gene and favouring production of the PRB isoform.   
2.3.1.3 Oestrogen  Receptor Alpha (ESR1) 
The gene ESR1 encodes the oestrogen receptor ERα which belongs to a family of 
transcription factors known as the nuclear receptor superfamily.  These receptors are 
responsible for mediating the effects of steroids on development, reproduction, 
proliferation, cellular homeostasis and gene expression.  In particular, the oestrogen 
receptor has a role in the growth, differentiation and function of the normal breast, 
therefore makes a good candidate gene for breast cancer susceptibility.  Many early 
studies reported that certain ESR1 variants were more common in breast cancer affected 
patients than in controls
180-182.  Previously associated variants include 478G>T 
(Gly160Cys)
181, 908A>G (Lys303Arg)
183 and 975C>G (common synonymous SNP in exon 4, 
rs18011132)
182;184, however Schubert et al
185 investigated these and seven other ESR1 
polymorphisms and found that inherited genetic variation is not a mechanism by which 
the oestrogen receptor is commonly involved in breast cancer development
185.  The best 
characterized SNPs in the ERS1 gene are the PvuII and XbaI restriction site polymorphisms.  
The polymorphisms, c454-397T→C (rs2234693) and c454-351A→G (rs9340799), are 397 
and 351 bp upstream of exon 2 and have been described by the name of detecting 
restriction enzyme, PvuII or XbaI respectively
186;187.  These SNPs are in strong linkage 
disequilibrium.  Boyapati et al
188 reported no overall association of these SNPs with breast 
cancer survival but the CC genotype of the PvuII polymorphism had a worse prognosis in 
ER-ve breast cancer patients.  Rapuri et al
189 found that women with either the CC or GG 
genotype had lower bone remodelling, lower rates of bone loss and had more beneficial 
effects from hormone therapy in postmenopausal women and Van Duijnhoven et al
190 
found that these polymorphisms were associated with an increase in mammographic 50 
 
density, a strong risk factor for breast cancer, and that these polymorphisms are 
associated with an increased susceptibility to the effects of hormone therapy on 
mammographic density
191.  
2.3.1.4 GATA Binding Protein 3 (GATA3) 
GATA3 encodes a transcription factor, belonging to a family of at least six members, 
however its function remains largely unknown.  The GATA proteins play critical roles in 
development, including cell fate specification, regulation of differentiation and control of 
cell proliferation and movement.  Hoch et al
192 first described the correlation in expression 
between GATA3 and oestrogen receptor status, and proposed that GATA3 is likely to 
regulate a set of genes involved in the hormone responsive phenotype.  GATA3 negative 
tumours have an eight fold higher risk of being unresponsive to hormone treatment when 
compared to GATA3 positive tumours
193. GATA3 is highly expressed by luminal epithelial 
cells in the breast
194 and has been found to have low expression in invasive carcinomas 
with a poor clinical outcome (higher histological grade, positive lymph node status, larger 
tumour size, ER and PR negative and ERBB2 positive as well as a shorter disease free and 
overall survival)
194.   High levels of GATA3 have been found in the luminal A subtype of 
breast cancer that is associated with oestrogen receptor expression and a favourable 
prognosis
67;68;192;195;196.  Usary et al
196 suggested that loss of GATA3 contributes to 
tumourigenesis in oestrogen receptor positive breast cancers.   
2.3.1.5 TOX3 
TOX3 (TNRC9) is a member of the high mobility group family of non-histone chromatin 
proteins, a large and diverse family of HMG-box proteins that function as architectural 
factors in the modification of chromatin structure by bending and unwinding DNA.    
Increased expression of TOX3 has already been associated with bone metastasis of breast 
cancer
197.  Smid et al
198 found that TOX3 was one of 69 genes that was differentially 
expressed in patients who experienced breast cancer relapse to bone versus those who 
experienced relapse elsewhere in the body.  Several SNPs in TOX3 have been investigated 51 
 
in relation to breast cancer.  Three TOX3 SNPs (rs12443621, rs8051542 and rs3803662) 
that are in strong linkage disequilibrium were identified as having a significant association 
with breast cancer risk.
21  The association between rs3803662 and breast cancer risk was 
not confirmed by Huijts et al
199, however they found that the minor allele of rs3803662 
was associated with a younger age of onset but this difference was not significant.  Huijts 
et al also found that the SNP rs12443621 was significantly more often negative for the 
progesterone receptor and the minor allele of SNP rs12443621 was significantly 
associated with a lower body mass index.   
2.3.1.6 TWIST1 
The TWIST gene encodes a basic helix-loop-helix transcription factor.  It has been shown 
to play a role in halting differentiation, inhibiting apoptosis and interfering with the p53 
tumour-suppressor pathway.
200 Mutations in this gene have been found in patients with 
Saethre-Chotzen syndrome, an autosomal dominantly inherited craniosynostosis 
(premature closure of one or more cranial sutures).  Sahlin et al
201 studied Saethre-
Chotzen affected women and found a novel association with this syndrome and breast 
cancer, indicating TWIST 1 may be a novel breast cancer susceptibility gene.  Since then 
Martin et al
202 found that TWIST is inappropriately expressed in breast cancer and may 
play a part in the progression of human breast tumours.  It has been shown to play an 
essential role in metastasis
203 and high expression levels are associated with invasive 
lobular carcinoma, a highly infiltrating tumour type.
203  Mironchik et al
204 demonstrated 
that TWIST overexpression in breast cancer cells can induce angiogenesis, correlates with 
chromosomal instability and promotes epithelial-mesenchymal-like transition that is 
pivotal for the transformation into an aggressive breast cancer phenotype. 
2.3.2  Growth Factors 
Growth factors are naturally occurring proteins or steroid hormones that are capable of 
stimulating a variety of cellular processes including cellular growth, proliferation and 
cellular differentiation.  Growth factors act as signalling molecules between cells, binding 
to cell surface receptors.  Many growth factors are quite versatile, stimulating cellular 52 
 
division in numerous different cell types; while others are specific to a particular cell-type, 
for example, bone morphogenic proteins stimulate bone cell differentiation while 
fibroblast growth factors and vascular endothelial growth factors stimulate blood vessel 
differentiation (angiogenesis).  Therefore mutations in growth factors or their receptors 
may contribute to excessive growth or proliferation of cells and may influence the growth 
rate of some cancers.  
2.3.2.1 Mitogen Activated Protein Kinase Kinase Kinase 1/MEK kinase 1 
(MAP3K1) 
MAP3K1 is a serine threonine kinase that is activated by many apoptotic stimuli and 
induces apoptosis.
205-207  Deng et al
208 found that MAP3K1 transmits signals leading to the 
transcriptional activation of genes that are involved in cell migration.  A SNP in MAP3K1 
(rs889312) has been identified as having a significant association with familial breast 
cancer risk in a genome wide association study
21 and Huijts et al
199 found that patients 
carrying one or two minor alleles of the rs889312 SNP were less likely to have lymph node 
positive breast cancer than those with no copies of the minor allele.   
2.3.2.2 Fibroblast Growth Factor Receptor 2 (FGFR2) 
FGFR2, a member of the fibroblast growth factor family, is a receptor with tyrosine kinase 
activity.  Activation of the receptor can induce cell migration, proliferation and 
differentiation, and can also stimulate angiogenesis.  FGFR2 can acquire transforming 
potential through gene amplification, protein over-expression and/or mutations, leading 
to a subsequent activation and aberrant downstream signalling.  It has previously been 
shown to be important in mammary gland development and neoplasia
209 and its 
amplification or over expression has been identified in breast cancer
210.  Two recent 
genome wide studies have identified SNPs in FGFR2 that have an association with breast 
cancer.  Hunter et al
40 identified four SNPs (likely in high LD due to their similar degree of 
association) in intron 2 of FGFR2 that were significantly associated with breast cancer 
(rs11200014, rs2981579, 1219648, rs2420946) Easton et al also identified rs2981582 as a 
susceptibility allele in breast cancer.
21  Huijts et al
199 investigated the association of the 53 
 
seven significant polymorphisms identified by Easton et al
21 with breast cancer 
characteristics in a Dutch cohort and found that FGFR2 was associated with a positive 
family history of breast and/or ovarian cancer.  FGFR2 rs1219648 and 
rs2981582
 genotypes were significantly associated with breast cancer in
 European-
American women with oestrogen receptor-positive (ER+), progesterone receptor-
positive
 (PR+) and HER2/Neu-negative (HER2–) tumours
211. 
2.3.2.3 ERBB2 
The ERBB2 gene, also known as HER-2 or neu, encodes a member of the epidermal growth 
factor receptor family of tyrosine kinases.  ERBB2 has no ligand binding domain of its own 
but forms heterodimers with other members of the EGF receptor family and enhances the 
kinase mediated activation of downstream signalling pathways, for example those 
involving mitogen activated protein kinase (MAPK) and phosphatidylinositol-3 kinase 
(PI3K).  Its amplification and/or overexpression has been reported in numerous cancers 
including breast and ovarian tumours
212;213.  In a population based case control study Xie 
et al
214 found that the valine allele of the val655ile polymorphism (rs1136201) was 
associated with an increased risk of breast cancer, particularly among younger women.  
The frequency of this allele was found to vary between different ethnic groups
215.   
2.3.2.4 Vascular Endothelial Growth Factor (VEGF) 
VEGF is an endothelial cell-specific mitogen that induces angiogenesis.  The formation of 
new blood vessels (neovascularisation) is needed by solid tumours in order to supply its 
metabolic demands and to provide potential routes for tumour dissemination and 
metastasis
216;217 and therefore plays a crucial role in the progression of cancer.  There is 
variability in the angiogenic profiles of tumours and it has been suggested that some of 
this variability could result from germline mutations in genes controlling angiogenesis
218 
and since pre-invasive and invasive tumours vary significantly in their angiogenic 
requirements, some women may be genetically predisposed to an invasive breast cancer 
phenotype
219.  Individuals with more significant angiogenic profiles have been shown to 
have a greater risk of breast cancer
220 and breast cancers of those with a more significant 54 
 
angiogenic profile are more likely to be histologically aggressive
221;222 and have a greater 
likelihood of metastatic disease.
223   
Several studies have investigated the association of VEGF polymorphisms with breast 
cancer risk but have had inconsistent results.  SNPs that have been investigated include 
936C/T (rs3025039), -1154G/A, -2578C/A, -634G/C (rs699947), -2489C>T, -1498C>T, -
7C>T, C-460T (promoter, rs83306), G+405C (5’UTR,rs2010963) and C+936T (3’UTR) C-406T 
and G+450C, 1612G>A
219;224-230.   
2.3.2.5 Insulin-Like Growth Factor 1 (IGF-1) 
IGF-1 has been implicated in breast cancer because of its role in stimulating mitogenesis 
and promoting differentiation as well as mammary gland cell proliferation and survival
231.  
Oestrogen plays a role in the aetiology of breast cancer and both regulates the IGF family 
and is itself influenced by the IGF family.  Results of studies investigating the association of 
IGF-1 with breast cancer have been inconsistent.
232-235  Several studies have investigated 
the effects of SNPs in IGF-1 on breast cancer risk.    The SNPs rs1520220 and rs2946834 
have been associated with mammographic density, one of the strongest risk factors for 
breast cancer
236. Canzian et al
237 identified a small but significant association between 
polymorphisms at the 5’ end of the IGF-1 (rs21262679, rs35765 and rs35767) gene and 
breast cancer risk, especially in younger women, and a UK case-control study of 4647 
cases and 4564 controls investigating the effects of nine SNPs in the IGF-1 gene and 
circulating IGF-1 levels and breast cancer risk found the tag SNP rs1520220 had the most 
significant association with IGF-1 levels, however it was suggested that rs6220 in the 
3’UTR region of the gene was most likely the causative SNP
238.   
2.3.3  Cytokines 
Cytokines are a diverse class of powerful signalling proteins that are used extensively in 
cellular communication, immune function and embryogenesis.  They are released from 
inflammatory tissue, connective tissue and immune system cells and act by autocrine (on 
the cell that released them) and paracrine (on another cell) mechanisms.  More than 50 55 
 
cytokines have been identified and the cytokine superfamily includes interleukins, 
chemokines, colony-stimulating factors, growth factors, interferons and the transforming 
growth factor and tumour necrosis factor families.  The cytokine network is complex and 
not yet fully understood, however it is clear they are important pathophysiological 
mediators and are implicated in the pathogenesis of numerous disease states.   
The terms growth factor and cytokine are sometimes used interchangeably.  Historically, 
cytokines were associated with haematopoietic (blood forming) cells and immune system 
cells (e.g., lymphocytes and tissue cells from spleen, thymus and lymph nodes), however it 
is now known that some of the same signalling proteins that the haematopoietic and 
immune systems use are also used by many other cells and tissues during development 
and in the mature organism.  
The cytokines involved in immune and inflammatory responses (interferon, interleukins, 
and TNF-alpha) are produced mainly from lymphocytes (lymphokines) and macrophages 
(monokines) but also from other leukocytes, endothelial cells and fibroblasts.  Cytokines 
act on high affinity receptors on the target cell.  Many of the lymphokines are also known 
as interleukins (ILs), since they are not only secreted by leukocytes but also able to affect 
the cellular responses of leukocytes. Specifically, interleukins are growth factors targeted 
to cells of haematopoietic origin.  
2.3.3.1 Interleukin-6 (IL-6) 
IL-6 is a pleiotropic proinflammatory cytokine involved in various physiological and 
pathophysiological processes in the body, including inflammation, bone metabolism and 
carcinogenesis.  IL-6 has been shown to have antiadhesive effects
239 and may increase the 
activity of 17-β- hydroxysteroid dehydrogenase which converts oestrone to oestradiol, 
which may in turn increase the concentration of oestradiol around breast tumours.
240  
Several studies have associated the presence of IL-6 with breast cancer.  Elevated serum 
levels have been found to be independent prognostic factors in breast cancer with 
increased IL-6 levels being associated with advanced stage disease and a worse 56 
 
prognosis
241-244 and it is one of several genes overexpressed in the ‘poor prognosis 
signature’ of inflammatory breast cancer.
245  In contrast IL-6 inhibits growth of breast 
cancer cell lines
246 and high levels of expression of IL-6 mRNA and protein have been 
associated with a better prognosis and less malignant breast cancer phenotype.
247-249  
Polymorphisms in the IL-6 promoter region have been studied extensively with 
inconsistent results.  The SNPs -572G>C and -174G>C have both been associated with 
breast cancer
250 and -174G>C (rs1800795), shown to influence protein expression rates in 
vivo by decreasing the rate of transcription
251;252, has been associated with an increased 
risk of breast cancer
253 and a more aggressive phenotype.
254. In contrast, the -174G>C SNP 
has been linked with an earlier stage of disease and significantly better survival in ovarian 
cancer
255, an improved outcome in high risk breast cancer
256 and has been shown to have 
no effect on breast cancer risk or severity
257. Patients who are exposed to over ten hours 
of passive smoke a week and have the IL-6 SNP rs2069832 have a four fold increase in risk 
of breast cancer.
258 
2.3.3.2 Transforming Growth Factor Beta (TGFB) 
TGFB is a multifunctional cytokine, regulating proliferation and differentiation in many 
different cell types, acting as a negative autocrine growth factor.  Dysregulation of TGFB 
activation and signalling may lead to apoptosis.  Upregulation of TGFB has been found in 
tumour cells.
259  Grainger et al
260 identified two polymorphisms in the promoter region, -
800G>A and -509C>T.  The -509C>T polymorphism (rs1800469) was found to be 
significantly associated with plasma concentrations of TGFB1, suggesting that 
predisposition to various diseases, including some forms of cancer, may be correlated with 
the presence of particular alleles at the TGFB1 locus.  TGFB has been studied in relation to 
breast cancer.  The activated TGFBR1 (TGF beta type 1 receptor) has been implicated in 
the formation of lung metastases, while impairing ERBB2 induced tumour growth.
261  
Dunning et al
262 found that the promoter SNP C-509T and the T+29C signal peptide SNP 
(encoding Leu10Pro), in strong linkage disequilibrium, were significantly associated with 
increased incidence of invasive breast cancer.  The C-509T SNP is not in a known 
consensus sequence for a promoter regulatory element so is unlikely to affect TGFB1 57 
 
expression whereas the Leu10Pro signal peptide substitution may potentially effect TGFB1 
secretion so it is likely it is this SNP having the effect, rather than C-509T and the L10P SNP 
(rs1982073) was also associated with risk of invasive breast cancer based on data 
contributed to the Breast Cancer Association Consortium, however this significant 
association was confined to patients with progesterone receptor negative tumours.
38   
2.3.3.3 Tumour Necrosis Factor Alpha (TNFA) 
The TNFA gene encodes a proinflammatory cytokine belonging to the TNF superfamily and 
is a major mediator of inflammation involved in regulating many biological processes 
including cell differentiation, proliferation and apoptosis.  Dysregulation and 
overproduction of TNFA have been implicated in a variety of human diseases including 
cancer.  When chronically produced, TNFA may act as an endogenous tumour promoter, 
contributing to the tissue remodelling and stromal development necessary for tumour 
growth and spread.
81  Overexpression of TNF confers invasive properties on some tumour 
cell lines.
263  In breast cancer, infiltrating macrophages are a major source of TNF, which 
may regulate an angiogenic enzyme in the tumour epithelium.
264     
The TNFA gene is a candidate predisposing gene, however its location within the MHC, a 
highly polymorphic region encoding numerous genes involved in immunological 
responses, makes its association difficult to study.
265 
2.3.4  Tumour Suppressors 
A tumour suppressor gene, or anti-oncogene, is a gene whose product reduces the 
probability that a cell in a multicellular organism will turn into a tumour cell.  If a tumour 
suppressor gene becomes mutated causing a loss or reduction in its function it can 
contribute to the development of cancer.  This usually occurs in combination with other 
genetic changes.  The proteins coded for by the tumour suppressor genes may act through 
a variety of mechanisms.  They may have a repressive effect on genes essential for the 
continuing of the cell cycle, couple the cell cycle to DNA damage in the cell or promote 
apoptosis if DNA damage cannot be repaired.  Some cell adhesion proteins may prevent 58 
 
tumour cells from dispersing by promoting contact inhibition, consequently loss of contact 
inhibition will promote metastasis of tumour cells.   
2.3.4.1 Tumour Suppressor Protein p53 (TP53) 
TP53 is the gene encoding the tumour suppressor p53.  p53 mediates cell growth arrest, 
senescence and apoptosis in response to DNA damage, chemotherapeutic drugs, UV light, 
hypoxia and aberrant growth (signals from oncoproteins) by blocking progression through 
the cell cycle.  Therefore polymorphisms in this gene are good candidates for genetic 
susceptibility to breast cancer.  The role of TP53 mutations in carcinogenesis is shown by 
the high incidence of early onset cancers, including breast cancer, in patients with Li-
Fraumeni Syndrome, a rare familial disease resulting from germline mutations in the TP53 
gene.  TP53 is mutated or deleted in many types of tumour
266;267 and is the most 
commonly mutated tumour suppressor gene in human cancers
268 suggesting it has a 
crucial role in the carcinogenesis of many tumours.  Mutated p53 is found in 
approximately 20% of all breast tumours
269 and inactivating mutations in the TP53 gene 
cause a loss in negative regulation on growth and proliferation, giving rise to an increase 
in cell proliferation.  One SNP, R72P (rs1042522) in exon 4 of the gene appears to have a 
significant association with the risk of breast cancer
270 and has frequently been studied 
and has been suggested as a prognostic marker in breast cancer
271;272 and associated with 
low grade histology.
273  However a recent pooled analysis by the Breast Cancer 
Association Consortium (BCAC) found strong evidence against there being an association 
between the R72P SNP and breast cancer.
39   
2.3.4.2 Mouse Double Minute-2 (MDM2) 
The human homologue of the mouse double minute 2 gene is a nuclear phosphoprotein 
that acts as a negative regulator of p53, by binding p53 and inhibiting p53 dependant 
transcription, and can enhance its degradation.  It has p53-independent effects on DNA 
double strand break repair.
274-276  MDM2 has been shown to be upregulated in 
approximately 40% of breast cancers.  
277  One well studied SNP in MDM2 is the SNP 
IVS1+309 (rs2279744).  This SNP is in the intronic promoter of MDM2 that is utilized by 59 
 
both the p53 and ras pathways to activate MDM2 transcription. This SNP was first 
analysed by Bond et al
278;279who found this SNP was associated with the early onset of 
different cancers.  The minor allele of this SNP was shown to have an increased affinity for 
Sp1, a transcriptional activator, causing an increase in MDM2 transcription and therefore 
higher levels of the MDM2 protein and increased inhibition of p53 followed by a 
subsequent acceleration in tumour formation.  Boersma et al found that there was a 
strong association between this SNP and the p53 status of a tumour which appears to 
modify the association between p53 status and breast cancer survival.
280  In contrast to 
this, Milikan et al
281 conducted a population based case-control study of African-
Americans and Whites in North Carolina and found that there was no association with this 
SNP and breast cancer risk, as did Ma et al
282 who investigated this SNP in a Chinese 
population and Wilkening et al found that this SNP alone did not have any effect on the 
risk or the age of onset of inherited breast cancer.
283 
2.3.5  DNA Replication and Repair 
DNA damage can occur through both normal metabolic activities and environmental 
factors such as UV light and radiation resulting in as many as 1 million individual molecular 
lesions per cell per day. The damage to the DNA molecule may alter or abolish the cell's 
ability to transcribe the gene that the affected DNA encodes or induce potentially harmful 
mutations in the cell's genome, which may affect the survival of its daughter cells after it 
undergoes mitosis.  DNA damage may also occur through mistakes in replication.  Most 
DNA replicates with fairly high fidelity, however mistakes do occur, with polymerase 
enzymes sometimes inserting the wrong nucleotide or too many or too few nucleotides 
into a sequence during replication.  Most of these errors are fixed through various DNA 
repair processes with repair enzymes recognizing structural imperfections between 
improperly paired nucleotides and excise the incorrect bases and put the correct bases 
back in their place. Some replication errors make it past these mechanisms and become 
permanent mutations.  Therefore the DNA repair process is crucial to maintaining the 
integrity of the genome and when normal repair processes fail and apoptosis does not 60 
 
occur, irreparable DNA damage may occur.  If the genes encoding the DNA repair enzymes 
themselves become mutated, mistakes begin accumulating at a much higher rate and can 
lead to cancer.   
Inherited mutations that affect DNA repair genes are strongly associated with high cancer 
risks in humans, for example hereditary nonpolyposis colorectal cancer (HNPCC) is 
strongly associated with specific mutations in the DNA mismatch repair pathway and 
mutations in BRCA1 and BRCA2, both associated with a large number of DNA repair 
pathways, confer an increased risk of breast cancer.   
BRCA1 regulates the cell cycle by keeping cells from growing and dividing too rapidly or in 
an uncontrolled way.  The protein made by the BRCA1 gene is directly involved in the 
repair of damaged DNA through interaction with the protein produced by the RAD51 gene 
in the nucleus of many cell types to mend breaks in DNA.   
2.3.5.1 Ataxia Telangiectasia Mutated Gene (ATM) 
ATM plays a crucial role in maintaining the integrity of the genome.  It is activated in 
response to DNA double strand breaks caused by ionising radiation.  Once activated it 
triggers the phosphorylation of various proteins promoting cell cycle arrest and activating 
repair of the damaged DNA.  It is mutated in a rare, recessive disorder, Ataxia 
Telangiectasia, which is characterised by progressive neurodegeneration, cell cycle check 
point defects, radiosensitivity and an increased predisposition to cancer.
284-288  There is an 
increased risk of breast cancer in relatives of patients with Ataxia Telangiectasia (AT)
284;289 
and mutations in the ATM gene may cause an increased risk of developing tumours with a 
poor prognosis.
290  Several SNPs in ATM, including rs1800054 (S49C) and rs1800056 
(F858L), have been shown to be associated with breast cancer susceptibility
291, however 
results are contradictory.
292-294  This may be because the many common variants that are 
found in the ATM gene have only a small increase in risk of breast cancer which is not 
detectable in most case control studies due to small sample size.
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2.3.5.2 BRCA1 
The BRCA1 gene encodes a nuclear phosphoprotein that plays a role in maintaining 
genomic stability.
296  It acts as a transcription factor and plays a role in DNA repair of 
double strand breaks and recombination.
297  Mutations in the BRCA gene are responsible 
for approximately 40% of inherited breast cancers and more than 80% of breast and 
ovarian cancers.  It has been indicated that BRCA1 may normally serve as a negative 
regulator of mammary epithelial cell growth and that this function is compromised in 
breast cancer either by direct mutation or by alterations in gene expression.
298  Several 
SNPs have been identified in BRCA1 that alter susceptibility to both breast and ovarian 
cancer.
299-301 
2.3.6  Metabolising Genes 
Metabolism is a term used to describe all the chemical processes occurring within cells. 
Some of these reactions involve the synthesis of larger molecules from smaller ones 
(anabolism) and some involve the breakdown of larger molecules into simpler ones 
(catabolism) and are aided by a complicated network of enzyme- catalyzed reactions that 
occurs in cells.  
Several breast cancer risk factors are thought to act by influencing lifetime exposure to 
steroid hormones, for example age at menarche, age at menopause, postmenopausal 
obesity and postmenopausal hormone use which all influence the dose and duration of 
oestrogen and progesterone exposure.  Endogenous steroid hormones exert growth-
promoting effects and induce breast cell proliferation by binding to intracellular receptors 
and regulating gene transcription and are therefore important in the development and 
progression of breast cancer.  Oestrogens are metabolized by a number of oxidative and 
conjugate reactions that lead to their deactivation and subsequent elimination and 
inherited alterations in the activity of any of these enzymes hold the potential to define 
differences in breast cancer risk associated with oestrogen carcinogenesis. 62 
 
Alcohol intake is also associated with increased breast cancer risk.  Ethanol is mainly 
oxidised in the liver by alcohol dehydrogenases to acetaldehyde, a weak mutagen, and is 
further detoxified to acetate by aldehyde dehydrogenases.  The metabolism of ethanol 
also releases reactive oxygen species that may induce oxidative damage.  Alcohol 
interferes with oestrogen pathways in multiple ways, influencing hormone levels and 
effects on the oestrogen receptors.  Functional variants in genes involved in alcohol 
metabolism result in differences between individuals in exposure to carcinogenic 
acetaldehyde, suggesting a possible interaction of genetic susceptibility and alcohol 
exposure in cancer.
302;303 
2.3.6.1 Cytochrome P450 1B1 (CYP1B1) 
CYP1B1, a monoxygenase, is a major enzyme catalysing the hydroxylation of oestrogens 
into the genotoxic catechol oestrogen 4-hydroxy-oestradiol, which has been shown to 
induce uterine adenocarcinoma
304 and can generate potentially mutagenic free radicals 
that induce single strand breaks in DNA.
305  CYP1B1 is expressed in various tissues in the 
body, but expression is particularly high in the breast, supporting a role in hormone 
mediated breast cancer
306  and is genetically polymorphic, which may account for some of 
the genetic susceptibility to breast cancer risk.
307  For example the Val432Leu (rs1056836) 
polymorphism, which has been associated with oestrogen mediated carcinogenicity, 
having a decreased catalytic efficiency for 4-hydroxylation of oestradiol as well as 
alterations in enzymic activity towards various other mammary carcinogens.
308-310  This 
SNP has also been associated with oestrogen receptor positive breast cancer in Caucasian 
patients
311, breast cancer susceptibility in Turkish women, especially those with a BMI 
(body mass index) greater than 24kg/m
2 312 and a higher risk of breast cancer in smokers 
with the Valine allele.
313;314  In contrast, there have been several studies that have 
reported no significant associations of CYP1B1 polymorphisms and breast cancer
306;311;315 
including a large Swedish case control study.
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2.3.6.2 Alcohol Dehydrogenase-1B (ADH1B) 
Epidemiological studies have identified alcohol consumption as a risk factor for breast 
cancer
317-320.  The first step in the detoxification of ethanol is oxidation and this can 
contribute to oxidative cellular and DNA damage, which can contribute to 
carcinogenesis
321 and its metabolism results in the production of an acetaldehyde, a 
reactive electrophile that can act as a weak mutagen and carcinogen
322.  Alcohol is 
metabolised by several mechanisms, one of which involves ADH, alcohol dehydrogenase, 
which is expressed in the mammary epithelium and its expression is significantly reduced 
in invasive breast cancer.
323  Genetic susceptibilities in genes affecting ethanol metabolism 
can affect breast cancer risk and the polymorphism G47A may modify the risk associated 
with high levels of alcohol consumption.
324    
2.3.7  Apoptosis Related Genes 
Apoptosis, or programmed cell death, is the process by which cells of multicellular 
organisms use specialized cellular machinery to destroy itself and is used to control cell 
number and eliminate cells that threaten the organisms survival.  Apoptosis involves a 
series of biochemical events that lead to a variety of morphological changes, including 
changes to the cell membrane such as loss of membrane asymmetry and attachment, cell 
shrinkage, nuclear fragmentation, chromatin condensation and chromosomal DNA 
fragmentation.  An insufficient amount of apoptosis results in uncontrolled cell 
proliferation, such as cancer. 
2.3.7.1 Death Associated Protein Kinase 1 (DAPK1)  
DAPK1 is a calcium/calmodulin dependant enzyme that phosphorylates serine/threonine 
residues on proteins (serine/threonine kinase).
325  It is involved in an intrinsic p53 
dependant apoptotic checkpoint which is designed to eliminate premalignant cells from 
cancer development
326, reacting to various stimuli including INFγ, TNFα, Fas, C6-ceramide, 
oncogene expression (such as c-Myc and p53) and detachment from the extracellular 
matrix.
325;327-330  Due to its proapoptotic actions it is known as a metastasis suppressor and 
its expression frequently lost in human tumours.
326  Loss of DAPK expression has been 64 
 
associated with highly aggressive, metastatic behaviour in tumours.
325;328  Transcriptional 
silencing by hypermethylation of CpG islands in the promoter is a common event in the 
multistep process of tumour metastasis
331 and has been associated with an invasive 
phenotype in breast cancer.
332;333  DAPK1 has been shown to play a role in uncoupling of 
stress fibres and focal adhesions, leading to a perturbation of the balance between 
contractile and adhesion forces and subsequent cell detachment, which might contribute 
to its pro-apoptotic activity
334.  The single nucleotide change c.1-6531A>G enhances the 
binding affinity of transcriptional factor HOXB7 and results in altered protein binding, 
causing an increased affinity for HOXB7 that downregulates DAPK1 transcription
335.  
2.3.7.2 Caspase 8 (CASP8) 
Caspases play an important role in apoptosis, which results from a cascade of protease 
reactions carried out by the caspases (aspartate specific cysteine proteases).  Caspase 8 is 
activated in response to DNA damage or external death signals.  A lack of functional 
caspase 8 results in resistance to TNFα induced apoptosis.
336  The rare H allele of D302H 
(rs1045485), an aspartic acid to histidine substitution, was associated with a reduced risk 
of breast.
337;338  BCAC (Breast Cancer Association Consortium), a large consortium 
established to conduct combined case control analysis with augmented statistical power 
to attempt to confirm putative genetic associations with breast cancer, typed nine SNPs, 
all with a previous association to breast cancer, and the strongest association found was 
with the D302H allele in the CASP8 gene with the D302H polymorphism having a 
protective effect on breast cancer risk
38. 
2.3.8  Invasion and Metastasis Associated Genes 
Tumour invasion and development of metastasis are the primary determinants of patient 
outcome and, consequently, molecules involved in these processes are obvious 
candidates to be identified as new prognostic markers in breast cancer.  Metastasis 
requires several sequential steps, such as changes in cell-ECM interaction, disconnection 
of intercellular adhesions, separation of single cells from the solid tumour tissue, 
degradation of ECM, locomotion of tumour cells into the ECM, invasion of lymph and 65 
 
blood vessels, evasion of the immune system, adhesion to endothelial cells, extravasation 
from lymph and blood vessels, proliferation of cells and induction of angiogenesis
339 
involving many different genes.    
2.3.8.1 Fibronectin 1 (FN1) 
The FN1 gene encodes fibronectin, an extracellular matrix glycoprotein of high molecular 
weight (430kDa), that plays a role in cell adhesion and morphology including processes 
such as embryogenesis, wound healing, blood coagulation, host defence and metastasis.  
It binds to cell membranes via a β1 integrin receptor, preventing apoptosis.  This 
interaction is also essential for cell proliferation in normal cells, however it is not 
necessary for proliferation of cancer cells.  It does, however, prevent apoptosis in cancer 
cells
340.  Previous studies have shown an association between FN1 expression and tumour 
progression and a shorter overall survival.
341;342  It has been associated with an 
unfavourable prognosis in ovarian cancer
343 and has been reported to be upregulated by 
oestrogens in breast cancer cells
344 and downregulated in HER-2 transfected cells
345. 
2.3.8.2 Integrin Binding Protein 4 (ITGB4) 
Integrins are transmembrane glycoprotein receptors that mediate cell-matrix or cell-cell 
adhesions and transduce signals regulating gene expression and cell growth.
346  They are 
heterodimers, comprising a non-covalently associated α and β subunit, and have different 
ligand binding specificities depending on their combination of α and β subunits.  ITGB4 
encodes the integrin β4 subunit and has specificity for the laminins.   The ITGB4 subunit 
commonly associates with the alpha 6 subunit and is likely to play a pivotal role in the 
biology of invasive carcinoma, as it was demonstrated in a breast cancer cell line that the 
α6β4 integrin promotes carcinoma invasion through a preferential and localised targeting 
of phosphoinositide-3 OH kinase (PI3K) activity and it was shown that α6β4 regulated PI3K 
activity is required for the formation of lamellae (dynamic sites of motility) in cancer 
cells.
347  Dajee et al
348 demonstrated that laminin-5 and ITGB4 are both required for 
human squamous cell carcinoma tumourigenesis.  Murgia et al
349 found that the 
interactions mediated by the beta-4 cytoplasmic domain are vital for adhesion of epithelia 66 
 
to the basement membrane and for proper cell cycle control of proliferation and Guo et 
al
350 investigated the effect of deletion of the cytoplasmic tail of the beta-4 subunit, 
finding that it promoted tumour progression by amplifying ERBB2 signalling.   
2.3.8.3 LSP1 
The LSP1 gene encodes a protein involved in leukocyte recruitment.  The SNP rs3817198 
in intron 10 of the LSP1 gene was recently identified by Easton et al
21 in a genome wide 
association study as being associated with breast cancer susceptibility and Huijts et al
199 
investigated the association of SNPs with breast cancer phenotype and found that the 
rs3817198 SNP was associated with lymph node positive breast cancer, however it had no 
effect on overall or disease free survival.   
2.3.8.4 Matrix Metalloproteinases (MMPs) 
The MMPs are a family of structurally and funtionally related zinc dependant 
endoproteinases.  Their primary function is degradation of the extracellular matrix (ECM) 
and they play an important role in tissue remodelling, being associated with various 
physiological and pathological processes such as morphogenesis, angiogenesis, tissue 
repair, cirrhosis, arthritis and invasion and metastasis
351;352. There are currently 26 known 
members of this family
353.  The MMPs are commonly divided into four groups based on 
their substrate specificity and domain organisation.  The four groups are; interstitial 
collagenases, gelatinases, stromelysins and the membrane type MMPs.  The interstitial 
collagenases degrade collagen types I, II and III, the major components of bone and 
cartilage.  The gelatinases (also known as the type IV collagenases) degrade gelatin 
(denatured collagen) and types IV, V, VII, IX and X collagen.  Type IV collagen is abundant 
in the basement membrane giving these MMPs a crucial role in invasion and 
metastasis
354;355.  Two members of this group have been identified; gelatinase A (MMP-2) 
and gelatinase B (MMP-9).  The stromelysins have a broad substrate specificity and 
catalyse the degradation of many ECM substrates, including proteoglycans, and non 
collagenous proteins such as laminin and fibronectin.  One of the main members of this 
group is matrilysin (MMP-7).  The membrane type group of MMPs have a transmembrane 67 
 
domain.  There are five members of this group, the best characterised being the 
membrane type I MMP.  There are however some MMPs that do not appear to fit into any 
of these categories and others that may apply to more than one group
356.  MMPs may play 
a role in breast cancer initiation
121;357;358, as well as angiogenesis, invasion and 
metastasis
355;357;359;360.  Inhibition of MMPs has been shown to decrease tumour 
growth.
361;362 
Many studies have implicated an involvement of MMP-2, MMP-7 and MMP-9 in breast 
cancer.  MMP-2 is up-regulated in many tumour types and is associated with prognosis in 
most of them
363.  MMP-2 expression and activity levels have been associated with breast 
tumour progression 
364, as well as with breast cancer phenotype
365 including large tumour 
diameter
366, high grade
367 lymph node involvement
364;368-373, bone and visceral 
metastases
373 and high expression of oestrogen receptors in malignant tumours
369 as well 
as a shortened overall survival independent of major prognostic indicators
366;374;375.  
Expression of both MMP-2 and MMP-9 is abundant in various malignant tumours
376 and 
has been linked to metastasis of breast cancer to the brain
60 and correlated with poor 
disease free survival in lymph node negative patients
377.  Expression and activity levels of 
MMP-9, a previously reported candidate metastasis associated gene
378, are elevated in 
malignant breast tumours
369, its expression has been associated with the infiltrating 
lobular breast cancer phenotype
364 and is a useful marker in both the prognosis and of the 
follow up of breast cancer patients, with an increased level being associated with worse 
prognosis disease relapse.
379  MMP-7 has been associated with the progression of many 
different types of cancer
380-383 including breast cancer
384, its expression has been shown to 
contribute to early stage mammary tumourigenesis.
358   
Several SNPs in the MMP genes have been investigated in relation to cancer.  A novel 
functional genetic variant in the MMP-2 promoter (rs17859818) was identified in 2001
385.  
This SNP abolishes the Sp1 binding site causing lower transcriptional activity.  It has since 
been associated with risk of lung cancer
386, development of gastric cardia 
adenocarcinoma
387, risk of occurrence and metastasis of oesophageal cancer
388, colorectal 68 
 
cancer development and invasion
389, development and aggressiveness of head and neck 
squamous cell carcinoma
390 and breast cancer susceptibility and progression
391;392.  This 
SNP has been found to have different effects on survival depending on the patient’s 
oestrogen receptor (ER) status, with the ER negative patients having a poor survival and 
the ER positive patients having good survival rates.
365  Another SNP in the MMP-2 gene, g-
1575A, was identified that affects the oestrogen receptor α binding site.  This leads to 
reduced transcriptional activity as the oestrogen receptor is essential for enhanced 
activity.
393  A polymorphism in the MMP-9 promoter (rs3918242) is related to the severity 
of coronary athersclerosis
394 and has since been linked to good prognostic features in 
breast cancer
365. 
2.3.8.5 RHOC 
The RHOC gene encodes a member of the Rho family of small GTPases.  RhoC (Ras 
homolog gene family, member C) is a small (~21 kDa) signalling G protein (more 
specifically a GTPase) and is a member of the Rac subfamily of the Rho family of GTPases.  
It functions as a molecular switch in signal transduction cascades.  Rho proteins promote 
reorganization of the actin cytoskeleton and regulate cell shape, attachment and motility.  
Overexpression of this gene is associated with tumour cell proliferation and metastasis
395.  
2.3.9  Gene Desert 
An LD block of approximately 110kb, containing no known genes, on chromosome 8q24 
has been shown to contain a SNP associated with breast cancer susceptibility.
21 
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2.4  SNP Selection 
260 SNPs (200 plus an additional 30% as requested by Sequenom in case of in silico design 
failure) were selected from the 30 candidate genes.   
The SNPs were selected for one of four reasons: 
1.  Previously reported (identified from extensive literature searching) 
2.  Non synonymous – identified using the UCSC database (Section   2.2.1) 
3.  Promoter region – SNPs in the region 5kb upstream (5’) on the gene 
4.  LD location – The remainder of SNPs were selected based on their LDU location to 
ensure coverage of the gene with one SNP selected at least every 0.5 LDU (r
2> 0.9 
(r-squared between adjacent SNPs in candidate genes) using data from the 
HapMap project (Section   2.2.2) 
161) 
All SNPs (other than those previously reported) had been previously reported in the 
HapMap CEU population (population with ancestry from northern and western Europe).  
Previously reported SNPs, promoter SNPs and those selected by LDU location had a minor 
allele frequency (maf) >5% and non synonymous SNPs had a maf>1%.         
 
Table 2: 206 Selected SNPs 
Gene  Chromosome  SNP  Type  location (bp)  P  OR (95% C.I.)  Reference  Tested for 
association 
BRCA1  17q21.31  rs8176318  3’ UTR  38,450,800        Yes 
    rs8176265  Intron  38,467,522        Yes 
    rs3737559  Intron  38,487,830        Yes 
    rs16940  Exon 
synonymous 
38,498,763        Yes 
    rs799905  Intron  38,530,713        Yes 
    rs11653069  Promoter  38,536,903        No 
TP53  17p13.1  rs12951053  Intron  7,518,132  0.00009  1.29 (1.06-1.58) ER-ve  Garcia-Closas et al. 
(2007) 
No 
    rs1625895  Intron  7,518,840  NA  0.49 (0.27-0.90) 
Smokers 
Gaudet et al. (2008)  No 
    rs1042522  Exon non-
synonymous 
7,520,197  NA  1.32 (1.00–1.74)  Gaudet et al. (2008)  Yes 
    rs12602273  Intron  7,523,738        No 
    rs2287497  Promoter  7,533,505        Yes 
ATM  11q22.3  rs228606  Promoter  107,593,057        Yes 
    rs4987876  Promoter   107,597,847    1.21 (0.64-2.29)  Baynes et al. (2007)  Yes 
    rs1800054  Exon non-
synonymous           
107,603,786  0.08  1.13 (0.99-1.30)  Cox et al. (2007)  No 
          0.004  1.69 (1.19-2.40)  Stredrick et al. (2006) 
    rs599164  Intron   107,625,649  NA  1.05 (0.88-1.24)  Baynes et al. (2007)  No 
    rs4986761  Exon non-
synonymous  
107,629,971  0.03  0.47 (0.23-0.93)  Stredrick et al. 
(2006) 
No 
    rs1800056  Exon non-
synonymous 
107,643,213  0.03  2.03 (1.05-3.90)  Stredrick et al. 
(2006) 
No 
    rs3092991  Intron  107,645,726  NA  1.12 (0.71-1.77)  Einarsdottir et al. 
(2006) 
Yes 
    rs1800058  Exon non-
synonymous 
107,665,560        No 
    rs1800889  Exon 
synonymous 
107,668,697  0.04  0.75 (0.49-1.13)  Stredrick et al. 
(2006) 
Yes 
    rs1801516  Exon non-
synonymous 
107,680,672  0.04  0.63 (0.27-1.49)  Edvardsen et al. 
(2007) 
Yes     
 
DAPK1  9q21.33  rs975256  Promoter  89,296,902        No 
    rs2058882  Intron  89,304,566        No 
    rs17399090  Intron  89,324,847        Yes 
    rs10746815  Intron  89,327,937        Yes 
    rs4878086  Intron  89,329,724        No 
    rs1045042  Intron  89,340,827        Yes 
    rs1041326  Intron  89,346,666        Yes 
    rs7038971  Intron  89,361,235        No 
    rs928114  Intron  89,368,626        No 
    rs11141901  Intron  89,380,485        Yes 
    rs11141904  Intron  89,386,866        No 
    rs7043056  Intron  89,392,167        No 
    rs13288504  Intron  89,410,000        No 
    rs7033344  Intron  89,426,667        Yes 
    rs11141918  Intron  89,436,202        Yes 
    rs943855  Intron  89,460,147        No 
    rs13285155  Intron  89,470,700        Yes 
    rs9410612  Intron  89,474,570        Yes 
    rs1007394  Intron  89,482,445        Yes 
    rs12056997  Intron  89,506,425        Yes 
    rs1056719  Intron  89,511,843        Yes 
CASP8  2q33.1  rs12693932  Promoter  201,801,640        Yes 
    rs2037815  Intron  201,809,960        No 
    rs6760993  Intron  201,819,162        Yes 
    rs12990906  Intron  201,822,869        Yes 
    rs10931936  Intron  201,852,173        No 
    rs1045485  Exon non-
synonymous  
201,857,834  5.7x10-7  0.74 (0.62-0.87)  Cox et al. (2007)  No 
          NA                                                      
NA 
0.58 (0.39-0.88)  MacPherson et al. (2004) 
          NA  0.49 (0.17-1.44)  Frank et al. (2005) 
IGF-1  12q23.2  rs2946834  Intron  101,311,944  0.0004    Tamimi et al. (2007)  Yes 
    rs5742714  Intron  101,313,982        Yes     
 
IGF-1    rs1520220  Intron  101,320,652  0.03  1.41 (1.11-1.79)  Ali Al-Zahrani et al. 
(2006) 
Yes 
    rs2373721  Intron  101,351,175        Yes 
    rs5742632  Intron  101,380,604        Yes 
    rs12821878  Intron  101,391,797        Yes 
    rs5742620  Intron  101,393,730        No 
    rs2162679  Intron  101,395,389        Yes 
    rs35766  Promoter  101,404,603        Yes 
ERBB2  17q12  rs903501  Promoter  35,093,019        Yes 
    rs1801200  Exon non-
synonymous 
35,133,114    0.68 (0.47-0.98)  Cox et al. (2005)  Yes 
    rs28933370  Exon non-
synonymous 
35,134,904        No 
    rs1058808  Exon non-
synonymous 
35,137,563        Yes 
TGFβ1  19q13.2  rs8179181  Intron  46,530,046        Yes 
    rs11466338  Intron  46,537,641        Yes 
    rs4803455  Intron  46,543,349        No 
    rs1800469  Intron                      46,552,136  NA                              
0.009 
0.31 (0.27-0.35)  Grainger et al. 
(1999) 
No 
            1.25 (1.06-1.48)  Dunning et al. (2003) 
    rs1982072  Promoter  46,556,349        Yes 
FGFR2  10q26.13  rs1649202  Intron  123,230,615        No 
    rs3135811  Intron  123,232,714        Yes 
    rs2912796  Intron  123,238,141        Yes 
    rs2912762  Intron  123,266,280        Yes 
    rs11199993  Intron  123,281,254        Yes 
    rs2912787  Intron  123,315,528        Yes 
    rs2981428  Intron  123,319,419        Yes 
    rs1219648  Intron  123,336,180  1.1x10-10  1.64 (1.42-1.90)  Hunter et al. (2007)  Yes 
    rs2981582  Intron  123,342,307  2x10-76  1.63 (1.53-1.72)  Easton et al. (2007)  Yes 
          0.00045  1.24 (1.11-1.38)  Antoniou et al. (2008) 
    rs4412700  Promoter  123,352,565        No 
    rs4752566  Promoter  123,257,621        Yes     
 
VEGF  6p21.1  rs699946  Promoter  43,840,647        No 
    rs699947  Promoter  43,844,367  0.03  1.99 (1.06-3.74)  Schneider et al. 
(2007) 
Yes 
    rs833061  Promoter  43,845,464    1.5 (0.9-2.5)  Lu et al. (2005)         No 
    rs833069  Intron  43,850,557        Yes 
    rs3024997  Intron  43,853,085        No 
    rs3025033  Intron  43,859,053        Yes 
    rs10434  3'UTR  43,861,190        Yes 
MAP3K1  5q11.2  rs889312  Upstream  56,067,641  7x10-20  1.27 (1.19-1.36) LN-ve   Easton et al. (2007)               Yes 
          0.044    Huijts et al. (2007) 
          0.02  1.12 (1.02-1.24) 
BRCA2 
Antoniou et al. (2008) 
    rs17661089  Promoter  56,141,753        Yes 
    rs1423622  Intron  56,149,199        Yes 
    rs16886383  Intron  56,161,453        No 
    rs252921  Intron  56,173,544        No 
    rs832574  Intron  56,195,639        Yes 
    rs702689  Exon non-
synonymous 
56,213,200        Yes 
IL-6  7p15.3  rs2056576  Promoter  22,727,727        No 
    rs1800795  Promoter  22,733,170  0.02  2.0 (1.1-3.6)  Hefler et al. (2005)  Yes 
    rs2069832  Intron  22,733,958  0.01  4.4 (1.5-12.8)  Slattery et al. 
(2007)  
No 
    rs1474348  Intron  22,734,433        Yes 
    rs2069845  Intron  22,736,674        Yes 
    rs2069860  Exon non-
synonymous 
22,737,563        No 
TNFα  6p21.33  rs2009658  Promoter  31,646,223        Yes 
    rs3093662  Intron  31,652,168        Yes 
LSP1  11p15.5  rs907613  5'UTR  1,830,868        Yes 
    rs2089910  Exon 
synonymous 
1,830,980        No 
    rs599774  Intron  1,835,212        Yes 
    rs592373  Intron  1,847,566        Yes 
    rs661348  Intron  1,861,868        Yes     
 
LSP1    rs3817198  Intron  1,865,582  3x10-9  1.17 (1.08-1.25)  Easton et al. (2007)  Yes 
    rs548195  3'UTR  1,869,953        No 
TOX3  16q12.1  rs2075236  Intron  51,037,272        No 
    rs1420542  Intron  51,039,776        Yes 
    rs1420546  Intron  51,046,208        Yes 
    rs1362560  Intron  51,058,858        No 
    rs8051542  Intron  51,091,668  10-12  1.19 (1.12-1.27)  Easton et al. (2007)  Yes 
    rs12443621  Intron  51,105,538  2x10-19  1.23 (1.17-1.30)  Easton et al. (2007)  No 
    rs3803662  Exon 
synonymous 
51,143,842  10-36  1.39 (1.26-1.45)  Easton et al. (2007)  Yes 
          0.00027  1.28 (1.11-1.46)  Antoniou et al. (2008) 
ADH1B  4q23  rs1042026  3’ UTR  100,447,489  0.044  1.04 (0.95-1.14)  Cox et al. (2007)  Yes 
    rs1789882  Exon 
synonymous 
100,454,076        Yes 
    rs1353621  Intron  100,460,598        No 
    rs1789888  Promoter  100,466,593        Yes 
CYP1B1  2p22.2  rs162549  3’ UTR  38,148,960        No 
    rs1800440  Exon non-
synonymous 
38,151,643  NA  1.3 (0.3-4.8)  Renee bailey et al. 
(1998) 
Yes 
            1.61 (0.96-2.70) risk  Justenhoven et al. (2007) 
            2.82 (1.37-5.82) ER-ve 
    rs1056836  Exon non-
synonymous 
38,151,707        Yes 
    rs2551188  Intron  38,156,298        No 
    rs10175368  Promoter  38,161,365        Yes 
AR  Xq12  rs17302090  Promoter  66,672,128        Yes 
    rs7061037  Intron  66,738,888        Yes 
    rs6624304  Intron  66,792,481        Yes 
    rs12011518  Intron  66,849,761        No 
    rs12014709  Intron  66,855,191        No 
    rs9332969  Exon non-
synonymous 
66,859,466        No 
ESR1  6q25.1  rs2077647  Exon 
synonymous 
152,170,770        No 
    rs827423  Intron  152,197,890        No     
 
ESR1    rs6557170  Intron  152,244,797        Yes 
    rs4870062  Intron  152,279,311        Yes 
    rs9371564  Intron  152,303,806        Yes 
    rs3020410  Intron  152,308,070        Yes 
    rs3020314  Intron  152,312,365        Yes 
    rs1884051  Intron  152,324,972        No 
    rs2982700  Intron  152,328,216        Yes 
    rs3020403  Intron  152,337,408        Yes 
    rs2144025  Intron  152,349,399  0.001    Einarsdóttir et al. 
(2008) 
Yes 
    rs12212176  Intron  152,351,700        No 
    rs6905370  Intron  152,367,890        Yes 
    rs2207232  Intron  152,381,981        Yes 
    rs2982735  Intron  152,410,380        Yes 
    rs9383607  Intron  152,422,011        Yes 
    rs9397484  Intron  152,435,930        No 
    rs9341052  Intron  152,458,318        Yes 
    rs9341066  Intron  152,461,219        Yes 
    rs2228480  Coding 
synonymous 
152,461,788        Yes 
    rs3798577  3'UTR  152,462,823  0.047    Zhang et al. (2008)  Yes 
TWIST  7p21.2  rs2285681  Promoter  19,125,291        Yes 
    rs2189000  Promoter  19,127,743        Yes 
GATA3  10p14  rs1244181  Promoter  8,131,383        No 
    rs1399180  Intron  8,138,725        No 
    rs3802604  Intron  8,142,278  NA  0.9 (0.76-1.06) risk  Garcia-Closas et al. 
(2007) 
Yes 
          0.02  0.72 (0.54-0.96) ER-ve 
                 
    rs570613  Intron  8,146,508  0.004  0.82 (0.69-0.96) risk    Garcia-Closas et al. 
(2007) 
No 
        8,151,415  0.006  0.71 (0.54-0.94) ER-ve 
    rs422628  Intron  8,158,099    0.97 (0.77-1.24)  Yes 
    rs263419  Intron  113,048,650        Yes     
 
RHOC  1p13.2  rs2999156  Intron  113,050,314        Yes 
    rs12144044  Intron  113,055,790        Yes 
    rs7522283  Promoter  100,414,396        Yes 
PGR  11q22.1  rs11224563  3'UTR  100,418,375        Yes 
    rs606789  Intron  100,438,622        Yes 
    rs1042838  Exon non-
synonymous 
100,442,270    1.06 (0.97-1.15)  Johnatty et al. 
(2008) 
Yes 
    rs11224579  Intron  100,473,333        Yes 
    rs694070  Intron  100,500,919        No 
    rs506487  Intron  100,503,981        Yes 
    rs3740753  Exon non-
synonymous 
100,505,711        No 
    rs518162  5'UTR  100,513,712        Yes 
    rs4754732  Promoter  71,218,460        Yes 
ITGB4  17q25.1  rs820227  Promoter  71,232,322        No 
    rs3862481  Intron  71,247,907        No 
    rs2290458  Intron  71,265,098        Yes 
    rs871443  Exon non-
synonymous 
215,940,366        No 
FN1  2q35  rs1250214  Intron  215,944,957        No 
    rs17449032  Exon non-
synonymous 
215,976,689        No 
    rs7572169  Intron  215,988,767        No 
    rs10207245  Intron  216,015,348        Yes 
    rs1250233  Promoter  67,493,429        No 
MDM2  12q15  rs1470383  Intron  67,502,788        Yes 
    rs3730556  Intron  67,518,247        No 
    rs3730646  Intron  54,062,829        No 
MMP-2  16q12.2  rs16955194  Promoter  54,066,374        Yes 
    rs1116195  Promoter  54,069,307        Yes 
    rs243865  Promoter  54,074,209        No 
    rs857403  Intron  54,081,206        No 
    rs243849  Exon 
synonymous 
54,085,183        Yes     
 
MMP-2    rs183112  Intron  54,089,186        No 
    rs17859981  Intron  54,089,959        No 
    rs2287076  Intron  54,094,264        Yes 
    rs11541998  Exon 
synonymous 
54,097,115        Yes 
    rs7201  3'UTR  101,903,803        Yes 
MMP-7  11q22.2  rs10502001  Exon non-
synonymous 
101,905,546        Yes 
    rs11225309  Intron  101,906,843        Yes 
    rs11568819  Promoter  101,912,401        Yes 
    rs1943779  Promoter  101,914,290        Yes 
    rs4754850  Promoter  101,919,669        No 
    rs17352599  Promoter  44,062,697        Yes 
MMP-9  20q13.12  rs6094237  Promoter  44,065,774        Yes 
    rs6065912  Promoter  44,069,142        Yes 
    rs3918241  Promoter  44,069,383        Yes 
    rs3918242  Promoter  44,073,632    1.88 (0.97-3.63)  Lei et al. (2007)  No 
    rs17576  Exon non-
synonymous 
44,075,813        Yes 
    rs2250889  Exon non-
synonymous 
44,076,518        No 
    rs2274756  Exon non-
synonymous 
44,076,999        No 
    rs3918261  Intron  128,424,800        Yes 
Desert  8q24.21  rs13281615  Genomic  1.28E+08  5x10-12  1.18 (1.101.25)  Easton et al. (2007)  Yes 78 
 
2.5  Patient Selection 
Patient material from the POSH study was used for our study.  
2.5.1  POSH Study (Prospective Outcomes in Sporadic versus Hereditary 
breast cancer (POSH) study)
396: 
The POSH study is a study of 3000 patients with invasive breast cancer with an age of 
onset less than 41 years who have been recruited from across the UK.  The study has been 
designed to give accurate information about hereditary factors that determine 
predisposition, prognosis and treatment responses in breast cancer.  Blood samples and 
pathology blocks are available from all recruits.  Family history for each recruit is recorded.  
The collection of genomic DNA and the meticulous documentation of clinical details about 
treatment and diagnosis, and a systematic pathological review will give the opportunity to 
investigate the role of the host genome in determining clinical outcomes, including 
tumour presenting characteristics and treatment responses.  This provides a unique 
dataset for hypothesis generation, looking for evidence to be replicated by larger studies.  
Advantages of using this cohort: 
•  Cases that have a young age of onset are more likely to be due to an inherent 
predisposition to the disease.  
•  Cases selected have no family history therefore are unlikely to have an underlying 
high risk genetic predisposition that could mask more subtle traits. 
•  Almost all cases are symptomatic (<2% screen detected) and so represent the true 
natural history of the tumour.  Breast screening may alter the presenting features 
of disease which causes problems when studying the influence of the genome on 
the natural history of breast cancer. 
•  The systematic pathology review, prospective clinical follow up and the remarkably 
consistent treatment choices allows for associations to be made with various 
phenotypes as well as risk and will help interpret the outcome data. 79 
 
•  The large sample size gives good statistical power to detect any associations in 
data generated.   
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2.6  DNA Extraction 
DNA was extracted from whole blood samples as documented below (  3.3.1.1). 
2.7  Genotyping 
Genotyping of our samples was carried out by Sequenom, using tier 2 of their iPLEX Gold 
service based on single-base primer extension and MALDI-TOF mass spectrometry 
(Section   9.1.1.1).  All of the 260 SNPs selected underwent in silico design and the top 210 
were selected (ensuring there was still full coverage of each gene) for genotyping in the 
1001 patients, of these 206 were successfully typed.   
2.8  Quality Control 
Missing genotype rates are an indicator of poor DNA quality.  58 individuals were removed 
from analysis as they had > 10% missing genotypes, leaving 943 individuals.  SNPs with 
over 10% data missing were identified and removed from analysis (60 SNPs).  A further 12 
SNPs were removed which had a minor allele frequency <5%.   
Deviations from Hardy-Weinberg equilibrium in the control samples would typically be 
used to exclude further SNPs, however in this study, only cases were genotyped and 
therefore the Hardy Weinberg equilibrium could not be applied as deviations may be a 
result of an association with breast cancer, rather than reflecting poor genotyping.  
Therefore we noted any SNPs with significant deviations from Hardy-Weinberg 
equilibrium (χ
2 ≥ 10) and the genotyping calls were verified by examination of the 
Sequenom cluster plots for these SNPs (Section   9.3).  On this basis, one additional SNP 
was removed.  This left 133 SNPs (64%) for analysis which is consistent with the 
genotyping tier (Section   9.2).   
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2.8.1  Population Stratification 
Population stratification refers to differences in allele frequencies between cases and 
controls due to systematic differences in ancestry rather than association of genes with 
disease.  It can cause false positive results to occur in association studies as genetic 
variations could be due to the individuals being of different ethnic origin and not a true 
association with disease.  The majority of individuals in the POSH cohort are of Western 
European ancestry therefore any individuals that appeared to be of different ancestry 
were removed.  To identify these individuals we performed a multi-dimensional scaling 
analysis on genome-wide average identities by state on the cohort using PLINK.  First the 
data was reduced to 82 autosomal SNPs with maximum pairwise r
2<0.2 to avoid 
confounding by including non-independent SNPs in strong linkage disequilibrium with 
eachother.  We ensured that all genotypes were configured to the positive strand of the 
reference sequence (National Cancer for Biotechnology Information [NCBI] build 36.1) and 
then merged the data from the POSH cohort with individuals from the HapMap project
161 
(60 Western European, 60 Nigerian, 45 Han Chinese and 45 Japanese).  It is recommended 
that over 10000 autosomal SNPs are used for this analysis
156, however we found plotting 
the first two components (which represent geographic and genetic variation) from the 
multidimensional scaling analysis of the 82 SNPs produced 3 separate clusters with our 
data representing the African, Asian and Caucasian populations.  We were therefore able 
to exclude 44 samples from the POSH cohort that were separate from the cluster of 
Caucasians (35 Africans and 9 Asians) leaving 899 patients (Figure 8).  The call rate for the 
133 SNPs in the remaining 899 individuals was 99%.   
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Figure 8: Multi-dimensional scaling analysis- Inference of ancestry by multidimensional scaling-POSH and 
HapMap samples plotted for the first two principal components obtained by multidimensional scaling of a 
matrix of pairwise identity by state (IBS) values. The blue diamonds occurring near the YRI and CHB+JPT 
clusters are the individuals excluded from the POSH cohort.  - CHB, Chinese; CUE, Western European; JPT, 
Japanese; POSH, Prospective study of Outcomes in Sporadic versus Hereditary breast cancer; YRI, 
Nigerian. 83 
 
2.8.2  Associations 
2.8.2.1 Association with Survival 
As the median time to follow up for the individuals passing QC in our study was only 2.4 
years and most individuals developing distant metastases will die from the disease, we 
used distant disease-free survival, defined as the time between diagnosis and the first 
distant metastasis, in place of survival in our risk associations.  Univariate analyses of DDFS 
(distant disease-free survival) were performed, by plotting Kaplan-Meier curves for each 
SNP and using the log rank test to compare Kaplan-Meier DDFS curves for the three 
genotypes of each SNP.  Tests were performed using SPSS v17 (SPSS Inc., San Francisco, 
CA, USA).  In seven cases the date of distant metastasis was not available and so the date 
of death was used. In one of these cases the cause of death was known to be unrelated to 
breast cancer.   
2.8.2.2 Association with Breast Cancer Phenotypes 
To identify SNPs associated with breast cancer biology the data was stratified into 
phenotypic subgroups.  The phenotypes investigated were ER status, lymph node 
involvement, lymphovascular involvement, distant metastasis and grade.  All phenotypes 
were divided on the basis of being positive or negative for that phenotype except for 
grade where the phenotypic extremes of grade 1 and grade 3 were compared since grade 
is a subjective phenotype and some grade 2 tumours have gene expression signatures 
similar to those of grade 1 or grade 3 tumours
155 and may be reclassified as eith grade 1 or 
3.  Associations were tested for using the Cochran-Armitage trend test and two-by-three 
tables of disease by genotype (tests performed using PLINK
156).   84 
 
2.8.2.3 Significance   
To correctly identify accurate levels of significance in association studies it is important to 
correct results for the number of tests performed.  HapMap suggest that the number of 
independent tests, rather than the total number of tests are corrected for therefore we 
corrected our data for the 82 independent tests performed, as determined by the 
multidimensional scaling procedure with maximum pair-wise r
2 values of less than 0.2, 
giving a threshold of significance of P< 0.0006 (0.05/82).   85 
 
Chapter 3  Methods for Functional Studies  
3.1  Overview 
A series of experiments were conducted to evaluate the function of SNPs in the promoter 
region of the MMP-9 gene.   
Firstly, our panel of cell lines was screened for expression of MMP-9 by PCR to help decide 
which cell line to use in functional experiments.  Total RNA was isolated using the RNeasy® 
Mini Kit Spin Method and the RNA was reverse transcribed using first strand cDNA 
synthesis by Superscript II reverse transcriptase (Invitrogen) and oligo (dT)15 primers 
(Promega).  The cDNA was then amplified for the detection of the MMP-9 gene and the 
products viewed on an agarose gel.  Expression of β-actin, a house-keeping gene found in 
all cells, was used as an internal standard for RNA integrity and accuracy of loading.  The 
primers used for detection of MMP-9 were as previously described by Menshikov et al
397.  
To confirm the result of the initial PCR, an additional PCR was carried out with a different 
primer set as described by Ricca et al
398.   
The luciferase reporter vector containing 2192bp (-2181 to +11) of the MMP-9 promoter 
was a kind gift from Professor Shu Ye.  The DNA construct contained the T allele at the 
−1562 polymorphic site (rs3918242).  The sequence was verified by sequencing and used 
as a template to generate three different reporter constructs (the T or C allele at -1562 
with either the A or T allele at -1803 (rs3918241) by site directed mutagenesis (SDM; 
QuikChange Site Directed Mutagenesis Kit, Stratagene) and the results of these were also 
verified by sequencing.  Five of each construct were made by SDM and DNA (mini-prep) 
from two of each was sequenced to check the allele sequence.  One of each construct 
showing the correct haplotype was selected for use in the reporter assays and DNA (maxi-
prep) sequenced with additional primers to check a wider area of sequence.    
Selected cell lines were plated and incubated for 24 hours before being transiently 
transfected with either 100ng or 200ng/well of firefly luciferase reporter construct using 
Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s instructions.  86 
 
Cells in each well were incubated with lipofectamine, MMP-9 promoter/luciferase 
construct and Opti-MEM at 37˚C for 3-4 hours.  The DNA/lipofectamine mixture was then 
removed and the medium was changed.  Cells were incubated for an additional 48 hours 
and luciferase activity was determined as per the manufacturer’s instructions.  Cells were 
co-transfected with 20ng PRLSV40 a Renilla luciferase expressing vector to serve as a 
reference for transfection efficiency to standardise results.  Experiments were performed 
in triplicate and repeated at least three times.  In addition, for controls, the same amount 
of empty PGL3 Basic vector was transfected into cells.   
Reporter assays were performed 48 hours after transient transfection of cells.  The cells 
were lysed and luminescence was measured using the Dual-Glo
™ Luciferase Assay System 
(Promega) and an automated chemiluminescence detector.  Reporter activity was 
measured as the ratio of firefly to Renilla luciferase activity to give RLU (relative light 
units) and results normalised to the plate by dividing each result (average of the triplicate 
repeats) by the average RLU for the plate.  Results from independent experiments were 
averaged.  One-way ANOVA and Tukey HSD post hoc testing with SPSSv17 software were 
used for the statistical analysis of the effect of the MMP-9 promoter SNPs in reporter 
assays.  
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3.2  General Materials 
3.2.1  Cell Lines 
BT474 – oestrogen receptor positive, progesterone receptor positive, Her-2 positive 
H1299 – non-small cell lung carcinoma cell line, partial deletion of TP53 gene resulting in 
no expression of p53 protein accounting in part for their proliferative propensity 
MCF-7 – oestrogen receptor positive, progesterone receptor positive, hormone 
responsive, poorly metastatic, adenocarcinoma 
MDA-MB-231 – oestrogen receptor negative, highly invasive, one of the most aggressive 
breast cancer cell lines, adenocarcinoma 
MRC5 – lung cancer fibroblast cell line 
NIH-3T3 – mouse embryonic fibroblast 
SKBR3 – metastatic breast cancer cell line, oestrogen receptor negative, Her-2 over-
expressing 
T47D – oestrogen receptor positive, progesterone receptor positive, hormone responsive 
ZR75.1– oestrogen receptor positive, progesterone receptor positive, hormone responsive 88 
 
3.3  General Methods 
3.3.1  Preparation of Nucleic Acids 
3.3.1.1 DNA Extraction from Whole Blood 
DNA was extracted from whole blood samples using the salting out method of extraction 
and was prepared over the period of time from 2005-2007 by myself and Human Genetics 
DNA bank staff, an additional batch of blood samples for DNA extraction was outsourced 
to Tepnel.   
Whole blood samples, received in 15ml Vacutainers™ and frozen at -80˚C for long term 
storage, were defrosted and mixed on a rotary mixer in the 4˚C cold laboratory.  Each 
blood sample was transferred into a labeled 50ml conical tube.  A clothes peg was placed 
on the bottom of the upturned Vacutainer™ and rested in the top of the conical tube 
allowing for natural drainage of blood from the Vacutainer™ and minimal blood loss.  The 
red cells were then removed by washing three times with erythrocyte lysis buffer (ELB); 
30ml ELB was added to each 10ml blood sample (15ml for blood samples with a very low 
volume (~2.5ml)), the samples were placed on ice on the rotary mixer for at least 15 
minutes, spun at 1500rpm for 10 minutes at 4˚C, the supernatant discarded in Virkon™ 
solution, the pellet loosened by gently flicking the bottom of the tube and the process 
repeated twice more.  After the final wash the supernatant was poured off into Virkon™ 
and any excess ELB was blotted with a white paper towel.  2ml nuclei lysis buffer (NLB) 
was added to each tube (for low volume samples: 5ml whole blood use 2ml NLB, 2.5ml 
whole blood use 1.5ml NLB) and the pellets washed into labeled 15ml conical tubes 
containing 1ml NLB, ensuring the pellet is resuspended.  The white cell pellet was lysed by 
addition of 250μl of 10% SDS to each sample and the samples shaken to disperse the SDS.  
150μl protease were added to each sample and the samples placed in a shaking incubator 
and left mixing gently at 37˚C overnight to allow for protein digestion.  The samples were 
removed from the incubator and allowed to cool to room temperature.  1ml saturated 
sodium chloride was added to each sample and the samples shaken vigourously by hand 
for 15 seconds to dehydrate and precipitate out the digested proteins (for low volume 89 
 
samples: 5ml whole blood use 750μl, 2.5ml whole blood use 500μl) before being spun in 
the centrifuge at 4000rpm for 20 minutes at room temperature.  The clear supernatant 
was removed and placed in a fresh, labeled 15ml conical tube.  The DNA was then 
precipitated using cold absolute ethanol, adding twice the volume of cold ethanol to each 
sample and mixing by gentle inversion until the DNA strands were visible and a pellet 
formed.  The DNA pellet was washed in 70% ethanol by removing from the 15ml conical 
tube using 200μl tip on a Gilson pipette and placing in a labelled microcentrifuge tube 
containing 1 ml of 70% ethanol.  The samples were spun in a microcentrifuge on the 
highest speed for 15 seconds and the ethanol removed from the tubes.  The DNA was 
allowed to dry.  Finally the DNA pellet was dissolved in 1ml TE buffer overnight at room 
temperature ready for storage (for low volume samples: 5ml whole blood use 500μl, 
2.5ml whole blood use 300μl-500μl TE buffer depending on pellet size).  Samples were 
stored at -20˚C, or -80˚C for very long term storage.   
NLB, ELB, 10% SDS, protease, saturated salt and TE buffer were made in advance by 
Human Genetics staff (  9.4).   
3.3.1.2 Total RNA Extraction from Cell Culture Preparations; RNeasy® Mini 
Kit Spin Method (Quiagen) 
Cells were grown on a 90mm culture dish until confluent, the medium was aspirated from 
cells and 10ml ice cold PBS added to wash the cells.  The PBS was removed to waste and 
another 1ml PBS added.  Using a rubber plunger the cells were scraped from the top to 
the bottom of the dish.  The cells and PBS were collected in a 1.5ml eppindorf and spun at 
3000rpm (900g) for 4 minutes.  The PBS was removed to waste and the cell pellet snap 
frozen and stored at -80˚C until needed.   
RNA was extracted from the cell culture preparations using the RNeasy® Mini Kit Spin 
Method according to the manufacturer’s instructions.   
The RNA pellet was thawed then loosened by gently flicking the tube.  350μl of Buffer RLT 
(with 1% β-mercaptoethanol) was added and the sample vortexed to mix.  The sample 90 
 
was then homogenized by vortexing for 1 minute.  1 volume (350μl) of 70% ethanol was 
added to the homogenized lysate and mixed by pipetting.  The sample, including any 
precipitate that may have formed, was added to an RNeasy® spin column placed in a 2ml 
collection tube, the lid closed and the sample centrifuged for 15 seconds at 8000g 
(10,000rpm).  The flow through was discarded.   
An optional on-column DNase digest was performed with the RNase-free DNase Set.  
350μl Buffer RW1 was added to the RNeasy® spin column, the lid closed and the sample 
centrifuged for 15 seconds at 8000g (10,000 rpm) to wash the spin column membrane and 
the flow-through discarded.   10μl DNase I stock solution was added to 70μl of Buffer RDD 
in a microcentrifuge tube, mixed by gently inverting the tube then centrifuging briefly 
before being added to the RNeasy® spin column membrane and left at room temperature 
for 15 minutes.  350μl Buffer RW1 was then added to the RNeasy® spin column, the lid 
closed, the column centrifuged for 15 seconds at 8000g (10,000rpm) and the flow-though 
discarded.   
To wash the spin column membrane, 500μl of Buffer RPE was added to the RNeasy® spin 
column and centrifuged for 60 seconds at 8000g (10,000rpm) and the flow through 
discarded.  This was repeated, centrifuging for 2 minutes the second time.  The RNeasy® 
spin column was then placed in a 1.5ml collection tube and 30μl RNase-free water added 
directly to the spin column membrane and left to stand for 1 minute to pre-wet the 
membrane before centrifuging for 1 minute  at 8000g (10,000rpm) to elute the RNA.   
3.3.1.3 Measurement of Nucleic Acid Concentrations 
To measure the concentration of nucleic acid (DNA and RNA) 1μl of the sample was 
analysed on a NanoDrop® ND-1000 Spectrophotometer according to the manufacturers 
instructions.   91 
 
3.3.2  cDNA Synthesis; First-strand cDNA Synthesis by SUPER SCRIPT II 
Reverse Transcriptase 
1μg target RNA, 1μl 0.5μg/ml oligo dT(15) (Promega) and 1μl 10 mM dNTP mix (Promega) 
were added to a PCR tube and made up to 12 μl with dH2O.   The sample was placed on a 
PCR machine and heated to 65˚C for 5 minutes, then put on ice for ~1min to ensure the 
oligo dT(15) annealed to the poly(A) tail of the RNA.  4μl RT Buffer (5x1st strand Buffer, 
Invitrogen)), 2μl 0.1M DTT (Invitrogen) and 1μl RNase out (Invitrogen), made as a 
mastermix, was added and mixed by pipetting.  The sample was incubated at 42˚C for 2 
minutes and then 1μl SScript II RT (Invitrogen) added and mixed by pipetting.  The sample 
was then incubated at 42˚C for 50 minutes, allowing synthesis of the complementary 
strand, and heated at 70˚C for 15 minutes to inactivate the enzyme.  cDNA was stored at -
20˚C short term (weeks), or -80˚C long term.   
3.3.3  Polymerase Chain Reaction (RT-PCR) 
RNA extracted from cell lines was reverse transcribed as described above (Sections   3.3.1.2 
and   3.3.2) and 2μl of the cDNA synthesis products were diluted in a 50μl reaction mixture 
containing 1x Buffer, 0.2mM dNTPs, 1.5mM MgCl2 (for MMP-9 PCRs, 3mM for β-actin), 
0.001U/μl GoTaq DNA polymerase and 0.4μM.   
MMP-9 PCR conditions were as follows:  94˚C for 3 minutes, followed by 35 cycles of 94˚C 
for 30 seconds, 58˚C for 30 seconds then 72˚C for 30 seconds and 72˚C for 2 minutes final 
extension and 10˚C final hold. 
β-Actin PCR conditions were as follows: 94˚C for 3 minutes then 20 cycles of 94˚C for 30 
seconds, 64˚C for 30 seconds, 72˚C for 30 seconds and 72˚C for 2 minutes for final 
extension and 10˚C final hold for β-actin.   
The oligonucleotide primers for MMP-9 were as described
397 and synthesised for us by 
Eurofins MWG Operon (Ebersberg, Germany) and were as follows:  MMP-9 F:  5’ –GTG 
CGT CTT CCC CTT CAC TTT CCT- 3’ MMP-9 R:  5’ –GGA ATG ATC TAA GCC CAG CG- 3’ giving 
a 199bp fragment.   92 
 
The presence of MMP-9 in the panel of cell lines was confirmed with a second set of 
MMP-9 PCR primers
398 synthesized for us by Eurofins MWG Operon (Ebersberg, Germany) 
and were 5’ –CAA GGA TAC AGT TTG TTC CTC G- 3’ and 5’ –CAG AGA ATC GCC AGT ACT 
TCC- 3’ giving a 460bp fragment.  The cycle was as follows: 94˚C 3 minutes start, 38 cycles 
of 94˚C for 1 minute, 57˚C for 1 minute, 72˚C for 1 minute, then 72˚C for 2 minutes at end 
with final hold 10˚C.   
Negative controls (samples lacking cDNA) were included in each assay.  The PCR products 
were subjected to electrophoresis in an agarose gel with SafeView™.   
3.3.4  Analysis of Nucleic Acids by Agarose Gel Electrophoresis 
PCR products were resolved using agarose gel electrophoresis in TAE (Tris-Acetate-EDTA) 
Buffer.  Different concentration gels were used depending on the size of the fragments to 
be viewed.  The 184 bp β-actin and 199bp MMP-9 fragments were analysed on a 2% gel 
and 460bp MMP-9 fragments were analysed on a 1.5% gel.  All gels were run at 70mA for 
45minutes.  Plasmids were viewed using a 0.6% gel.   
To make the gels, agarose was measured in a conical flask and 75ml 1xTAE Buffer added 
to the conical flask.  The flask was then heated in a microwave oven on full power until all 
agarose had dissolved.  3.75μl SafeView™, a safe nucleic acid stain for the detection of 
double-stranded DNA, single-stranded DNA and RNA in agarose gels, was then added to 
the flask (0.05μl/ml TAE) and the gel poured into the gel tray with the gel comb in 
position.  The gel was allowed to set and the comb removed.  15μl of PCR product was 
loaded into the wells with 3μl of orange G loading dye.  5μl 100bp marker with 3μl loading 
dye was also loaded onto the gel for easy molecular weight reference.  The gel was 
subsequently viewed with a UV light.   
3.3.5  Cloning procedures 
The luciferase reporter plasmid for MMP-9 contains 2192bp (-2181 to +11) of the human 
MMP-9 promoter cloned into the promoterless plasmid vector (pGL3 Basic) containing the 
coding sequence for firefly luciferase and was kindly provided by Professor Shu Ye
394.  This 93 
 
plasmid contained the T allele of the SNP rs3918242 at -1562bp.  The DNA construct was 
verified by sequencing (Geneservice).   
Site Directed Mutagenesis; QuikChange™ Site-Directed Mutagenesis Kit (Stratagene) 
Additional point mutations (Figure 9) were introduced into the luciferase reporter plasmid 
using the QuikChange™ Site-Directed Mutagenesis Kit (Stratagene).  
Two complementary oligonucleotide primers containing the desired mutation (alternate 
alleles of rs3918241 and rs3918242) were designed and synthesised by Eurofins MWG 
Operon (Ebersberg, Germany).   
Primer design requirements: Both mutagenic primers must contain the desired mutation 
and anneal to the same sequence on opposite strands of the plasmid, primers should be 
25 and 45 bases in length and the melting temperature Tm of the primers should be 
greater than or equal to 78˚C and the primers optimally should have a minimum GC 
content of 40% and should terminate in one or more C or G bases.   
Sample reaction:  5μl of 10x reaction buffer, 1μl (50ng) of dsDNA template, 1μl (125ng) of 
each oligonucleotide primer, 1μl (125ng), 1μl dNTP mix (1μl of each A, C, G, T), ddH2O to a 
final volume of 50μl and 1μl PfuTurbo DNA polymerase (2.5 U/μl).  Samples were then 
heated to 95˚C for 30 seconds, then 18 cycles of 95˚C for 30 seconds, 55˚C for 1 minute, 
68˚C for 18 minutes (2min/kb of plasmid length).  The samples were transfered to ice and 
1μl of Dpn I restriction enzyme (10U/μl) added directly to each amplification reaction.  
Each reaction was mixed gently and thoroughly by pipetting up and down several times 
and then spun in a microcentrifuge for 1 minute and immediately incubated at 37˚C for 1 
hour to digest the parental DNA, then placed on ice.   
The SDM primers used were as follows: rs3918241 F:  5’ –TGT AAA GGA AGT TAA TTA TCT 
CC- 3’; rs3918241 R:  5’ –GGA GAT AAT TAA CTT CCT TTA CA- 3’,rs3918242 F:  5’ –GGC GTG 
GTG GCG CAC GCC TAT AAT ACC- 3’; rs3918242 R:  5’ –GGT ATT ATA GGC GTG CGC CAC 
CAC GCC- 3’ 94 
 
3.3.5.1 Preparation of LB Broth 
A stock of LB broth was maintained by Cancer Sciences Division Staff.   
3.3.5.2 Preparation of Selective Agar Plates 
A stock of ampicillin agar plates was maintained by Cancer Sciences Division staff.   
3.3.5.3 Transformations 
15ml falcon tubes were pre-chilled.  50μl chemically competent XL-1 E.coli cells were 
thawed on ice.  The end was clipped off a pipette tip (cell saver pipette tip).  The vial of 
cells was stirred to encourage thawing.  50μl of the competent cells were added to each 
falcon using the cell saver pipette tip.  0.5μl DNA was added to each tube and stirred with 
the pipette tip and the tube flicked gently to mix.  The falcon tubes were then left on ice 
for 20 minutes, heat shocked at 42˚C for exactly 45 seconds and placed back on ice for 2 
minutes.  250μl of broth was added to each tube.  The tubes were then left in the shaker 
at 200rpm, 37˚C for 1 hour 30 minutes.  The tubes were taken out of the shaker, the 
contents streaked onto the selective LB (100μg/ml Ampicillin) agar plate and the plates 
placed in the incubator overnight (37˚C).   
3.3.5.4 Selection and Culture of Colonies 
A single colony was selected from the freshly streaked selective ampicillin plate and 
inoculated in 5ml LB broth with 5μl 1000mg/ml ampicillin (final conc 100μg/ml) and 
incubated overnight at 37˚C with vigorous shaking (220rpm).   
The bacterial cells were harvested by centrifugation for 10 minutes at 1500rpm and the 
supernatant was removed by inverting the tube until all medium had drained out.   
If growing up cells for DNA Maxiprep, the contents of the universal was poured into a 
500ml conical flask with with 125ml broth with 125μl ampicillin and incubated (overnight) 
at 37˚C with vigorous shaking (220rpm).   95 
 
3.3.5.5 DNA Extraction from Transformed Bacterial Cultures; QIAprep Spin 
Miniprep Kit (Qiagen) 
Plasmid DNA was extracted using the QIAprep Spin Miniprep kit according to the 
manufacturer’s instructions.   
The pelleted bacterial cells were resuspended in 250μl Buffer P1 and transferred to a 
microcentrifuge tube, 250μl Buffer P2 was added and mixed thoroughly by inverting the 
tube 4-6 times, 350μl Buffer N3 was added and mixed thoroughly by inverting the tube 4-
6 times and then centrifuged for 10 minutes at 13,000 rpm (17,900g) to form a compact 
white pellet.  The supernatant was decanted into the QIAprep spin column, centrifuged 
for 30-60 seconds and the flow-through discarded.  The spin column was washed by 
adding 0.75ml Buffer PE and centrifuging for 30-60 seconds, the flow through discarded 
and the column centrifuged for a further minute to remove any residual wash buffer.  
Finally the QIAprep spin column was placed in a clean 1.5ml microcentrifuge tube and 
50μl Buffer EB (10mM Tris-Cl, pH 8.5) or water added to the centre of the spin column and 
the column left to stand for one minute, then centrifuged for one minute to elute the 
DNA.   
3.3.5.6 DNA Extraction from Transformed Bacterial Cultures;  QIAfilter 
Plasmid Maxi Kit (QIAgen) 
Plasmid DNA was extracted using the QIAfilter Plasmid Maxi Kit according to the 
manufacturer’s instructions.   
The culture media was poured into two labelled 50ml falcon tubes and pelleted by 
centrifugation at 6000g for 15 minutes, the medium was poured off to waste and the first 
pellet was resuspended completely in 10ml Buffer P1 by vortexing, transferred into the 
second falcon and vortexed to break up the second pellet.  10ml Buffer P2 was added and 
mixed thoroughly by vigorously inverting the tube 4-6 times, then incubated at room 
temperature for 5 minutes.  During the incubation the QIAfilter Cartridge was prepared 
and placed in a convenient tube.  10ml Buffer P3 was added to the lysate and mixed 
thoroughly by inverting vigorously 4-6 times and the lysate immediately poured into the 96 
 
barrel of the QIAfilter Cartridge and incubated at room temperature for 10 minutes.  
During the incubation the QIAGEN-tip 500 was equilibrated by applying 10ml Buffer QBT 
and the column allowed to empty by gravity flow.  The cap was removed from the 
QIAfilter Cartridge outlet nozzle and the plunger inserted gently into the QIAfilter Maxi 
Cartridge and the cell lysate filtered into the previously equilibrated QIAGEN-tip.  The 
cleared lysate was allowed to filter by gravity flow and the tip then washed with 2x30ml 
Buffer QC.  The Buffer QC was allowed to pass through the QIAGEN-tip by gravity flow.  
Once the Buffer QC had passed through the filter the QIAGEN-tip was placed over a fresh 
labelled falcon tube containing 10.5ml isopropanol.  15ml Buffer QF was added to the 
QIAGEN-tip to elute the DNA and allowed to pass through the filter by gravity flow.  The 
tubes were centrifuged for 4000rpm at 4˚C for 30 minutes to pellet the DNA.  The 
isopropanol was poured away and 1ml 70% ethanol added to the tube and vortexed.  The 
contents of the tube was transferred to a microcentrifuge tube and centrifuged for 5 
minutes at 10500xg.  The 70% ethanol was removed and the tube left, with the cap off to 
dry and then resuspended in 1xTE diluted in 300μl dH2O overnight, stored in the fridge.   
3.3.5.7 Sequencing of Plasmid DNA 
All sequencing orders were placed online at sequencing@geneservice.co.uk.  10μl of 
3.2pmol/μl primer and 15μl at 100ng/μl of sample were required.  The MMP-9 promoter 
region of the initial plasmid sent was sequenced using the RV3 and GL2 primers and the 
SDM-created constructs were sequenced with the RV3 primer to check the region where 
mutations were introduced and with the GL2 and MMP9_Int_F (designed by Dr Blaydes, 
synthesized by Eurofins MWG Operon (Ebersberg, Germany)) primers to check a wider 
region to ensure no other base changes had been introduced in the three reporter 
constructs selected for functional experiments.     
3.3.6  Transfection Procedures 
All cell culture procedures were performed in a filtered hood in sterile conditions.  Good 
laboratory practice was performed at all times and good asceptic conditions maintained 97 
 
when handling cell cultures and reagents.  All liquid waste (cells) was treated with 10% 
Trigene prior to disposal.   
3.3.6.1 Preparation of Cells 
MCF-7, MDA-MB-231, MRC5 and NIH-3T3 were maintained in Dulbecco’s modified Eagle’s 
medium, DMEM (Invitrogen), and H1299 cells maintained in Roswell Park Memorial 
Institute medium, RPMI 1640 (Invitrogen), both mediums were supplemented with 10% 
foetal calf serum (Autogen Bioclear) and penicillin/streptomycin solution (1%) (Cambrex) 
and L-Glutamine solution (1%) (Cambrex).  Cells were incubated at 37˚C and 10% CO2 for 
those in DMEM or 5% CO2 for those in RPMI.  All cell lines had been tested for 
Mycoplasma contaminations and found to be negative.  Generally cell cultures were re-
fed every other day with culture medium until confluent.   
Cells in culture flasks were maintained by periodic ‘splitting’.  When confluent cells were 
trypsinised according to the Standard Operating Procedure, JPB2_cell culture, and about 
80% of the cells were removed and an equal volume of fresh medium is added, depending 
on experimental requirements.  
Retrieval of frozen cells:  Stocks of cell cultures were stored in vapour phase liquid 
nitrogen tanks.  To retrieve cells, they were transferred to a 37˚C water bath or the CO2 
incubator then rapidly thawed in 10mls of complete medium (DMEM or RPMI) in a 15ml 
falcon tube.  Cells were spun at 1000rpm for 3 minutes, the supernatant removed to 
waste and the pellet resuspended in 10mls fresh medium (5mls if small pellet) and the cell 
suspension transferred to a T-75 (or T-25 if vial was sparse) tissue culture flask and 
incubated at the required CO2 concentration.   
Contact-dependent co-cultures were established by plating 1.5x10
6 MRC-5 and 1.5x10
6 
MCF-7 cells in a 90mm culture dish and made up to 10mls with DMEM and incubated at 
37˚C and 10% CO2 for 48 hours.   98 
 
3.3.6.2 Transfection with Plasmid DNA 
Cells were plated 24 hours in advance of transfection experiments.  The medium was 
aspirated and the cells washed with 10ml HBSS (T75 culture flask) and the HBSS aspirated.  
One ml of Trypsin-EDTA in HBSS was added to the culture flask and the cells agitated to 
encourage detachment from the flask.  8ml medium was pipetted over the cells and 
pipetted up and down to break up any clumps that may have formed.  The cell suspension 
was transferred to a falcon tube, leaving 1-2mls depending on confluency of the cells in 
the flask to maintain a stock of cells (made up to 10mls with fresh medium and replaced in 
incubator).  The falcon tube was inverted to mix and 40μl of the cell suspension was 
pipetted into a clean haemocytometer and the cell number counted (average of three 
grids), giving the number of cells x10
4/ml.  2x10
4 cells/well were transferred into a 96-well 
cell culture plate and the volume made up to ~150μl with fresh medium.  The cell culture 
plates were incubated at 37˚C for 24 hours.   
Prior to transfections the plated cells were examined under a light microscope to ensure 
cells were ~80% confluent.  Fresh dilutions of plasmids were made as required before 
each transfection experiment (either 100ng/μl or 200ng/μl for plasmid DNA and 20ng/μl 
for the Renilla luciferase expressing plasmid PRLSV40) and centrifuged at 4˚C, 10.5rpm, for 
10 minutes.    Separate mastermixes were made for each plasmid being transfected of 
200ng reporter vector and 20ng of PRLSV40 in 25μl Opti-MEM per reaction.  A second 
mastermix of 25μl Opti-MEM plus 0.6μl Lipofectamine 2000 reagent per reaction was 
made and incubated at room temperature for 5 minutes in the filtered hood.  25μl per 
reaction of the lipofectamine/Opti-MEM mix was then added to each of the 
reporter/Opti-MEM mixes and incubated at room temperature in the filtered hood for 20 
minutes.  The culture medium on the plated cells was carefully taken down to a volume of 
100μl.  50μl of transfection mix was added per well and mixed.  The cells were then 
incubated for 3-4 hours in CO2, the transfection mix was removed and the cells re-fed with 
100μl fresh medium and then incubated for ~48hours.  Transfections were performed in 
triplicate for each construct and repeated at least three times to ensure reproducibility of 99 
 
the results.  Total amounts of transfected plasmid were equalised by addition of the 
empty vector pGL3-noluc (pGL3 Basic vector with the luciferase gene removed).   
3.3.7  Reporter Gene Assay 
3.3.7.1 Luciferase Reporter Assay; Dual-Glo
™ Luciferase Assay System 
(Promega) 
Cells were removed from the incubator.  Medium was taken down to 50μl/well.  50μl Dual 
Glo Luciferase reagent was added per well, pipetted up and down to mix and incubated at 
room temperature for 10 minutes.  The lysed cells were transferred to an optiplate, 
covered with a sticky film and processed on a chemiluminescence detector.    50μl 1x Stop 
and Glo reagent was added to each well and processed on the plate reader.  The reporter 
activity was measured as the ratio of firefly to Renilla luciferase to normalise results.  
Results from independent transfection experiments were normalised, averaged and 
standard error calculated.  One-way ANOVA and Tukey HSD post hoc testing with SPSSv17 
software were used for the statistical analysis.  
 
Figure 9: Diagram of pGL3-MMP-9 promoter construct.  Plasmids were created for the four possible 
haplotype combinations of the 2 SNPs (rs3918241 T/A and rs3918242 C/T) using site directed mutagenesis 
of the original plasmid.   100 
 
Chapter 4  Results 
4.1  Analysis Results 
4.1.1  Overview 
SNPs from 30 candidate genes were selected and genotyped.  The genotype data was 
screened to remove poor quality data and the remaining SNPs associated with grade, 
lymph node status, oestrogen receptor status, presence of distant metastases and 
lymphovascular invasion using the Cochran-Armitage trend test and 2-by-3 tables of 
disease by genotype.  The effect of these SNPs on risk was investigated using the Log rank 
test to compare Kaplan-Meier survival curves.   
4.1.2  Analysis QC results 
After performing quality control checks on the data, 73 SNPS and 58 individuals were 
removed from the analysis due to poor genotyping.  After population stratification a 
further 44 individuals were removed leaving 899 for the analysis.   
4.1.3  Patient Cohort 
The phenotypic characteristics of the breast cancer cases that were genotyped and passed 
quality control are shown in Table 3, grouped according to their oestrogen receptor status 
and grade.  Of the 899 cases successfully genotyped, 26 had missing phenotype data.  Our 
cohort of young onset breast cancer patients contains more high grade, oestrogen 
receptor negative tumours than would be expected in breast cancer cohorts including 
individuals aged 40 years and over at diagnosis
399, having nearly 10% more ER-negative 
tumours compared with women aged 40 years and older at diagnosis
399 (30.9% in POSH 
versus 21.4% in women aged ≥ 40 years).   101 
 
Table 3: Summary statistics– phenotypic characteristics of the 899 individuals successfully genotyped 
according to oestrogen receptor status and grade (% of total). 26 individuals were missing phenotype data 
 
   ER+  ER-  Unknown  Total 
Grade 1  60  3  1  64 
Grade 2  276  28  2  306 
Grade 3  267  239  7  513 
Unknown  12  3  1  16 
Total  615  273  11  899 
4.1.4  Association with Phenotype 
The SNPs that passed QC were investigated to determine any association with different 
aspects of tumour biology using Cochran-Armitage trend test and 2-by-3 tables of disease 
by genotype, using Plink
156.   The frequency of both alleles in the patient cohort was 
recorded as well as the chi-square, asymptotic p-value and an estimated odds ratio for the 
minor allele for each SNP.  An odds ratio above 1 indicates a positive association with the 
phenotype and a value below one a negative association.  A corrected P value of 0.0006 or 
less indicated a significant result.   
4.1.4.1 Association with Grade 
Comparison of phenotypic extremes of grade (grade 1 vs. grade 3) were compared to 
ensure significant results and gave evidence that two SNPs in ESR1, and a SNP in IGF1 and 
LSP1 were significantly associated with grade, with ESR1 and IGF1 SNPs being associated 
with a higher grade, and the LSP1 SNP with lower grade (Table 4).  None of these 
associations remained significant after Bonferroni correction for the 82 independent tests.   
Table 4- Association with grade 
Frequency  GENE  SNP  A1 
Grade 3  Grade 1 
A2  CHISQ  P  OR 
ESR1  rs2228480  A  0.2178  0.1032  G  9.031  0.00265  2.421 
ESR1  rs3798577  C  0.5088  0.373  T  8.275  0.00402  1.741 
IGF-1  rs2373721  G  0.25  0.1406  C  7.509  0.00614  2.037 
LSP1  rs661348  C  0.3694  0.4921  T  7.146  0.00752  0.6046 
ATM  rs4987876  T  0.0765  0.1406  G  6.108  0.01346  0.506 
DAPK1  rs11141901  G  0.2173  0.3125  A  5.855  0.01553  0.611 102 
 
4.1.4.2 Association with Lymph Node Involvement 
Several SNPs in genes including CASP8, ERBB2, CYP1B1, ATM, MMP-9 and IGF-1 appear to 
be associated with lymph node status, however none of the differences are significant 
(Table 5).   
Table 5-Association with lymph node involvement 
Frequency  GENE  SNP  Minor 
Allele  LN+  LN- 
Major 
Allele 
CHISQ  P  OR 
CASP8  rs6760993  G  0.5196  0.4622  A  5.712  0.01685  1.259 
ERBB2  rs1058808  C  0.3054  0.3578  G  5.371  0.02047  0.7891 
CYP1B1  rs10175368  T  0.2978  0.2481  C  5.256  0.02188  1.285 
ATM  rs1800889  T  0.04039  0.06463  C  5.172  0.02295  0.6092 
MMP-9  rs2250889  G  0.05991  0.03667  C  5.016  0.02511  1.674 
IGF-1  rs5742714  C  0.06522  0.09413  G  4.986  0.02556  0.6714 
4.1.4.3 Association with Oestrogen Receptor Status 
Comparisons of genotypes of patients with oestrogen receptor positive and negative 
breast cancer produced strong evidence that SNPs in FGFR2 and TOX3 are associated with 
oestrogen receptor positive breast cancer and two SNPs in the ATM gene were associated 
with oestrogen receptor negative breast cancer (Table 6).  The two FGFR2 SNPs and one 
ATM SNP remain significantly associated after conservative correction for multiple tests.   
Table 6-Association with Oestrogen receptor status 
Frequency  GENE  SNP  Minor 
Allele  ER+  ER- 
Major 
Allele 
CHISQ  P  OR 
FGFR2  rs2981582  T  0.478  0.3595  C  21.59  0.00000338  1.632 
FGFR2  rs1219648  G  0.4853  0.3741  A  18.91  0.00001372  1.578 
ATM  rs1801516  A  0.1092  0.1769  G  14.6  0.0001331  0.5704 
TOX3  rs1420546  C  0.3649  0.2854  T  10.41  0.001256  1.438 
ATM  rs3092991  G  0.1254  0.1807  A  9.444  0.002119  0.6503 
DAPK1  rs9410612  T  0.3068  0.3668  A  6.215  0.01267  0.7641 
4.1.4.4 Association with Distant Metastasis 
Three SNPs in the MMP-9 gene were significantly associated with the presence of distant 
metastases (Table 7), however only one of the associations remained significant after 
Bonferroni correction for the 82 independent tests.  When the data was stratified into ER-103 
 
positive and ER-negative groups these associations increased in significance in the ER-
positive cohort, with three SNPs in the MMP-9 gene (rs6065912, rs3918241 and 
rs3918261) maintaining significance after correction for multiple tests (Table 9), but were 
of no significance in the ER-negative group (Table 8).   Two SNPs in ATM and one in IGF-1 
were significantly associated with the presence of distant metastasis in ER-negative 
patients before Bonferroni correction for the 82 independent tests.   
Table 7-Association with distant metastasis 
Frequency  GENE  SNP  Minor 
Allele  Mets  No Mets 
Major 
Allele 
CHISQ  P  OR 
MMP-9  rs6065912  A  0.325  0.1323  G  12.31  0.00045  3.159 
MMP-9  rs3918241  A  0.325  0.1464  T  9.747  0.001796  2.806 
MMP-9  rs3918261  G  0.325  0.1471  A  9.653  0.001891  2.793 
IGF-1  rs2373721  G  0.425  0.2312  C  8.153  0.0043  2.458 
DAPK1  rs1041326  T  0.275  0.1295  C  7.181  0.007368  2.55 
DAPK1  rs11141901  G  0.375  0.2226  A  5.19  0.02272  2.095 
 
Table 8– Association with Distant metastasis in ER-negative patients 
Frequency  GENE  SNP  Minor 
Allele  Mets  No Mets 
Major 
Allele 
CHISQ  P  OR 
ATM  rs1801516  A  0.5  0.1687  G  8.859  0.002916  4.929 
ATM  rs3092991  G  0.5  0.1729  A  8.5  0.003552  4.783 
IGF-1  rs2373721  G  0.5833  0.2283  C  8.199  0.004191  4.732 
IGF-1  rs1520220  G  0.4167  0.1552  C  5.937  0.01483  3.889 
IGF-1  rs2946834  A  0.6  0.3  G  4.161  0.04137  3.5 
RHOC  rs2999156  G  0.75  0.4604  C  3.955  0.04674  3.516 
RHOC  rs12144044  A  0.5  0.2528  C  3.742  0.05306  2.955 
 
Table 9- Association with Distant metastasis in ER-positive patients 
Frequency  GENE   SNP  Minor 
Allele  Mets  No Mets 
Major 
Allele 
 CHISQ   P   OR 
MMP-9  rs6065912  A  0.3929  0.1307  G  15.93  0.00006582  4.304 
MMP-9  rs3918261  G  0.3929  0.148  A  12.62  0.00038200  3.725 
MMP-9  rs3918241  A  0.3929  0.1494  T  12.37  0.00043570  3.684 
DAPK1  rs1041326  T  0.3214  0.1326  C  8.243  0.00409100  3.099 
FN1  rs10207245  A  0.2143  0.4311  T  5.258  0.02184000  0.3599 
MMP-7  rs11225309  A  0.3929  0.2125  C  5.244  0.02203000  2.399 104 
 
4.1.4.5 Association with Lymphovascular Invasion 
Two SNPs in DAPK1 appear to be associated with lymphovascular invasion, whereas a SNP 
in the MMP-7 gene has a protective effect (Table 10).  None of these associations 
remained significant after Bonferroni correction for the 82 independent tests.   
Table 10-Association with lymphovascular invasion 
Frequency  GENE  SNP  Minor 
Allele  LVI  No LVI 
Major 
Allele 
CHISQ  P  OR 
DAPK1  rs10746815  G  0.4016  0.3349  A  7.8  0.005226  1.333 
DAPK1  rs1041326  T  0.1572  0.1118  C  7.072  0.00783  1.482 
MMP-7  rs1943779  C  0.252  0.2966  T  4.07  0.04364  0.7989 
DAPK1  rs11141901  G  0.248  0.2081  A  3.715  0.05393  1.255 
MAP3K1  rs889312  C  0.2882  0.3311  A  3.506  0.06114  0.8179 
ESR1  rs3020403  G  0.2987  0.3402  C  3.192  0.07398  0.8258 
DAPK1  rs9410612  T  0.3465  0.3054  A  3.143  0.07626  1.206 
4.1.5  Association with Survival  
The association of the SNPs passing QC with survival was investigated using distant 
disease free survival as a surrogate for overall survival.   Kaplan-Meier survival curves for 
the three genotype combinations for each SNP were compared using the Log rank test.  
Before correction for multiple testing, significant associations were seen with seven SNPs 
representing five genes, one SNP in DAPK1 (rs1045042), the previously reported SNP in a 
gene desert (rs13281615), two SNPs in ESR1 (rs2228480 and rs3020410), one SNP in LSP1 
(rs599774), one SNP in MAP3K1 (rs889312) and one SNP in MMP-7 (rs1943779).    
Association of the MMP-9 SNP rs3918241 with distant disease free survival was more 
significant in ER positive patients than ER negative patient but did not quite reach 
significance.   105 
 
   
   
 
 
 
 
 
 
Figure 10: SNPs affecting prognosis (p<0.05) 
identified by Kaplan-Meier analysis. Survival curves 
for rare homozygotes are shown as yellow lines, 
heterozygotes by green lines and common 
homozygotes by blue lines.  P values shown are 
derived from the log-rank test. 
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4.2  Functional Study Results 
4.2.1  Overview 
The functional significance of the MMP-9 promoter SNPs rs3918241 and rs3918242 were 
investigated with a series of transient transfection experiments into a range of cell lines.  
The SNP rs3918242 has previously been shown to have functional significance
394 and 
rs3918241 is close by in the promoter region and demonstrated a significant association 
with distant metastasis in this study.  Our panel of cell lines was screened to see which 
expressed MMP-9 mRNA and those cell lines selected for transfection experiments with a 
luciferase reporter vector containing one of the four haplotypes of the two promoter 
SNPs.   
4.2.2  Cell Line RT-PCR 
RT-PCR showed MMP-9 expression in the H1299, MCF-7, SKBR3 and ZR75.1 cell lines, but 
not in the T47D, BT474, MDA-MB-231 or MRC-5 cell lines (Figure 11) and this was 
confirmed with the second primer set (Figure 12).  No increase in expression was seen on 
co-culture of MCF-7 cells with MRC-5 fibroblasts.   
 
Figure 11: MMP-9 expression identified by RT-PCR - primer set 1 
 
199 bp→ 107 
 
 
Figure 12: MMP-9 expression identified by RT-PCR - primer set 2 
 
 
 
Figure 13: B-actin expression identified by RT-PCR, used as an internal standard for RNA integrity and 
accuracy of loading.   
4.2.3  Luciferase Reporter Assays 
We transfected the luciferase reporter vector into both H1299 and MCF-7 cells as both of 
these cell lines showed expression of MMP-9 by RT-PCR.  We also transfected the 
luciferase reporter vector into the mouse fibroblast cell line NIH-3T3 and the human lung 
fibroblast cell line MRC5, as well as the metastatic breast cancer cell line MDA-MB-231.  
RT-PCR did not show a positive expression of MMP-9 in the MDA-MB-231 cell line, 
460 bp→ 
184 bp→ 108 
 
however literature suggested this cell line expressed MMP-9
400;401 and there is a great deal 
of literature reporting the significance of fibroblast MMP-9 expression in breast cancer
84.   
Cells were co-transfected with Renilla Luciferase to control for transfection efficiency and 
the ratio of firefly to Renilla luciferase calculated to give RLU.  The triplicate repeats for 
each plasmid were averaged and results normalised to the plate by dividing the average 
result for each plasmid by the average RLU for all transfections on that plate.   
4.2.3.1 H1299 Transfections 
There were no significant differences between any of the plasmids when transiently 
transfected into H1299 cells (p=0.061).  The minor allele (A) of the SNP rs3918241 gives 
slightly higher levels of activity than the wild type (T) in this position, as does the wild type 
(C) allele of rs3918242.   
4.2.3.2 MCF-7 Transfections 
There were no significant differences between any of the plasmids when transiently 
transfected into the oestrogen receptor positive MCF-7 cell line (p=0.249).  Results show a 
slightly increased activity with the minor allele (A) at rs3918241 especially in the context 
of the wild type C allele at rs3918242.   
4.2.3.3 MDA-MB-231s Transfections  
Statistically significant differences in activity were observed on transfection of the 
oestrogen receptor negative, highly metastatic MDA-MB-231 cell line with our plasmids.  
The C allele of the SNP rs3918242 yields approximately a 1.5 fold increase in activity over 
the T allele and is marginally increased with the presence of the T allele at rs3918241.  
With the T allele present at rs3918242, the SNP rs3918241 appears to have no effect.    
4.2.3.4 NIH-3T3 Transfections  
There were no significant differences between any of the plasmids when transiently 
transfected into NIH-3T3 cells (p=0.256), however a similar pattern was observed as with 109 
 
the MCF-7 and H1299 cell lines, with the AC haplotype giving the highest levels of activity 
in reporter assays.     
4.2.3.5 MRC-5 Transfections  
The MRC-5 cell line did not transfect well enough with our plasmids to give reliable 
results.   
   
   
 
Figure 14: Effects of MMP-9 promoter polymorphisms on MMP-9 expression in MCF-7 (A) H1299 (B) MDA-
MB-231 (C) and NIH3T3 (D) cell lines.  Plasmids are referred to by the allele present at rs3918241 and 
rs3918242 respectively.  Cells were transfected with 200ng/well of luciferase reporter construct and 20ng 
PRLSV40 to serve as a reference for transfection efficiency.  Reporter activity was measured as the ratio of 
firefly to Renilla luciferase activity to give RLU (relative light units).  Results of each transfection were 
normalised to the plate by dividing each result (an average of the triplicate repeats) by the average RLU 
for the plate.  Results from indepedantly repeated experiments were averaged ((A) and (B) n=9 (C) and (D) 
n=4).  Results shown +/-  standard error of the mean.  P-values were generated using one-way ANOVA.   
A  B 
C  D 
P=0.249  P=0.061 
P=0.00002549  P=0.256 110 
 
Chapter 5  Discussion  
5.1  Discussion 
Breast cancer affects around 46 000 people in the UK each year and is a leading cause of 
death amongst women in the western world.  There is a clear genetic component to 
breast cancer with approximately 30% of breast cancers being familial.  Despite this, only 
a fraction of the genes involved in breast cancer susceptibility have been identified.  With 
mutations in the known high (BRCA1, BRCA2, TP53) and intermediate (ATM, BRIP, CHEK2, 
NSB1, PALB2, PTEN, RAD50) penetrance susceptibility genes, accounting for less than 50% 
of familial breast cancer cases, a lot remains to be elucidated.  Recent GWAS have begun 
to identify several low penetrance susceptibility alleles that may account for some of 
unknown genetic susceptibility.  Our study investigated whether these common genetic 
variants might predispose to a certain type of cancer by selecting SNPs in candidate genes 
and using statistical tests to look for associations with certain tumour phenotypes.  We 
discovered SNPs in various genes that showed associations with different tumour 
phenotypes both confirming previous associations and identifying novel associations, 
including three SNPs in the MMP-9 gene associated with distant metastasis.  Distant 
metastasis is the most life-threatening aspect of cancer and remains the overwhelming 
cause of death in breast cancer patients
157 and MMP-9 has been clearly implicated in 
progression of breast cancer.  We therefore persued a more detailed investigation into 
the functional significance of the MMP-9 promoter SNPs rs3918241 and rs3918242 as the 
ability to more accurately predict the risk of distant metastasis will have significant 
therapeutic implications.     
5.1.1  Identifying Common Genetic Variants 
Common genetic variants depend on very large scale studies to ensure statistical 
significance of a suspected SNP association.  Genome wide association studies have the 
power to identify associations between a disease and common genetic variants with low 
penetrance.  However sample size and replication of results are concerns and the 111 
 
detection of further susceptibility loci will require genome-wide studies with more 
complete coverage and using ever larger numbers of cases and controls and there is doubt 
as to whether such large studies are possible, or worthwhile
402 as they may still not 
produce associations with sufficient predictive power to be of practical use.  There is 
increasing concern that in modern research, false findings may account for the majority or 
even the vast majority of published research claims
403 and would be worthless for risk 
prediction
50.  Many GWAS have been underpowered to detect real associations.  It has 
been suggested that more than 2000-5000 samples are needed to identify significant 
association in these studies
404.   
A large number of new susceptibility alleles have been identified and each confers only a 
very small increase in breast cancer risk.  The high frequency of these variants in the 
population and their low predictive value currently makes them of little use in clinical 
practice, however either alone or in combination with each other, and with the 
identification of further alleles, a combination of these may give a much increased odds 
ratio and thus become appropriate for predictive genetic testing
21.  It is thought it will be 
possible to identify those individuals that are susceptible to breast cancer by their 
genotype profile and prevent disease by targeting certain interventions to the at risk 
individuals.  This will provide improvements in the efficacy of population-based programs 
of interventions for cancers such as mammography by targeting women who are at the 
greatest risk for breast cancer according to genotype.   
Although each SNP may only contribute a small increase in risk, the overall effect of 
combinations of SNPs on breast cancer risk may be substantial.  This polygenic effect of 
SNPs may be additive or synergistic and may account for most genetic risk.  Recently, 
attempts have been made to identify breast cancer risk that is conferred by SNP-SNP 
interactions,
44 the strategy developed identified interactions suggesting cross-talk 
between genes from different pathways such as DNA repair and metabolism pathways 
and has the potential to identify more complex interactions that may include three or 
more SNPs in cross-talk between different cancer pathways providing insights into the 112 
 
multi-genic nature of cancer and the effect of cell functions on breast cancer 
development.  This knowledge may ultimately improve breast cancer risk management.   
Our study identified several associations of SNPs with different tumour phenotypes, 
including three (rs2981582, rs1219648, and rs1801516) in two different genes that 
remained significant after stringent correction for multiple testing.  We confirmed 
previous associations of SNPs in the FGFR2 gene (rs2981582, rs1219648) with ER-positive 
breast cancer
211.  Also three SNPs were identified in MMP-9 that were strongly associated 
with the presence of distant metastasis, one of which was significant after correction for 
multiple testing in ER-positive patients.   
The potential role of SNPs in guiding treatment decisions is promising, however little is 
known about the roles that these susceptibility alleles play.  It is likely that the smaller the 
odds ratio for a given association, the more likely it is that environmental factors will 
predominate.  Therefore improved understanding of genetic risk factors and their 
interactions with the environment may allow more accurate predictions of disease and 
facilitate prevention through measures directed towards people at higher than average 
risk.     
5.1.2  Functional Significance of Common Genetic Variants 
We identified SNPs in the promoter region of MMP-9 that were significantly associated 
with the presence of distant metastasis and given the extensive literature documenting an 
association of MMP-9 with tumour progression we decided to investigate this further.  
The proposed role of MMP-9 in breast cancer has been based mainly on observations of 
high levels of expression in malignant tumours and association of elevated MMP-9 levels 
with poor prognostic features such as higher grade.  We performed a series of transient 
transfection experiments to see if a SNP was responsible for some of the increase in MMP-
9 observed in cancer.  We investigated the effect of two promoter SNPs, rs3918241 and 
rs3918242.  Although rs3918242 did not type in our cohort, it has been previously 
reported to have a fuctional effect on MMP-9 expression
394 and rs3918241 is close by in 113 
 
the promoter region, and was significantly associated with distant metastasis before 
Bonferroni correction in the whole cohort and significantly associated with distant 
metastasis after Bonferroni correction in the ER-positive cohort in this study.  Our results 
indicated that the common, wild type, allele (C) of SNP rs3918242 leads to an increased 
production of MMP-9.  This contradicts the only study to date on the functional effect of 
this SNP which reports a 1.5 fold increase in MMP-9 expression with the minor (T) allele of 
this SNP.  Although not significant, our data also suggests that the minor (A) allele of 
rs3918241 is associated with an increased production of MMP-9 in MCF-7, H1299 and 
NIH-3T3 cells.   
5.1.2.1 The Matrix Metalloproteinases 
The MMPs are zinc dependent proteases whose primary function is extracellular matrix 
degradation and remodelling.  These actions can impact on the behaviour of tumour cells 
by creating a space into which tumour cells can migrate, promoting metastasis.  MMPs 
can also cleave growth factors, cell surface receptors, cell adhesion molecules and 
chemokines/cytokines,
405-408 modifying the activity of these signalling molecules.
409  
Matrix metalloproteinases may also regulate angiogenesis both positively and 
negatively.
157;410;411  
Despite several MMP family members being specifically implicated in the progression of 
breast cancer, the regulation of MMP expression and activity in tumours appears complex 
and the manner in which MMPs collectively contribute to breast tumour progression is 
not well understood
56. 
MMPs are mostly secreted into the matrix as latent zymogens (proenzymes) by various 
stromal and epithelial cell types, including mesenchymal cells, T cells, monocytes, 
macrophages, neutrophils, keratinocytes and tumour cells.  The zymogen is cleaved into 
an active enzyme, usually in the pericellular or extracellular space.  Activation of MMPs in 
the local micro-environment can result in discrete alterations in tissue architecture
412.   114 
 
Endogenous MMP inhibitors are the tissue inhibitors of metalloproteinases (TIMPs).  
TIMPs are produced by the same cells that produce MMPs and act by forming complexes 
with the MMPs.  Under normal physiological conditions MMPs are present in tissues at 
low levels, usually in the latent form, and are responsible for normal tissue turnover
413 
with their local activity in tissues being regulated by the TIMPs.   
The function of the MMPs is tightly regulated by several different mechanisms
407;409;414:  at 
the level of transcription, at the point of activation from the precursor zymogens, 
interaction with specific ECM components, modulation of MMP mRNA half-life by growth 
factors and cytokines has been documented
415 and inhibition by the TIMPs
56;415;416.  If 
MMP-9 production is excessive, TIMP inhibition can be insufficient to control the MMPs 
which can cause an imbalance in the ECM breakdown and repair system
413.   
Several MMPs have been implicated in the development and progression of cancer but 
the majority of the literature focuses on the gelatinases (MMP-2 and MMP-9) which have 
been implicated in several aspects of tumourigenesis, particularly invasion and 
metastasis.
417 
MMP-9 is regulated primarily at the transcriptional level.  Its expression is regulated 
tightly and specifically
418;419  under the control of a 2.2kb upstream regulatory sequence 
that is known to harbour binding sites for AP-1 (activator protein 1), NFκB (nuclear factor 
κB), SP-1 (specificity protein 1) and PEA3/Ets (PEA3-polyoma enhancer activator 3).
420  
Data by Yao et al
417 suggests there is also a heregulin-β1-response element in the MMP-9 
promoter region from -84bp to -241bp.  Multiple signalling pathways can induce MMP-9 
gene transcription by activating sequence specific transcription factors which bind to 
these cis-elements on the MMP-9 promoter
418;419;421 in turn promoting the further 
recruitment of chromatin remodelling complexes, co-activators and transcriptional 
machinery to induce MMP-9 expression.
421  Transcription of the gene generates a 2.5kb 
transcript that is translated into the latent 92kDa protein product, which is activated by 
several enzymes including stromelysin, MMP-2 and cathepsin G by the removal of 73 
amino acids at the N-terminus.
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5.1.2.2 The Role of MMP-9 in Breast Cancer 
For distant metastasis to occur tumour cells must detach from the primary tumour site, 
intravasate into the blood or lymphatic system and extravasate at distant sites of the 
body.  This invasive process is regarded as a multi-step phenomenon.  In 1986 Lance 
Liotta
422 proposed the three step theory of invasion hypothesis that describes the series of 
biochemical events occurring during invasion of the ECM by tumour cells.  The first step is 
tumour cell attachment via cell surface receptors which specifically bind to components of 
the matrix such as laminin and fibronectin.  The second step is local proteolytic 
degradation of basement membrane and the extracellular matix (including degradation of 
the attachment components) by hydrolytic enzymes secreted by, induced by, or activated 
by the anchored tumour cell.  The third step is tumour cell locomotion into the region of 
the matrix modified by proteolysis.  Continued invasion of the matrix may take place by 
cyclic repetition of these three steps 
422;423.  Malignant cells continually stimulate the host 
stromal and vascular cells to carry out physiological invasion and this activation of the 
local invasive environment seems to create a permissive field for the malignant cell
76;88;138.   
Therefore the localised degradation of the ECM by enzymes, step two of the three step 
theory of invasion, is crucial for tumour cells to be able to detach from the primary 
tumour, invade the stromal tissue, enter the circulation, arrest at the peripheral vascular 
bed, extravasate, invade the target organ interstitium and parenchyma, and form a 
metastatic colony and migrate
56;415;424;425 playing a key role in the process of invasion and 
subsequent metastasis.   
Various classes of proteolytic enzymes such as the matrix-metalloproteinases (MMPs), 
serine proteinases and cathepsins have all been implicated in the proteolytic process 
170;351;426-429.  However, some components are very resistant to proteolytic attacks, and are 
degraded only by matrix metalloproteinases, particularly the interstitial collagens
170.   
Type IV collagen is the main protein of the basement membrane, an insoluble continuous 
but flexible structure beneath the epithelial linings and around vascular structures which 
is impermeable to large proteins
430,  and it forms the first barriers through which the 116 
 
invading and metastasizing cells must penetrate
55.  The basement membrane becomes 
locally permeable to cell movement only during tissue remodelling.  Type IV collagen is an 
important substrate because it constitutes the structural scaffolding upon which the other 
components of the matrix are assembled.  Degradation of this structural protein is 
believed to be preferentially performed by two specific type IV collagenases/gelatinases-
namely, the 72kDa (MMP-2) and the 92kDa (MMP-9) forms
56;431.   
Therefore, MMP-9 is of crucial importance in the process of invasion and metastasis since 
production of basement membrane-degrading enzymes by cancer cells is necessary for 
invasive growth
55;414;422;432  and direct evidence of its role in tumour progression has been 
derived from transfection experiments in which the MMP-9 gene in non-metastatic cells 
endowed them with the ability to metastasize
433.   
Differential proteinase expressions have been identified in breast cancer suggesting that 
distinct proteinase profiles may be involved at different stages of the metastatic cascade, 
depending on the surrounding components of the ECM
434 and it has been described that 
production and activation of MMP-9 occurs during the late cancerous stage
77;359;435  which 
could explain its impact on prognosis in clinically detected invasive breast tumours 
157.  It 
is possible that a somatic mutation leading to an increased level of MMP-9 will alter the 
balance between host proteases and protease inhibitors and increase the likelihood of a 
patient’s tumour becoming invasive.   
Numerous studies have been conducted to localise expression of MMP-9 however it 
remains controversial as to which cells secrete MMP-9 and which cells regulate its 
activation in cancer.  The expression of MMP-9 in breast tumour tissue has been examined 
by different methods with varying results, including ELISA
436, northern blotting
437, 
zymography
417;435;438;439, in situ hybridization
440 and immunohistochemistry
56;440.  Many 
reports show that MMP-9 is expressed in tumour cells, however it has become apparent 
that production of MMP-9 is not solely a characteristic of malignant tissue as secretion of 
MMP-9 has been also been demonstrated in several other cell types
364.   117 
 
Many studies have shown that MMP-9 is expressed in breast cancer tissue, but there are 
conflicting results regarding the identity of the cells that express this protease.  MMP-9 
has continually been identified to some extent in breast tumour cells
55;56;364;434.  However 
the most significant expression appears to be in the stromal cells, in particular the 
inflammatory cells, predominantly the macrophages
56;80;364;414;424;434;440-442 and 
fibroblasts
55;364;434 and to a small degree in endothelial cells
55;414;424 with no MMP-9 
expression seen in normal breast tissue
56;364.   
There is very little literature on the expression of MMP-9 in breast cancer cell lines, and 
reports are conflicting.  In agreement with our results, RT-PCR has identified MMP-9 
expression in SKBR3
417 and MCF-7
443 and no expression seen in MDA-MB-231 cells
99.  In 
contrast to our results MMP-9 mRNA expression has also been identified in MDA-MB-231 
at high
400 and low
401 levels and in T47D cells but not in MCF-7, SKBR3 or ZR75.1
99.   
In many cancers MMP-9 expression was not localised to the tumour cells themselves but 
to the surrounding stromal cells suggesting that tumour cell-host cell communication is 
critical to the regulation of MMP-9 regulated tumour cell progression and in contrast to 
the above studies, several reports have shown that direct cell-cell contact is required for 
MMP-9 expression
99;425;444 and a malignant phenotype
445.   
Some studies have found that direct cell-cell interactions between tumour cells and their 
stroma are essential in the induction of MMP-9 expression in breast tumour-derived 
stromal fibroblasts.   Co-culture of MCF-7 cells with breast tumour derived fibroblasts 
induced MMP-9 activity
99 in the tumour fibroblasts, shown by RNase protection assays.  
This was not seen in our results which demonstrated a high level of expression of MMP-9 
in MCF-7 cells alone, and no increase in activity upon co-culture of MCF-7 cells with the 
MRC5 fibroblast cell line.  However, many reports have demonstrated that this contact 
dependant stromal expression of MMP-9 is dependent on the malignancy of the tumour 
cell line
104;425;444.  An increased invasiveness of malignant cells has been seen on co-
cultivation with macrophages due to a TNFα-dependant MMP induction in the 
macrophage, this induction was not seen with a benign cell line
80.  Therefore co-culture of 118 
 
the more malignant cell line MDA-MB-231 with human fibroblasts may show an increase 
in MMP-9 expression and in fact this has been previously shown to increase production of 
MMP-9 when compared with breast cancer single cell culture or fibroblast single cell 
culture experiments as demonstrated by zymography and Western immunoblot 
analysis.
446  Some reports, however, have suggested that direct cell-cell contact is not 
necessary and that MMP-9 expression is induced in the tumour cell via a soluble factor 
released from the fibroblasts.
446;447   
With so many studies demonstrating that MMP-9 expression is dependent on the 
malignancy of the cell line, it fits that MMP-9 expression be associated with a more 
malignant phenotype
433;441;445;448 with increased metastatic potential
364;415;417;449-456 and so 
MMP-9 levels may well be a good prognostic marker in cancer.   
To date only a few studies have investigated the prognostic value of MMP-9 in breast 
cancer and, as with the localisation of expression of MMP-9, results are not consistent.  
The majority of the studies use immunohistochemical techniques.  MMP-9 expression has 
been associated with several aggressive factors
437 such as a higher grade 
359;457, presence 
of distant metastases
157;449, lymph node metastasis
368, and poor survival
157;437;457.  A poor 
survival in hormone responsive small tumours with an increased stromal expression was 
also reported.
414  In contrast to the above studies, the same group also reported that 
increased tumour cell expression of MMP-9 was associated with smaller tumours and a 
low recurrence rate, favouring survival.  When stratified into subgroups based on lymph 
node involvement (positive or negative) an increased MMP-9 expression was correlated 
with a favourable prognosis
56 and lower grade and reduced lymphovascular and vascular 
invasion
434 in the lymph node negative patients.  However, several reports have found no 
association between an elevated MMP-9 expression and prognostic factors.
364;458-460  
Macrophage MMP-9 expression has also been implicated in tumour progression by 
increasing angiogenesis, tumour invasion and metastasis.
83;461  
The inconsistent results of association with disease progression from 
Immunohistochemistry studies may be explained in part by the use of different 119 
 
antibodies. Antibodies may be specific for different forms of the MMP-9 protein, for 
example they may be specific for latent, active, or total MMP-9, or all three.  Also, some 
antibodies may recognise only uncomplexed MMP-9 whereas others may only recognise 
MMP-9 complexed with TIMP. It is often not made clear which forms of MMP-9 are 
recognised by the antibodies, making it difficult to compare studies.  The importance of 
the form of the protein recognised by the antibodies was demonstrated by Garbett et al
462 
who found the latent form of MMP-9 in both tumour and background breast tissues but 
only the active form of this enzyme in tumour tissue of paired samples. Davies et al
359 also 
found that there was a higher proportion of active enzyme with increasing tumour grade.   
The antibodies used by Scorilas et al
56 and Baker et al
434 recognize only the latent form of 
the enzyme and this may explain the apparently positive effect of MMP-9 expression in 
lymph node negative patients, since it is likely that initially MMP-9 presenting in tumours 
from node negative patients is in the inactive form and as the tumours become more 
aggressive the balance shifts towards the active form.  This shift to the active form could 
lead to metastatic progression and increased malignancy, for example via enhanced 
angiogenic activity and therefore the latent MMP-9 staining disappears
414.  This 
explanation fits with the evidence of increasing MMP-9 expression in the later stages of 
carcinogenesis.
77;435   
The increase in positive stromal MMP-9 expression found to predict poor survival in the 
hormone-responsive, small tumours (i.e. in a group with usually very good prognosis) may 
be a consequence of interaction with hormones.
414  ERα activation has been shown to 
lead to tumour progression by stimulating cell growth and invasiveness through increased 
expression of MMPs, including MMP-9
463 and other studies have also confirmed the 
relationship between steroid hormones and increased gelatinase activity.
464;465 However 
there is conflicting evidence showing oestrogen induces a decrease in intracellular and 
secreted protein levels of MMP-9 and tamoxifen increases protein levels in oestrogen 
receptor positive MCF-7 cells.
466  Studies have shown that MMP-9 may act as both a 
positive and negative regulator of angiogenesis
467 by generating pro-angiogenic factors, 120 
 
such as VEGF, as well as the anti-angiogenic factors such as angiostatin
407;411;468 and 
therefore Tamoxifen may be associated with an increase in production of anti-angiogenic 
fragments via modulation of MMP-9.
466;466  Therefore, although an association of of MMP-
9 over expression with breast cancer progression is well documented, it is becoming 
evident that its role in neovascularisation of tumour and proliferation of cancer cells may 
also be of great significance in tumour growth and progression, and regulation of the 
activity of these proteinases may to be of great importance at different stages in tumour 
progression.   
To investigate the effect of MMP-9 promoter SNPs on MMP-9 expression levels we 
performed a series of transient reporter gene transfection experiments with a plasmid 
containing approximately 2kb of the MMP-9 promoter with one of four allele 
combinations of two SNPs, a potentially functional SNP, rs3918242 in the MMP-9 
promoter which has been reported to lead to an increased expression of MMP-9 and a 
SNP 241bp upstream that we identified as being strongly associated with distant 
metastasis, especially in ER-positive patients.  Plasmids were transfected into five cell lines 
but significant results were only obtained with the highly invasive, metastatic MDA-MB-
231 breast cancer cell line.  Results indicated that the minor allele of rs3918242 caused a 
decrease in MMP-9 expression compared to the wild type in a highly metastatic cell line 
conflicting the only published literature on the functional role of this SNP in which the 
minor allele was demonstrated to cause an increase in MMP-9 expression in macrophages 
by altering affinity of a puatitve repressor binding site for the repressor protein although 
to my knowledge there is no published literature validating this finding.  TFSEARCH did not 
show any changes in transcription factor binding sites with the minor allele.   
There is a significant amount of literature that has identified an association of the minor 
allele of this SNP with several diseases however its role in breast cancer has not been 
extensively investigated and results are conflicting and of low significance with most 
sample sizes being fairly small.  The minor allele (T) has been associated with a significant 
increase in progression and invasion in a small case control study in the Iranian 121 
 
population
469 and a moderately increased risk for the TT genotype, or a protective effect 
of the CC genotype, was observed in a Swedish cohort, however the rarity of risk 
genotypes limits the prognostic significance
392.  In contrast, the CT/TT genotype was found 
to have a marginally better prognosis compared to the CC genotype in an Australian 
cohort, and the T allele was significantly more frequent in patients with ER+ tumours and 
wild type TP53
365 and no effect in a South Brazillian cohort
470.  A Polish study
471 found the 
C>T polymorphism had no influence on expression level and suggested that the putative 
repressor that may bind to the sequence with the C allele is not expressed in breast cancer 
cells.  A further study evaluating effect of this SNP and metastatic spread of breast cancer 
LN- and LN+ patients of mixed ethnicity found the CT genotype was associated with LN+ 
disease and this association strengthened when the cohort was stratified to look at 
Caucasians only.  However, there was no association of the T allele with node status in the 
mixed ethnicity group after the Caucasians were removed suggesting the discrepancies 
reported between associations in the literature may, in part, be explained by ethnic 
differences
472.  Further investigation is needed to clarify the role, if any, that this SNP may 
play in breast cancer.   
Although the results did not reach significance, the ER-positive MCF-7 cell line and the 
NIH-3T3 fibroblast cell line both showed an increase in MMP-9 expression with the A allele 
(minor allele) of r3918241.  This SNP is located in the core of a sequence of a GATA motif 
which may bind GATA transcription factors increasing MMP-9 transcription
473.  PROMO, a 
virtual lab for identification of putative transcription factor binding sites in DNA 
sequences, uses transcription factor binding site data from the TRANSFAC database and 
indicates the A allele of rs391841 introduces a GATA1 binding site, and TFSEARCH, which 
also uses data from the TRANSFAC database to predict transcription factor binding sites, 
predicts the A allele creates an extra GATA-1, Oct-1, GATA-2 and GATA-x binding motifs 
and ESEfinder shows the A allele may enhance promoter activity and a recent paper has 
suggested that this may be responsible for increases in expression observed in non-atopic 
asthma in children
473.   122 
 
It is known that metastasis requires degradation of type IV collagen (cleaved by MMP-9) 
however, once past the basement membrane, tumour cells needs to invade the interstitial 
stroma (types I and III collagen) to reach vasculature and disseminate at distant sites.  
Types I and III collagen are degraded by MMP-1
357, therefore expression of additional 
MMPs may also be of importance and the effect of MMP-9 on metastastis may be limited 
if expression of additional MMPs are low, so it could be more beneficial to investigate 
relative levels of several MMPs rather than of individual MMPs.   
5.1.2.3 The Potential Use of MMP-9 as a Target for Therapy 
As a consequence of studies focusing almost exclusively on cancer cells, nearly all of the 
currently used cancer therapeutic agents target the cancer cells that, due to their inherent 
genomic instability, possess an evolutionary advantage and frequently acquire therapeutic 
resistance.
474  In recent years it has become clear that the tumour microenvironment 
clearly plays a role in the development and progression of cancer.  This knowledge has 
significant implications in cancer therapy since these cells are thought to be more 
genetically stable than the tumour cells they are less likely to develop an acquired 
resistance to cancer therapy.  A better understanding of the cross-talk between tumour 
and stroma are needed to help understand the biology of aggressive cells of metastatic 
tumours.  Various features of the metastatic tumour stroma have been identified as 
potential targets for therapy such as the tumour associated macrophages
475 and rigorous 
validation of these targets over the next few years may lead to new classes of anticancer 
agents such as anti-angiogenic, anti-stromal and anti-metastatic drugs becoming common 
place in clinical practice.  Although eradication of a tumour is preferable, it is not always 
possible with aggressive chemotherapy which can be harmful to the patient.  Instead it 
may be that cancers can be managed long term in a similar way to chronic diseases, with 
drugs constraining the malignant potential of the cancer cells.  Our investigation found 
that an increase in MMP-9 was associated with an increase in metastasis so this may be a 
potential target for anticancer therapy.  The importance of MMPs in tumour invasion is 
widely acknowledged.  The most compelling evidence of the involvement of MMP-9 in 
tumour invasion came from a study showing that the overproduction of this 123 
 
metalloproteinase in non-metastatic rat embryo cells conferred a metastatic phenotype 
on these cells
433.  Since then, other studies have confirmed its crucial role in tumour 
development and recent studies have demonstrated that MMP-2 and MMP-9 are 
expressed not only by cancer cells, but also by surrounding host cells 
425;431;476;477 and 
several studies have shown an association of MMP-9 with various prognostic factors
437;457 
suggesting the contribution of the host-derived gelatinase to tumour progression.   It has 
also been shown that it may be possible to revert the malignant phenotype by correcting 
environmental cues and normalising signal transduction cascades, demonstrating that the 
microenvironment can dominate over the malignant genotype.
478  Therefore, tumour 
metastasis may be reduced by inhibiting MMP-9 activity whether the tumour cell itself 
secretes MMP-9 or whether it is produced by the stromal cells, suggesting the usefulness 
of MMP-9 inhibitors for protection from metastasis in anticancer therapy. 
157;423;479  
Current therapeutic strategies using synthetic inhibitors of MMPs have already 
demonstrated the clinical potential of regulating protease activity.
364;480  
It is more efficient to decrease MMP-9 levels by preventing transcription of a low number 
of gene copies than to neutralise a high number of proteolytically active molecules that 
are secreted by cells over-expressing MMP-9.  However, MMP-9 is upregulated via 
multiple signalling pathways and some inhibitors may block more than one pathway to 
repress MMP-9 expression.
417  Several transcription factors known to regulate MMP-9 
gene expression have pleiotropic effects, for example AP-1 or NF-κB antagonists can 
inhibit phosphorylation of c-Jun and the expression of several inflammatory genes such as 
IL-2, IFN-γ and TNF-α therefore these inhibitors will likely block other members of the 
MMP family that are either under transcriptional control of these cytokines or contain 
recognition motifs in their promoter that are specific for these transcriptional elements, 
for example MMP-1, -3, -13 and -14 which are induced by TNF-α and contain AP-1 
responsive elements meaning specificity of inhibitors is crucial in achieving success. 
481      
Many matrix metalloproteinase inhibitors (MMPI’s) have been investigated for anticancer 
properties.  MMPI’s are thought to inhibit primary tumour invasion and metastasis
60 but 124 
 
most are broad spectrum MMP inhibitors such as Batimastat and the second generation 
Marimastat and have many musculoskeletal side effects with inflammation of the tendons 
and joints.  Some MMPs have a protective role against cancer and therefore targeting the 
whole family will undoubtedly fail therapeutically which may explain the limited efficacy 
seen in the clinic. 
423  There are recent reports of gelatinase (MMP-2 and MMP-9) 
inhibitors in animal models and these have demonstrated clinical potential preventing the 
migration of tumour cells, tumour growth and invasion in animal models and prolonging 
survival in xenograft-bearing animals
482. 
In the future improved diagnostics and public awareness will lead to an increased number 
of patients presenting with earlier stage disease, a cohort of which will be at high risk for 
tumour progression.   Patients who are at a high risk of cancer progression and 
development of metastases may benefit from therapies specifically targeting MMP-9 
expression while sparing the expression of the ‘protective’ collagenases
420.  Stratifying 
patients into sub groups in this way will help treatment decisions and allow a more 
personalised targeted treatment of breast cancer.  Scorilas et al
56 found that increased 
MMP-9 levels were associated with prognosis in breast cancer and suggested that the 
over-expression of MMP-9 in breast cancer may be also used as a marker to subdivide 
node negative breast cancer patients in order to determine optimal treatment modality. 
This could be useful clinically as 20-35% of node-negative breast cancer patients 
relapse
377, and determination of MMP-9 expression may help to separate patients with 
better prognosis from those with a poor prognosis and identify patients which may 
benefit from different treatment modalities that may include protease inhibitors.
56   
This study found that the SNPs in the promoter of the MMP-9 gene that were associated 
with distant metastasis were in fact more significant in ER+ patients, reaching significance 
after correction for multiple testing, and this could be very useful in identifying a subgroup 
of ER+ patients at high risk of developing distant metastases who may benefit from 
adjuvant anti-metastatic agents.  This could be particularly useful for those ER-positive 
patients who do not respond to hormonal therapy.   125 
 
Approximately 70% of all primary breast tumours express ER-α, known to be important in 
the development and course of the disease.  The SERM (selective oestrogen receptor 
modulator) Tamoxifen targets and inhibits ER- α and is the standard endocrine treatment 
for hormone receptor positive breast cancer in both the initial adjuvant therapy and as 
treatment of patients with metastatic disease.  It has been used for more than 30 years to 
treat, and more recently, to prevent breast cancer.
483  However, even among ER+ 
tumours, response to Tamoxifen is variable.  When diagnosed at an early stage adjuvant 
systemic tamoxifen therapy can cure approx 10% of the patients
484.  In recurrent disease 
approx 50% of patients have no benefit from Tamoxifen (intrinsic resistance)
485;486.  From 
the other half of the patients who initially respond to therapy a large proportion will 
eventually develop progressive disease due to acquired resistance.
485  Tamoxifen 
resistance is a major cause of death in patients with recurrent breast cancer.  Current 
clinical factors can correctly predict therapy response in only half of the treated 
patients.
485   
In recent years several studies have been published suggesting that response to 
anticancer therapies such as Tamoxifen depends not only on the characteristics of the 
tumour but also on characteristics of the host, for example a genetic polymorphism in the 
CYP2D6 gene is associated with intrinsic resistance to Tamoxifen predicting altered 
Tamoxifen metabolism and a poorer outcome than expected with the wild-type 
genotype
483  thus the future of personalised treatment approaches will involve analysis of 
both the tumour and host characteristics.     
Umar et al 2009
485 identified a putative protein profile associated with Tamoxifen 
resistance, and the top discriminating protein was the extracellular matrix 
metalloproteinase inducer EMMPRIN.  Levels of EMMPRIN were higher in the therapy 
resistant tumours and associated with earlier disease progression.  EMMPRIN was 
validated in an independent patient cohort and was significantly associated with 
resistance to Tamoxifen therapy and a shorter time to progression upon Tamoxifen 126 
 
treatment in recurrent breast cancer.  This further supports the role of matrix 
metalloproteinases in breast cancer progression.   127 
 
Chapter 6  Conclusions 
Until recently cancer research has been focussed on the tumour cell itself, now the focus 
is moving towards the role of the microenvironment of the tumour and how the 
environment may be ‘permissive’ for cancer growth, progression and metastasis.  It is 
likely that an individual’s genetic make-up may influence susceptibility to cancer and also 
the type and aggressiveness of the tumour that may develop.  Identifying genetic variants 
that may predispose to cancer or to certain types of cancer will be invaluable in cancer 
treatment and maybe even prevention.   
This study aimed to identify SNPs that may predispose to cancers with a certain 
phenotype, such as oestrogen receptor status, or indicate aggressiveness, for example 
grade or propensity to metastasise.   We confirmed previously reported associations of 
the TOX3 gene and SNPs rs2981582 and rs1219648 in the FGFR2 gene with ER-positive 
disease and identified a novel association of rs1801516 in the ATM gene with ER-negative 
disease.  We also identified several SNPs in the MMP-9 gene that were associated with 
distant metastasis.  As metastasis is the major cause of morbidity and death for cancer 
patients and there is a wealth of literature associating increased MMP-9 levels with 
cancer, we investigated this further looking at the effect of two MMP-9 promoter SNPs on 
expression levels using Luciferase reporter assays.  The minor allele of rs3918242 
decreased MMP-9 expression 1.5 fold compared to the wild type in the highly metastatic 
MDA-MB-231 cell line, whereas the minor allele of rs3918241 increased expression of 
MMP-9 in the ER-positive MCF-7 cell line and the NIH-3T3 fibroblast cell line, although not 
significantly.  The minor allele of rs3918241 introduces a GATA1 binding site which may be 
responsible for the increase in expression observed in ER-positive cells.  The minor allele 
of rs3918242 has been reported to alter a repressor binding site
394.  Further investigation 
is needed to identify which of these SNPs, or indeed any of the other SNPs they are in LD 
with, are responsible for the functional effect observed.   
When stratifying patients on the basis of ER status we found that the three MMP-9 
promoter SNPs, including rs3918241, significantly associated with the presence of distant 128 
 
metastasis were even more significant amongst the ER-positive group, remaining 
significant after stringent correction for multiple testing.  Sex steroids play a dominant 
role in breast carcinogenesis and there is evidence of an interaction of oestrogen and 
MMP-9 however the mechanisms are still largely unknown.   
It would be of interest to genotype rs3918242 in our cohort and repeat the association 
with distant metastasis to establish how significant the effect of this SNP is and if the 
minor allele is associated with the presence of metastasis or, as our functional studies 
indicate, is protective against metastasis.    
Tamoxifen is known to increase MMP-9 expression in hormone responsive MCF-7 cells
466 
so repeating the transfection experiments in MCF-7 cells in the presence of Tamoxifen 
may help increase the significance of the results.   
Electrophoretic mobility shift assays could be used to assess whether either of the 
promoter SNPs investigated here alter nuclear factor binding to help identify if either of 
these SNPs are responsible for an alteration in MMP-9 expression.   
The mean survival time in our cohort was only 2.4 years so association of the SNPs with 
survival was not studied in depth here, however association with survival could be further 
investigated using Cox regression analysis to identify any SNPs that may have a significant 
effect on risk, over and above the known risk factors including grade, ER status, tumour 
diameter and pathological nodal status.   
In summary, the search for risk alleles may identify alleles contributing only a very small 
overall risk that may not be of use clinically, but in combination may prove useful in 
identifying individuals with an increased risk of breast cancer.  It may be more useful to 
further investigate how SNPs relate to prognostic features allowing stratification of breast 
cancer patients based on the type or aggressiveness of cancer they may develop.  Current 
markers correctly predict therapy response in only half of treated patients.  Approximately 
one third of ER-positive tumours are refractory to Tamoxifen
486 and in recurrent disease 
approximately half of all patients treated will have no benefit from Tamoxifen (intrinsic 129 
 
resistance)
485;486 and of those that initially respond, a high percentage will develop an 
acquired resistance.  Identifying further biomarkers that may help predict response to 
treatment or even act as a target for drugs will help guide treatment decisions, for 
example by identifying a subset of ER-positive patients who may be likely to develop 
metastatic disease, will determine patients who could benefit from treatment with 
adjuvant anti-metastatic therapy giving a more personalised approach to therapy.   
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Chapter 7  Future Work 
This study has identified some novel associations of SNPs in genes with various aspects of 
breast tumour biology, however all of these associations need to be validated.  In order to 
validate these results SNPs that reached significance in this study, or even borderline 
significance, need to be replicated in another cohort.  The remaining 2000 patients in the 
POSH study would be an ideal cohort in which to validate the results as it is a unique, 
large, well characterised cohort with data on survival, pathology data and treatment 
received for each patient allowing the same associations with tumour characteristics to be 
made as in the present study.     
This study also identified a strong association between SNPs in the promoter region of the 
MMP-9 gene with the presence of distant metastasis.  The literature is very conflicting 
regarding the cellular localisation of MMP-9 (Figure 15).  In several cancers, including 
colon
431 and skin
487, there is a lot of evidence for a significant stromal expression of MMP-
9, particularly in the tumour associated macrophages.  In breast cancer several studies 
have identified stromal expression to varying extents
359;364;368;414;442, although some 
studies have shown strongest expression in the carcinoma cells
55;56;157;377.  Many of the 
previous studies have used immunohistochemistry to study the expression of MMP-9 and 
the different expression patterns observed might be explained by the use of different 
antibodies with different specificities for the active, latent or complexed forms of MMP-9, 
or all three and often it is not made clear which the antibodies regognise making 
comparisons between studies difficult.  The majority of studies have also been conducted 
in a relatively small number of samples only.   131 
 
 
 
In order to establish the cellular localisation and expression levels of MMP-9 protein, 
immunohistochemistry with specific antibodies needs to be performed in a large number 
of breast tissue samples.  The POSH cohort will again provide a very good cohort for this, 
with a large number of breast tissue samples available to use for such a study.  Breast 
tissue samples from approximately 1000 of the POSH patients have been called and over 
600 so far have been assembled on tissue microarrays.  Formalin fixed paraffin embedded 
(FFPE) tissue gives good preservation of tissue morphology so it is usually relatively easy to 
specify the cellular localisation of the stain in this tissue.  Antibodies to MMP-9 would 
need to be tested on whole tumour sections in a range of breast cancers from the 
pathology laboratory (approximately 20-30 cases) to review the staining patterns and 
optimise the conditions.  Once happy that the stain works optimally the TMAs could be 
stained and scored on intensity of expression.  Using tissue samples from this cohort will 
then give us the opportunity to correlate the expression data with various aspects of 
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Figure 15: Schematic representation of the tumour microenvironment summarising literature 
documenting the cellular localisation of MMP-9 132 
 
tumour biology such as oestrogen receptor status, propensity to metastasise and survival 
and also to associate with genotype data to investigate how expression levels vary with 
the presence of the MMP-9 promoter SNPs.  As treatment such as chemotherapy and 
adjuvant hormonal therapy can alter MMP-9 expression
377 it will be of benefit to know the 
treatment received for each patient when making comparisons.  This work would require 
the help of an experienced histopathologist to optimise the stain and agree a scoring 
system.  In situ hybridisation could also be performed to investigate MMP-9 DNA or mRNA 
levels in the tumour tissue to compare with the protein levels identified.   
Several studies have documented cell-cell contact is needed between tumour and stroma 
cells to induce MMP-9 expression in the host
425.  Although co-culture of MRC5 and MCF-7 
did not appear to increase MMP-9 expression in RT-PCR, co-culture of fibroblasts with a 
more invasive cell line such as MDA_MB_231 might show an increase in MMP-9 as it has 
been demonstrated that co-cultures with more malignant cell lines only promote MMP-9 
expression
104;425.  Previous studies have also shown that orthotopic fibroblasts are 
required to induce an increase in MMP-9
101 so co-culture with breast fibroblasts may 
significantly alter MMP-9 expression, which can be identified by RT-PCR or qRT-PCR.  
Transfections with the plasmids created in this study could be performed in either the 
cancer cell line or the fibroblast cell line, and after 24hrs co-cultured with either 
untransfected fibroblasts or cancer cells respectively to investigate the effect of co-culture 
on MMP-9 expression, and allow identification of the cell type responsible for the most 
significant increase in MMP-9.  These experiments would demonstrate the important role 
of the host cells in tumourigenesis and the effect of the promoter polymorphisms in host 
cells.   
An increased expression of MMP-9 has been associated with breast cancer in numerous 
studies.  Carcinoma cell expression of MMP-9 has been associated with both with 
good
56;414 and bad
157;377 prognostic factors.  Stromal cell expression of MMP-9 has been 
associated with poor prognostic factors
414 therefore there could be very cell specific 
effects of MMP-9 and of the promoter SNP.  It would be of interest to perform 133 
 
transfections with our four plasmids in a macrophage cell line to see if these cell specific 
differences account for the contradictory result observed to that previously reported
394.   
Functional studies were conducted to investigate the role of two promoter SNPs, one 
previously reported and one in very strong linkage with it identified in our association 
study.  We found a significant increase in MMP-9 expression with the wild type allele of 
the previously reported SNP rs3918242 meaning the minor allele, leading to a decrease in 
MMP-9 expression, was associated with the presence of distant metastasis.  This 
unexpected result is difficult to interpret in terms of the current concept of the molecular 
mechanisms involved in tumour invasion and metastasis, and conflicts the results of the 
only published data on its functional effect.  However there is data clearly challenging the 
classical beliefs that MMP-9 is solely a pro-metastatic enzyme
488;489, promoting tumour 
invasion exclusively by modulating the remodelling of the ECM, for example MMPs may 
also regulate angiogenesis either positively through their ability to activate proangiogenic 
factors such as VEGF, or negatively via the generation of angiogenesis inhibitors such as 
angiostatin, endostatin and tumstatin
407;488;490 (Figure 16) therefore our result could be 
explained by MMP-9 having an anti-angiogenic effect.  It has been shown that oestrogen 
decreases MMP-9 expression levels and Tamoxifen increases them
466.  Since Tamoxifen is 
known to have anti-angiogenic effects by generating endostatin via MMP-9 production
466, 
this supports the hypothesis of MMP-9 playing an anti-angiogenic role.  The potential role 
of MMP-9 on angiogenesis could be investigated by transfecting the MDA_MB_231 cell 
line with MMP-9 plasmids and measuring levels of angiostatin and endostatin produced 
by the cells.  Mouse xenograft models using breast cancer cells overexpressing MMP9 
from a stably transfected plasmid could also be used however these would be complex 
to set up.   134 
 
 
 
Investigation of the MMP-9 promoter region using the TFSEARCH database revealed that 
the promoter SNP rs3918241 introduced a GATA-1 binding site in the promoter sequence.  
To investigate the effect of GATA-1 in relation to our promoter SNPs GATA-1 in breast 
cancer cell lines could be inhibited using siRNA to see if the effect is still observed in the 
absence of GATA-1 or cells could be co-transfected with both the plasmid reporter vectors 
created in this study and a GATA-1 expressing plasmid to see if this has any SNP-
dependent effects.  In addition, chromatin immunoprecipitation (ChiP) experiments or 
electrophoretic mobility shift assays (EMSA) could be performed to investigate the 
location of DNA binding sites for GATA-1 protein and determine the protein-DNA 
interactions that may be occurring.   
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Figure 16: Network diagram of factors affecting MMP-9 expression and their potential consequences.  
Yellow arrows indicate an increase in expression and blue arrows a decrease.  Red arrows indicate the 
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Chapter 8  Papers and Abstracts 
8.1  Papers 
•  Named author on a paper outlining the POSH study protocol
396.   
•  Named author on paper titled ‘The influence of genetic variation in 30 selected 
genes on the clinical characteristics of early onset breast cancer’
491.   
8.2  Abstracts and Posters 
•  Poster presented at the Cancer Sciences Division Conference, June 2007 and the 
British Society for Human Genetics, Sept 2007 titled ‘Inherited mutations in BRCA1 
are much more frequent than in BRCA2 amongst young breast cancer cases’.   
•  An abstract on the work carried out in year 2, titled ‘An inherited genetic 
polymorphism in the oestrogen receptor gene is associated with poor prognosis in  
young breast cancer patients’ was presented at the Cancer Sciences Division 
Conference, July 2008.  
•  Poster presented at the National Cancer Research Institute conference titled ‘An 
inherited genetic polymorphism in the oestrogen receptor gene is associated with 
poor prognosis in young breast cancer patients’ October 2008.   
•  Oral presentation titled ‘The Role of Genetic Factors in Breast Cancer Aetiology’ 
was given at the Faculty of Medicine, Health and Life Sciences Postgraduate 
Conference, University of Southampton, June 2009 for which the prize of ‘best oral 
presentation’ was awarded.   
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Chapter 9  Appendices 
9.1  Appendix 1 - Sequenom 
Sequenom offer a genotyping service called iPLEX Gold.  This uses the MassARRAY® 
platform developed by Sequenom to specifically meet the requirements of moderate to 
high throughput genetic analysis and is suitable for genotyping tens to hundreds of SNPs 
in hundreds to thousands of samples. It offers cost effective, high quality custom SNP 
genotyping combining single-base primer extension biochemistry and MALDI-TOF mass 
spectrometry.  The service includes primer and assay design through to the production of 
genotypes. All steps involved are highly automated and are tracked using a laboratory 
management system with bar coding.  
9.1.1.1 SNP analysis using Sequenom MassARRAY Genotyping 
Assay Design – The MassARRAY® Designer software can automatically design both PCR 
and MassEXTEND® primers for multiplexed assays using sequence information from public 
databases.  The primer design sequence is automatically transferred into an 
oligonucleotide requisition form for ordering of the primer.  
multiplex PCR – this is the first step of the genotyping process.  It is carried out to 
generate short PCR products (> 100 bp) containing one SNP or insertion deletion.  
Excess dNTPs are then removed from the reaction by incubation with 0.3 U shrimp 
alkaline phosphatase (USB). 
MassEXTEND® Reaction - MassEXTEND® is a primer extension reaction in which an 
oligonucleotide primer anneals immediately upstream of the polymorphic site being 
genotyped. The extension of the primer is according to the sequence of the variant site 
and can be a single complementary base or a series of complementary bases. This results 
in an allele-specific difference in mass between extension products.  137 
 
The genotype data is generated by analysis of minisequencing reaction products by mass 
spectrometry.   
Genotype Calling and Results - The extension product is then spotted onto a 384 well 
spectroCHIP® and the spectoCHIP placed into the MALDI-TOF (Matrix Assisted Laser 
Desorption/Ionization Time-of-Flight) mass spectrometer.  Oonce inside, a laser is fired 
onto the pads and an electrical charge is applied, attracting the extended oligonucleotides 
to a detector. The time taken to reach the detector (TOF, time of flight) is solely based 
upon the mass of the oligonucleotide.  This mass difference allows the data analysis 
software to differentiate between SNP alleles.  The resulting spectra is converted into 
genotype using a software system called the SpectroTYPER-RT (RT for real-time). Through 
the assay design process, the software is informed of the expected mass of all possible 
extension products. If a peak is seen where expected the software calls the allele, but if no 
peak is seen, the laser is fired again until a spectra is achieved containing the expected 
peaks.  
Sequenom offer different ‘tiers’ that vary slightly in assay design, validation and 
genotyping product.  For our study we opted for tier 2.  This does not require that DNA 
samples undergo a functional QC, there will be up to 2 attempts made to generate a data 
point, and customers will be charged on a possible data point basis rather than delivered 
genotype basis and for all assay designs and materials, regardless of whether all the SNPs 
type successfully.  138 
 
9.2  Appendix 2 - Sequenom Tier Descriptions 
 
Assay Design and Validation 
 
Tier 1: Assays are both designed and validated. 
A.) Assays are designed using Spectrodesigner for the first two attempts. Manual 
intervention (if necessary) is used for the third attempt. 
B.) Validation involves testing the assays on control samples for: 
1.  Robustness. Each assay is tested to ensure that it is capable of 
generating at least 90% data on reliable DNA samples. 
2.  Reproducible. Each assay is tested to ensure that it generates 
reproducible results (at least 99.3%) 
3.  Accurate. Each assay is tested to ensure that it generates accurate 
results. Depending on the project accuracy may be tested by: 
a.  comparison with genotype results from independent 
platforms 
b.  evaluation of Mendelian inheritance 
c.  evaluation of Hardy-Weinberg values 
C.) Tier 1 is required if the client desired to have guaranteed data delivery in 
production. That is, if we promise to deliver at least 90% of the possible data 
for a given assay and at least 95% of the data for a given project, we must 
ascertain beforehand that the assay is capable of meeting those standards. 
D.) As the number of production DNA samples increase, it may actually be less 
expensive for the client to choose Tier 1 as opposed to Tier 2. This is because 
non-functioning assays will be removed and not applied in production. 
E.) Customer is charged only for assays that validate; they are not charged for 
failed assays. 
 
Tier 2: Assays are designed and applied directly into production 
A.) Saves time, as production can begin immediately 
B.) Useful when an appropriate validation cohort is not available 
C.) May be more cost effective; especially with projects involving fewer DNA 
samples 
D.) Cannot be used in conjunction with Tier 1 genotyping (guaranteed delivery) 
E.) Customer is charged for all assay designs and materials, regardless of whether 
they end up working. 
 
Tier 3: Customer designs are used. 
A.) Allows customer to transfer MassARRAY designs from their own labs or other 
service providers to Sequenom. 
B.)  Allows customer to use designs from previous service projects within the 
Services Department. 139 
 
1.  If assays were validated (Tier 1) previously, Tier 1 genotyping 
(guaranteed delivery) is possible. 
2.  If assays were developed under Tier 2 previously, Tier 1 genotyping 
(guaranteed delivery) is not possible. 
C.) Customer is charged a modest assay management fee for the necessary 
bioinformatics work 
 
Genotyping Production 
 
Tier 1: Guaranteed Delivery 
A.) Requires that assays were developed under Tier 1 above 
B.) Requires that DNA samples undergo a functional QC  
C.) Guarantees that the customer will get at least 90% of the data on a per assay 
basis (ie no assays will be delivered with less than 90% of the possible data). 
D.) Guarantees that the customer will get at least 95% of the possible data for the 
entire project (DNA samples x validated assays x .95). 
E.)  Customer is charged only for data that is delivered. 
 
Tier 2: Attempted Genotype Pricing 
A.) Can use any tier of assay development above 
B.) Does not require that DNA samples undergo a functional QC  
C.) Makes no guarantee regarding data delivery 
D.) Services will make up to two attempts to generate a data point. 
E.) Customers are charged on a possible data point basis rather than delivered 
genotype basis. Thus, there is no difference between the estimated project 
cost and the maximum project cost as with Tier 1 genotyping. 
F.)  Turnaround time will typically be faster than with Tier 1 genotyping 
G.) Cost will typically be cheaper than with Tier 1 genotyping. 
H.) For many applications, this option may offer the greatest value. 
 
Tier 3: Single Pass Genotype Pricing 
A.) Can use any tier of assay development above 
B.) Does not require that DNA samples undergo a functional QC  
C.) Makes not guarantee regarding data delivery 
D.) Services will make a single attempt to generate a data point. 
E.) Customers are charged on a possible data point basis rather than delivered 
genotype basis. Thus, there is no difference between the estimated project 
cost and the maximum project cost as with Tier 1 genotyping. 
F.)  Turnaround time will typically be faster than with either Tier 1 or Tier 2 
genotyping 
G.) Cost will be cheaper than with Tier 1 or Tier 2 genotyping. 
H.) This option is recommended for quick first pass scans, where missing data will 
not adversely impact results. 140 
 
9.3  Appendix 3 - Sequenom Cluster Plots 
rs7038971 – the high mass homozygous cluster does not look like a heterozygous on the 
spectrum.  The low mass peak(s) are significantly lower than in the true hets, in green. 
 
rs243849 – low mass allele peak does not meet peak criteria and extension primer 
conversion appears complete  
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rs1801516 – Both peaks are present for het calls  and homozygote calls are clear.   
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9.4  Appendix 4 - DNA Extraction Reagents 
Nuclei lysis buffer – (10mM Tris, 400mM NaCl, 2mM sodium EDTA)To make up 500ml; 5ml 
1.0M tris pH 8.0, 40ml 5.0M sodium chloride, 2ml 0.5M EDTA pH 8.0, 453ml UHQ StillPlus 
water.  Stored at room temperature.   
Erythrocyte lysis buffer x10 – To make up 500ml; 5.05gm potassium hydrogen carbonate, 
41gm ammonium chloride, 1ml 0.5M EDTA pH 8.0, make up to 500ml with UHQ StillPlus 
water (made in advance by Human Genetics staff, autoclaved for 15mins at 121˚C.  Stored 
at room temperature until needed.  Place in fridge overnight to cool to 4˚C ready for use 
the next day and dilute 1 in 10 for use.   
10% SDS (sodium dodecyl sulphate)- 10gm SDS in 100ml UHQ StillPlus water, stored at 
room temperature.   
Protease – (40mg/ml) 800mg made up to 20ml with UHQ StillPlus water, stored in -20˚C 
freezer.   
Saturated salt (6M sodium chloride) – 35gm NaCl in 100ml UHQ StillPlus water, stored at 
room temperature.   
Ethanol 70% - 350ml ethanol plus 150ml water, stored at room temperature.   
TE buffer – (10mM Tris/1.0mM EDTA buffer pH 7.5)  To make up 500ml; 5ml 1.0M Tris pH 
7.5, 1ml 0.5M EDTA pH 8.0, 494ml UHQ StillPlus water (usually made up in advance by 
Human Genetics staff, autoclaved for 15mins at 121˚C in 80ml volumes).  Stored at room 
temperature.   
2% Virkon™ - 40gm dissolved in 200ml tap water 
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